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Abstract 
Antibody mimetics are a novel class of potential therapeutic agents which improve on several 
limitations which hinder antibodies. As a result, they are the subject of increasing interest from 
both the pharmaceutical and academic sectors. They are commonly selected via phage display 
against an immobilised target. However the presentation of these targets, particularly in the 
case of membrane proteins, is often a rate limiting step in their production.    
In this study, several commonly-used protein tags were compared in their ability to immobilise 
a model membrane protein - MPSIL0294, a metal ion transporter from Enterococcus faecalis, a 
streptavidin binding peptide tag, an Avitag which has undergone in vivo biotinylation and a 
chemically biotinylated C-terminal cysteine. A fourth method of immobilisation was also 
included, aspecific chemical biotinylation of lysine residues in AcrB, a component of an E.coli 
multidrug efflux pump. The tags were compared using a phage display assay, in which 
designed ankyrin repeat proteins (DARPins) from a naïve library were screened against both 
model membrane proteins, which were both solubilised in n-Dodecyl-β-D-maltopyranoside 
(DDM). With the exception of the C-terminal cysteine variant of MPSIL0294, no DARPins 
capable of binding could be selected by any of the other immobilisation techniques after two 
rounds of phage display. Furthermore, the C-terminal cysteine MPSIL0294 also yielded poor 
success rates and only two binding DARPins were identified. Despite showing a moderately 
high level of sequence similarity, these two DARPins showed different binding activities during 
validation experiments. The alternative tags under test however; do not appear to be 
beneficial in the selection of antibody mimetics against immobilised membrane protein 
targets.    
Different methods of protein solubilisation were also compared in an identical manner: 
detergent solubilisation (in DDM), lipid nanodiscs and styrene maleic acid lipid particles 
(SMALP). These solubilisation methods were compared using a panel of membrane proteins 
composed of MPSIL0294, AcrB, NupC, an E.coli concentrative nucleoside transporter and 
VcCNT, NupCs homologue from Vibrio Cholerae. SMALPs of AcrB, VcCNT and NupC displayed 
the highest success rate for selecting DARPins capable of binding the respective targets. 
Subsequent validation tests showed that the best DARPins selected against AcrB SMALPs and 
nanodiscs behaved in a similar manner. SMALPs are relatively easy to produce, especially 
compared to nanodiscs so this study concludes that SMALPs are the best format for phage 
display.  
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1.1 Membrane proteins in modern research 
Membrane proteins are a class of biological molecules of intense interest in several different 
sectors of biological research today; none more so than the pharmaceutical sector. This is 
especially apparent since approximately 60% of all currently prescribed drugs target 
membrane proteins (Klammt, Maslennikov et al. 2012, Moraes, Evans et al. 2014). Of this 60%, 
increasing proportions are protein therapies (for example monoclonal antibodies) as opposed 
to small molecule drugs. In 2010 17% of the total profit made by the global pharmaceutical 
market was due to therapeutic proteins and this trend is predicted to continue (i.e. 
monoclonal antibodies and recombinant proteins combined)(Elvin, Couston et al. 2013). This 
amount of investment is indicative of the importance of treatments targeting membrane 
proteins.  
There are several reasons why novel methods of selecting proteins capable of binding to 
membrane proteins would be of great interest, the level of investment being one. From a 
research point of view, novel methods of developing crystallisation chaperones (which are 
membrane protein binding partners) are of great interest, as they aid in crystallogenesis which 
in turn allows X-ray crystallography and protein structure determination to be performed. 
From the point of view of the pharmaceutical industry, improved methods of selecting 
antibodies and other binding proteins specific for membrane protein targets are of great 
interest as such methods would greatly benefit drug development. Their potential as drug 
targets is epitomised in the fact that 20 – 30% of the open reading frames in genomes across 
all life encode membrane proteins. For humans specifically it is estimated to be 26% (Krogh, 
Larsson et al. 2001, Fagerberg, Jonasson et al. 2010, Moraes, Evans et al. 2014). 
The main difficulties that arise when attempting to research membrane proteins are their high 
sensitivity to environmental changes, due to the fact that they are amphipathic. In order to 
integrate properly into a cell membrane they require hydrophobic domains which can exist 
stably within the phospholipid bilayer. Membrane proteins also tend to have hydrophilic 
domains that exist outside of the membrane (either extracellularly, intracellularly or both), 
which will often play a role in protein function. Therefore they need to be kept within a 
membrane or membrane mimetic structure at all times. Furthermore, the surrounding lipids 
can interfere with experiments aimed at determining their structures such as x-ray 
crystallography or nuclear magnetic resonance (NMR) (Franzin, Gong et al. 2007). Detergents 
such as Triton X-100 or n-Dodecyl β-D-Maltopyranoside (DDM) are employed due to their 
ability to disorganize membranes, resulting in the creation of micelles (spherical aggregates 
formed whenever a membrane is treated with a surfactant) in which membrane proteins are 
 18 
soluble when the detergent is present above a threshold concentration known as the critical 
micelle concentration (CMC). Thereby making them more easily extracted for subsequent 
techniques such as high throughput screens. However when membrane mimetic environments 
are employed (e.g. solubilisation by detergents) there is a risk that membrane proteins may 
adopt non-native conformations (Otzen 2011) (see section 1.3.1).  
This chapter shall discuss the main themes which this thesis impacts, starting with a discussion 
of the most common methods of membrane protein solubilisation employed in current 
research including detergent solubilisation as well as detergent free methods such as the use 
of membrane scaffold proteins (MSP) in order to construct nanodiscs, or the use of polymers 
such as styrene maleic acid (SMA) or amphipols. This is followed by a brief profile of each of 
the membrane proteins under test in this study before several in vitro selection strategies are 
introduced. The strategies discussed include phage, bacterial and yeast display, all of which 
use entire cells in order to display proteins of interest. Followed by a discussion of cell free 
methods of selection, namely ribosome and mRNA display. .  Various antibody mimetics are 
then discussed, namely single chain variable fragments (scFvs), nanobodies, designed ankyrin 
repeat proteins (DARPins) and adhirons before the chapter concludes with the overall aim of 
this study.  
1.2 Solubilising membrane proteins  
1.2.1 Detergent solubilisation 
Solubilising detergents are chemicals which have the ability to mimic the lipid bilayer due to a 
hydrophilic ‘head’ region and hydrophilic hydrocarbon ‘tail’. Above a certain threshold 
concentration (known as the critical micelle concentration – CMC), this amphipathicity allows 
detergents to form micelles into which membrane proteins can be encapsulated. The 
formation of micelles is spontaneous once a detergent is exposed to an aqueous environment 
as the hydrophobic tails move to minimise their interaction with water. Depending on the 
detergent used, solubilisation of membrane bilayers can either occur rapidly or slowly, 
depending upon the rate at which detergent is flipped from the outer membrane to the inner 
membrane (Lichtenberg, Ahyayauch et al. 2013). The overall mechanism of solubilisation 
differs between rapid and slow solubilisation. The rapid solubilisation process involves the 
initial rapid insertion of detergent monomer into the outer membrane, followed by the 
detergent monomers flipping into the inner membrane. Once both the inner and outer 
membranes have become saturated with detergent, compartments are then directly removed 
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either by the micelles in an ‘all or nothing’ manner via the trans-bilayer mechanism, or open 
vesicular intermediates. Thus, in rapid solubilisation it is believed that lipids and membrane 
protein are co-extracted with one another into thread like mixed micelles (Kragh-Hansen, le 
Maire et al. 1998, Stuart and Boekema 2007, Lichtenberg, Ahyayauch et al. 2013).  
Significantly different mechanisms have been proposed in the literature for slow solubilisation, 
however, although it is generally agreed that it results in only part of the phospholipid in 
micelles. Micelle formation is thought to occur either as the result of the saturation of 
membrane vesicles from which micelles ‘pinch off’ (Stuart and Boekema 2007), or as result of 
direct binding of micelles to the bilayer and extraction of membrane components by the 
micelle itself (Kragh-Hansen, le Maire et al. 1998, Lichtenberg, Ahyayauch et al. 2013).        
Detergents such as Triton X-100 and dodecyldimethylamine oxide (DDAO) are examples of fast 
solubilising detergents, while sodium dodecyl sulphate (SDS) and n-Dodecyl-β-D-
maltopyranoside (DDM) are both examples of the slow solubilising class (Lichtenberg, 
Ahyayauch et al. 2013).  
Detergents are classified based on their structure within four main classes. The first are ionic 
detergents which encompass detergents with a charged head group and a hydrophobic 
hydrocarbon chain such as SDS. These detergents are often effective solubilising agents, but 
also have a tendency to denature membrane proteins. The second class are the non-ionic 
detergents which have uncharged hydrophilic head regions composed of glycosidic groups, 
such as the DM, DDM and the other maltoside detergents, or polyoxyethylene group, such as 
Triton X-100. They are considered a milder class of detergents and are thus often capable of 
solubilising membrane protein in a functional state, although this effect is dependent upon the 
length of the hydrophobic chain. Thirdly, there are zwitterionic detergents such as DDAO, 
which exhibit features of both the ionic and non-ionic detergents, although they tend to 
inactivate membrane proteins more often. Finally, there are the bile acid salts such as sodium 
cholate, which exhibit a polar and apolar face instead of a hydrophobic head group. This is due 
to the steroidal groups which form their backbone. The bile acid salts are quite mild and these 
detergents have a lower tendency to denature proteins because their head groups are 
combined with their steroidal backbones (le Maire, Champeil et al. 2000, Seddon, Curnow et 
al. 2004).          
The choice of detergent for protein solubilisation may have an effect on protein- protein 
interactions with membrane proteins. Depending on the length of the hydrophilic chain, the 
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resultant micelle may be large enough to engulf potential surface epitopes thus rendering 
them inaccessible to potential binding partners (Kunji, Harding et al. 2008). The effect of 
micelle size upon selection experiments, an overview of which is presented in section 1.3, has 
not yet been investigated in the literature and remains an unknown factor in the selection of 
binding proteins to protein targets.        
 As previously stated, detergents can interfere with several experimental techniques that 
would provide valuable information regarding membrane proteins, such as mass 
spectrometry, NMR and X-ray crystallography. Therefore, several alternative methods of 
membrane protein solubilisation have arisen which aim to more closely mimic the native 
membrane environment, several of which will now be discussed.  
 
1.2.2 Nanodiscs 
Nanodiscs are membrane mimetics composed of 130-160 phospholipids arranged in a bilayer 
surrounded by two membrane scaffold proteins (MSP) derived from apolipoprotein 1 in a 
double belt configuration. They form spontaneously without the need of detergent and appear 
as flat disks, approximately 10-20 nm in diameter (depending on the MSP used) with a mass of 
approximately 150 kDa. The entire nanodisc population adopts the same specific size and is 
monodisperse once their construction is complete (Bayburt and Sligar 2010, Rajesh, Knowles 
et al. 2011).  
The MSP can be altered in several ways prior to nanodisc formation, including biotinylation, 
tagging via polyhistidine, FLAG tags etc. with cleavage sites for later removal. The size of the 
nanodisc is dependent on the length of MSP which is used in its construction. This has been 
exploited and led to the generation of several different MSPs with extra helices inserted in the 
centre of the protein, thereby increasing the size of the nanodisc (Denisov, Grinkova et al. 
2004, Schuler, Denisov et al. 2013). A result of these MSP alterations showed that the first 22 
residues of the MSP may not be involved the formation of the discs as their deletion failed to 
affect its size (Grinkova, Denisov et al. 2010).         
To entrap a membrane protein within a nanodisc, the protein first needs to be solubilised from 
the cell plasma membrane with detergent and subsequently purified in detergent. The general 
procedure involves treating the purified membrane protein (in detergent) with MSP and 
phospholipids in a very precise ratio. This ratio is specific to the membrane protein of interest. 
Once the detergent is removed, the membrane protein is drawn into the nanodisc as it 
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spontaneously forms, as the protein, MSP and lipid all seek to minimise their hydrophobic 
regions interaction with ambient water (see Figure 1.1A).  
In theory, insertion into a nanodisc should increase the likelihood of the protein retaining its 
native conformation and functionality due to the presence of a phospholipid bilayer, the lipids 
of which can be altered to better suit its native environment if need be (Bayburt and Sligar 
2010). However, if the protein adopts a non-native confirmation as a result of detergent 
solubilisation, presumably this confirmation will be carried forward into the nanodisc.    
Nanodiscs also aid in membrane protein research due to their homogeneity, consistent size 
and minimal light scattering. Most importantly, however, is the fact that once a membrane 
protein is encapsulated within them, they can be handled like soluble protein in an aqueous 
solution, thus making the use of techniques such as surface plasmon resonance (SPR) or NMR 
easier (Justesen Bo and Günther-Pomorski 2014).    
Nanodiscs have the potential to be a very powerful tool not only in membrane protein 
research but also in drug discovery, as they not only stabilise the proteins but also should aid 
in their screening. For example, the fact that any lipid can be used in their production means 
that, excessive tagging of proteins may be unnecessary as they can be encapsulated in 
nanodiscs formed with biotinylated lipid and immobilised on streptavidin surfaces this way 
(Goluch, Shaw et al. 2008, Bayburt and Sligar 2010). They also allow access to both sides of the 
lipid bilayer (Justesen Bo and Günther-Pomorski 2014) and thus both sides of the encapsulated 
protein. This, in theory, maximises the selected of binding proteins against a target. To this 
end, nanodiscs containing bacteriorhodopsin have been used in a phage display screen using 
the random 12-mer library of binding peptides (a commercially available library consisting of 
2.7 x 109 random dodecapeptides). This selection resulted initially in 69 peptides which were 
considered positive. After further validation, three were characterised further and shown to 
bind to the extramembranous regions of bacteriorhodopsin (Pavlidou, Hanel et al. 2013).        
1.2.3 Polymer solubilisation  
Amphipathic polymers are an alternative class of compounds, some of which have shown a 
capability to solubilise membrane proteins. An early example of these polymers are the 
amphipols which are composed of hydrophilic backbones grafted with hydrophobic side 
chains. Despite their ability to solubilise membrane proteins, they still require the proteins to 
initially be purified in detergent (see section 1.2.3.2). Alternatively In recent years, the 
 22 
amphipathic co-polymer styrene-maleic acid has been shown to remove membrane proteins 
directly from membranes, solubilising them in a pH dependent manner (see section 1.2.3.1). 
1.2.3.1 Styrene-maleic acid 
Styrene-maleic acid (SMA), an amphipathic co-polymer, is capable of forming disc like 
structures around membrane proteins due to its ability to associate with lipids. The copolymer 
itself is composed of alternating hydrophobic styrene groups and hydrophilic maleic acid 
groups. The polymer is able to remove membrane proteins directly from membranes without 
the inclusion of detergent at any point (Rajesh, Knowles et al. 2011). SMA is actually the 
hydrolysed form of styrene-maleic anhydride copolymer, a commonly used substance in the 
manufacture of plastics.  
The procedure required to encapsulate membrane proteins involves directly treating 
membrane preparations with the SMA polymer. This causes the spontaneous entry of SMA 
into the membrane in a pH-dependant manner creating disc like structures known as styrene-
maleic acid lipid particles (SMALPs), which are 9-12 nm in diameter (see Figure 1.1B). When 
the pH drops below 6 the SMA becomes insoluble due to protonation of the maleic acid and 
the SMALPs fall apart; when the pH is increased again, the SMALPs reform.  
There is a major advantage to using SMALPs over nanodiscs, namely the lack of an MSP. From 
a drug discovery point of view this gives advantages in terms of screening, as binding partners 
that associate with the MSP instead of the target protein will no longer be an issue. Also the 
fact that SMALPs are generally smaller and scatter less light, makes them better suited for 
biophysical studies such as circular dichroism (CD)(Knowles, Finka et al. 2009, Jamshad, Lin et 
al. 2011, Rajesh, Knowles et al. 2011). A major benefit of SMALPs is the fact that the co-
polymer encapsulates membrane proteins directly from the membrane therefore, it 
presumably retains its native structure and function (Postis, Rawson et al. 2015). It is theorised 
that the benefits of SMALPS arise due to their ability to encapsulate the lipids in the immediate 
vicinity of the protein along with the target, although this is currently not known. Due to their 
novelty, investigations into their suitability as phage display platforms have not yet been 
published. They have, however, proven to be beneficial during electron microscopy (Postis, 
Rawson et al. 2015).      
 23 
 
Figure 1.1: Cartoon models of a Nanodisc and a SMALP:  A) a nanodisc encapsulating the target GPCR (Beta2-
adrenergic receptor) and B) a SMALP encapsulating the same target protein. Original images taken from: A) the 
paper “Functional reconstitution of Beta2-adrenergic receptors utilizing self-assembling Nanodisc technology” 
(Leitz, Bayburt et al. 2006) and B) From the University of Warwick, Molecular Organisation and Assembly in Cells 
website: “Novel biophysical methods for membrane protein research” under the supervision of Dr David I Roper. 
1.2.3.2 Amphipols 
Amphipols are manufactured flexible amphipathic polymers consisting of a highly hydrophilic 
backbone grafted with many closely spaced hydrophobic side chains. This allows them to 
associate and solubilise membrane proteins by forming a belt around their hydrophobic 
regions, thereby protecting these regions from exposure to aqueous surroundings, while 
simultaneously burying its own hydrophobic side chains (Tribet, Audebert et al. 1996, Zoonens 
and Popot 2014). Amphipols are generally rather short in order to maximise the homogeneity 
of an amphipol/protein solution and minimise the amount of cross bridges between individual 
amphipol/protein complexes (Zoonens and Popot 2014).  
Early amphipols consisted of a polyacrylic acid backbone grafted with octylamine and 
isopropylamine side chains in arbitrary positions. A grafting ratio of 25% was shown to confer a 
desirable level of amphipathicity while retaining the polymers solubility in water. This 
synthesis gave rise to the most prominent of the amphipols – A8-35 (35% free, ungrafted 
carboxylic acid groups), which has become the most extensively researched (Tribet, Audebert 
et al. 1996, Zoonens, Zito et al. 2014). In aqueous solution, A8-35 forms 40 kDa globular 
particles containing four A8-35 macromolecules and approximately 80 octyl chains above a 
critical association concentration (CAC) of 0.002 g L-1 (Gohon, Giusti et al. 2006, Giusti, Popot et 
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al. 2012). More recently, entire libraries of amphipols have been developed which aim to 
maximise their potential applications. For instance, substituting the isopropyl groups for 
sulfonate groups gave rise to a range of amphipols resistant to pH change, designated the 
sulfonated amphipols (Dahmane, Giusti et al. 2011). Alternatively, zwitterionic amphipols were 
synthesised by the inclusion of phosphocholine polar head groups which are resistant to low 
pH, high salt concentrations and the presence of divalent ions (Diab, Tribet et al. 2007). Non-
ionic amphipols have also been produced by the incorporation of sugar groups (Sharma, 
Durand et al. 2012). Similarly the amphipol polymer can be directly tagged, biotinylated or 
associated with fluorophores (Le Bon, Popot et al. 2014).                  
However, amphipols are weak detergents, while they are able to permeabilize lipid vesicles 
and adsorb onto cell surfaces, they are unable to directly remove proteins from a membrane 
(Popot, Berry et al. 2003, Zoonens and Popot 2014). Although it has been suggested that A8-35 
was capable of directly removing the E.coli maltose transporter as well as the human insulin 
transporter (which was over expressed in Chinese hamster ovary (CHO) cells) from their 
respective membranes, these instance are few and far between (Popot, Berry et al. 2003). In 
most cases, the solubilisation of proteins by amphipols is very similar to the production of 
nanodiscs, in that detergent solubilised protein is mixed with amphipol and the concentration 
of detergent is lowered below the CMC, often with bio-beads (Popot, Berry et al. 2003, 
Zoonens, Zito et al. 2014). Like nanodiscs, the optimal amphipol to protein ratio is required in 
order to keep the protein soluble, however for amphipols it is determined experimentally. The 
ratio is dependent on several factors including: the size of the protein and transmembrane 
region and the tendency of the protein to oligomerize. Initially, an excess of amphipol is 
typically added to the detergent-solubilised protein in order to form protein/micelle/amphipol 
complexes which are monodisperse, due to their weak dissociating power (Zoonens and Popot 
2014, Zoonens, Zito et al. 2014). Once the amphipol/membrane protein complexes are 
formed, some polymer will be left as free particles in the sample. When large membrane 
proteins (over 40 kDa) are used, this free polymer can be removed by size exclusion 
chromatography (SEC). Alternatively the excess amphipol can be removed by affinity 
chromatography such as immobilised metal ion affinity chromatography (IMAC) if the protein 
is tagged. Thirdly the free polymer can be removed by analytical ultracentrifugation (AUC) 
(Zoonens, Zito et al. 2014). Despite the fact that amphipol protein complexes are more stable 
than their detergent micelle counterparts, they were not included in this study.  
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1.3 The membrane protein panel under test 
The panel of membrane proteins selected for this study were chosen in order to provide a 
range of oligomeric states and extramembranous regions. The first is predicted to be a divalent 
metal transporter which was highlighted as part of the membrane protein structure initiative 
in Leeds (MPSIL) designated MPSIL0294. There is not currently a crystal structure for 
MPSIL0294 therefore it is difficult to predict protein’s accessibility to binding probes during 
phage display. The second member of the panel is a component of a major E.coli multidrug 
efflux pump called AcrB. This protein (which functions as a trimer in E.coli) has previously been 
subjected to phage display with DARPins and isolated high affinity binders, some of which 
were used in co-crystallisation trails. Also AcrB is well characterised and has a large 
extracellular domain which should be highly accessible to potential binding partners 
(Brandstatter, Sokolova et al. 2011, Eicher, Cha et al. 2012, Johnson, Cheong et al. 2012). 
Finally, a concentrative nucleoside transporter (CNT) from Vibrio Cholerae (VcCNT) along with 
its E.coli homologue NupC are included in the panel of membrane proteins. The crystal 
structure of VcCNT show that it exists as a trimer and therefore provides a good model of 
multimeric proteins during phage display. The background of each of the membrane target will 
be introduced separately below.  
1.3.1 MPSIL0294 
MPSIL0294 is a divalent metal cation transporter from Enterococcus faecalis and is a member 
of the NRAMP family of metal transporters, although the metal ions which it is able to 
transport remains unclear. It is more commonly known as Ef MntH Cβ1 and research into its 
function have shown that MPSIL0294’s overexpression results to an increase in sensitivity to 
cadmium, cobalt and iron metal ions in E. coli. Intriguingly, no increase in sensitivity was 
reported for manganese (which is thought to be a key ion transported by the MntH proteins) 
(Richer, Courville et al. 2003). Conversely, recent investigations carried out in Enterococcus 
faecalis showed that MPSIL0294s expression is downregulated in the presence manganese 
ions (and to a lesser extent copper ions) and upregulated in the presence of iron and zinc 
(Abrantes, Kok et al. 2013). This investigation also suggested that the MPSIL0294 gene is under 
the control of the EfaR regulator, a co-repressor which, in the presence of manganese, is able 
to bind to a DNA binding motif which encompasses the promotor, thus suggesting that 
MPSIL0294 is a manganese transporter in Enterococcus faecalis (Abrantes, Kok et al. 2013).  
MPSIL0294 was included in this study due to the fact that both its N- and C-termini are 
cytosolic, potentially making them easier to attach affinity tags to without interfering with 
 26 
biosynthesis or function. It has also proven difficult to produce crystals of MPSIL0294, 
therefore it is hoped that the use of crystallisation chaperones will aid in determining its 
structure. Its predicted 12 transmembrane helix (TM) topology differs from most of its 
bacterial homologues, which have an 11 TM topology and a periplasmic C-terminus. With this 
topology, it more closely resembles its human homologues in the divalent metal cation 
transporter or “Natural Resistance-Associated Macrophage Protein” (NRAMP) family with 
which it shares a 34% sequence homology (White, Stewart et al. 2004, Ma 2013). The latter, 
which undergoes extensive post-translational N-linked glycosylation, is more difficult to 
express and work with than MPSIL0294. In this study, MPSIL0294 was used to compare three 
of the four methods of immobilisation (the fourth is aspecific biotinylation, which was 
performed on AcrB, see section 1.6). Samples of MPSIL0294 were also encapsulated in 
nanodiscs and SMALPs, and compared after rounds of phage display using a 7.5 x 109 library of 
DARPins. A DARPin which successfully bound MPSIL0294 was also included in the proteins 
stopped flow Zn2+ uptake assay with the hope of testing its effect on protein function. 
Relatively little is known about MPSIL0294 specifically, so instead, the background of the 
NRAMP family will be discussed, in particular the human NRAMP. 
While a structure of neither MPSIL0294 nor NRAMP is currently available, a crystal structure of 
a close homologue of NRAMP2 (also known as divalent metal transporter 1- DMT1) from 
Staphylococcus capitis (ScDMT) was solved by co-crystallisation, using nanobodies which 
bound to the exposed C-terminal of the protein (Ehrnstorfer, Geertsma et al. 2014).  
Structurally, ScDMT is composed of eleven transmembrane helices, the first and sixth of which 
are interrupted by a short loop and are directly involved in substrate translocation. The 
structure displays the LeuT fold in which two five helix units are structurally related to one 
another forming a ten helix subdomain (the eleventh helix of ScDMT is not involved in the fold) 
(Khafizov, Staritzbichler et al. 2010). In ScDMT the five helix units show a twofold rotation 
around an axis in the centre of the membrane. It is formed of a sequence which is 37% 
identical to NRAMP2 and 59% homologous, its structure shows that it has a cytoplasmic N-
terminal and a periplasmic C-terminal. Transport experiments with ScDMT which had a 44 
residues from its N-terminal removed in order to stabilise it, showed that the protein was able 
to transport manganese and cadmium with micromolar affinity (similar to wild type) 
(Ehrnstorfer, Geertsma et al. 2014).  
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1.3.1.1 NRAMP 
Two members of the NRAMP family are encoded within the human genome, NRAMP1 and 
NRAMP2 (also known as Solute Carrier Family 11 members 1 and 2 (SLC11A1 and SLC11A2)). 
The two are very similar in amino acid sequence (approximately 61% identity) and in 
hydropathy profiles (Pinner, Gruenheid et al. 1997, Mackenzie and Hediger 2004). Despite 
seemingly performing the same function of proton-dependant divalent metal ion transport, 
they differ from one another in some regards, the most notable being their localization in the 
body.         
NRAMP1 is found on the phagolysosomal membrane within phagocytes and appears to play a 
role within the immune response (Lam-Yuk-Tseung, Govoni et al. 2003). It is likely that it 
functions primarily following phagocytosis of bacteria such as Mycobacterium. Phagocytosis 
leads to the formation of a phagosome which fuses with a lysosome to form a phagolysosome. 
The NRAMP1 protein is located in lysosomal membranes, as indicated by the presence of 
lysosomal targeting motifs within its sequence and through co-localisation experiments using 
full length and truncated NRAMP1 tagged with GFP and the lysosomal marker, lysosomal-
associated membrane protein 1 (LAMP1), tagged with RFP (Cheng and Wang 2012). Its 
localisation suggests that NRAMP1 is placed into the phagolysosomal membrane upon 
phagosome/lysosome fusion.   
NRAMP1 is subsequently thought to contribute to the establishment of detrimental 
environmental conditions within the phagosome which result in the encased pathogens 
adopting either a bacteriostatic or bacteriolytic state (Nada Jabado 2004). There are multiple 
theories concerning the mechanisms by which NRAMP1 establishes such conditions. For 
example, research suggests that recruitment of NRAMP1 results in the co-transport of protons 
and divalent metal ions such as Mn2+ or Fe2+, essential for bacterial growth, out from the 
phagolysosome (see Figure 1.2). This is plausible as acidification of the phagolysosome could 
activate the efflux activity of NRAMP1 (Mackenzie and Hediger 2004, Fortin, Abel et al. 2007). 
It has also been reported that NRAMP1’s presence within this membrane may help to prevent 
Mycobacterium from blocking the fusion of the phagosomes with lysosomes (a defence 
mechanism that several Mycobacteria strains are thought to employ) (Frehel, Canonne-
Hergaux et al. 2002).  
Alternatively, it has been suggested that with the influx of Fe2+ into the phagolysosome is the 
primary function of NRAMP. It is proposed that NRAMP1 is able to generate hydroxyl radicals 
via the Fenton/Haber-Weiss reactions using a proton/ferrous cation antiporter mechanism in 
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which Fe2+ ions are pumped into the phagolysosome (Lafuse, Alvarez et al. 2000, Goswami, 
Bhattacharjee et al. 2001). Despite the theoretical plausibility of this mechanism (contradictory 
evidence supporting both the co-transporter and antiporter activities of NRAMP1 is present in 
the literature), there are some fundamental problems with this hypothesis. Fe2+ is an essential 
metal ion for bacterial growth; importing it would thus aid bacterial survival within the 
phagolysosome. Also, more importantly, in order to achieve the aforementioned H+/Fe2+ 
antiporter mechanism, NRAMP1 would need to be topologically opposite in the 
phagolysosome compared to the topology of NRAMP2 in the plasma membrane (see below). 
Due to the high level of structural similarity between NRAMP1 and NRAMP2, such a drastic 
difference in function and topology seems unlikely (Lam-Yuk-Tseung, Govoni et al. 2003, Nada 
Jabado 2004). 
 
Figure 1.2: NRAMP 2’s role in the immune system: A schematic of a possible mechanism by which NRAMP1 helps 
the immune system to kill phagocytised pathogens, using proton/divalent metal cation co-transporter activity. 
Note: Picture was adapted from a figure appearing in the paper “Host Genetics of Mycobacterial Diseases in Mice 
and Men: Forward Genetic Studies of BCG-osis and Tuberculosis” (Fortin, Abel et al. 2007)  
NRAMP2 (also known as either Divalent Metal Transporter 1 (DMT1)) is far more ubiquitously 
found in the human body and its mechanism of transport has been better characterized. It is 
present in a variety of tissues ranging from the erythrocytes to intestinal cells (Lam-Yuk-
Tseung, Govoni et al. 2003). There has even been some evidence to suggest that NRAMP2 may 
play a role in transporting Mn2+ across the blood brain barrier as it is found in the membranes 
of the astrocytes (Aschner 2006). In Mice, NRAMP2 was found to localize in the brush border 
of the absorptive epithelium in the duodenum, where it is  thought to be responsible for the 
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cellular uptake of dietary Fe2+ (Jabado, Cuellar-Mata et al. 2003, Lam-Yuk-Tseung, Govoni et al. 
2003, Mackenzie and Hediger 2004). An endosomal proton gradient is established by the 
Na+/H+ exchanger, thereby creating an acidic microclimate at the duodenum brush border 
membrane (Mackenzie and Garrick 2005). This microclimate provides NRAMP2 with plenty of 
available protons for co-transport with Fe2+ into the enterocyte where it can be stored in the 
intracellular iron pool (also known as the labile iron pool). However, since free iron in the 
blood is usually transported in its ferric form (Fe3+) bound to the iron transporter transferrin 
and iron enters cells via the transferrin receptor (see Figure 1.3), it is unclear if NRAMP2 in the 
plasma membrane plays a role at cellular uptake of iron in tissues other than the duodenum 
(Trinder, Fox et al. 2002, Zhang, Canonne-Hergaux et al. 2008). NRAMP2 is more typically 
localised in endosomal membranes, where it is responsible for the translocation of essential 
metal ions such as Fe2+ from the endosome into the cytoplasm (see Figure 1.3).  Ferritin is 
endocytosed with iron in its ferric form and the endosomal Fe3+ is reduced to Fe2+ prior to 
transportation by NRAMP2 (Sendamarai, Ohgami et al. 2008). The endosomal 
metalloreductase STEAP3 is thought to be responsible for the reduction of ferric iron (see 
Figure 1.6). However, STEAP3 has also been shown to have the ability to bind a large range of 
other divalent metals including Mn2+, Co2+, Cd2+, Zn2+ and Pb2+.  
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Figure 1.3: NRAMP2’s role in iron absorption: A diagrammatic representation of the role of NRAMP2 in co-
transporting protons and ferrous iron from the endosome into the cytosol, following liberation of ferric iron from 
endocytosed transferrin/transferrin receptor complexes and its reduction by STEAP3. Note: this picture was 
adapted from an image found in the paper “Single gene effects in mouse models of host: pathogen interactions” 
(Fortier, Min-Oo et al. 2005). 
NRAMP2 activity is pH dependant and is activated by an acidic pH, thereby providing further 
evidence for the direction of transport. A high concentration of protons is required before 
NRAMP2 is able to co-transport metal ions out of the endosome, utilising the electrochemical 
gradient which is the cumulative force produced by the different concentration of metal ions 
across the membrane and the electrical difference produced by the charge of the ions (Lam-
Yuk-Tseung, Govoni et al. 2003).  
1.3.2 AcrB 
AcrB is a large component of a multi drug efflux pump in E. coli, alongside the outer membrane 
channel TolC and the membrane fusion protein AcrA. AcrB is composed of a 12 helix 
transmembrane domain and a very large extracellular loop which forms the porter domain and 
the TolC docking domain. The AcrB/TolC/AcrA complex is a member of the resistance–
nodulation–division (RND) family of transporters which are spread throughout Gram-negative 
bacteria. As such, it is able to export a wide array of substrates including cationic, anionic, 
zwitterionic and neutral compounds and is major cause of drug tolerance in E. coli (Murakami, 
Nakashima et al. 2006).   
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AcrB self-associates into a homotrimer, with each monomer providing components of the 
various extracellular domains. The porter domain consists of a bundle of helices which play a 
role in the proteins function. In the TolC docking domain, the protein opens like a funnel into 
which TolC (a trimeric β-barrel channel protein which extends from the outer membrane into 
the periplasm) docks directly. The AcrB/TolC complex is surrounded by AcrA which interacts 
with both components of the complex and acts as a linker between the two (Mikolosko, Bobyk 
et al. 2006, Murakami, Nakashima et al. 2006, Pos 2009).  
The efflux mechanism is energised by a proton motive force and occurs in a substrate/proton 
antiporter manner. The leading theory of drug export is named the peristaltic pump 
mechanism, and proposes a three part rotary procedure conceptually similar to that of ATPase, 
without the physical rotation. The three protomers of AcrB are thought to adopt three distinct 
states; the ‘loose’ state, the ‘tight’ state and the ‘open’ state. Substrates from the outer leaflet 
of the inner membrane bind to the ‘loose’ protomer which, as a consequence, undergoes a 
transition into the ‘tight’ conformation. This transition is dependent upon an 11 amino acid 
residue switch loop, the flexibility of which appears to determine the ease of this transition 
and the size of compound which can be translocated (Eicher, Cha et al. 2012, Cha, Muller et al. 
2014). Finally by utilising energy procured from the translocation of periplasmic protons by the 
transmembrane domain, the ‘tight’ conformation transitions into the open conformation and 
the drug is released into a central funnel towards TolC. This transition is also thought to be 
dependent on substrate binding into the adjacent ‘loose’ site. The porter domain is then 
thought to constrict, thereby driving unidirectional translocation of the substrate toward TolC 
and out of the cell (Murakami, Nakashima et al. 2006, Pos 2009, Nakashima, Sakurai et al. 
2011, Eicher, Cha et al. 2012).  
AcrB was selected for this study due to the ease with which it can be overexpressed and 
purified in E.coli. More importantly, the large extracellular loop of AcrB increases the likelihood 
of selecting DARPins which bind tightly to this domain. Due to a cluster of histidine residues in 
the C-terminal of AcrB, it is a very common E.coli contaminant when IMAC is used (Veesler, 
Blangy et al. 2008). Therefore a DARPin capable of binding AcrB tightly may be used to develop 
a column capable of specifically removing it from E.coli membrane preparations. As part of this 
study, samples of purified AcrB were aspecifically biotinylated via their lysine residues using 
NHS-biotin. They were also encapsulated in nanodiscs constructed with an MSP which itself 
had been biotinylated and prepared in SMALPs. Like MPSIL0294, each AcrB sample was 
compared with one another using two rounds of phage display with a DARPin library.        
 32 
1.3.3 NupC and VcCNT 
In E. coli, nucleosides can be used as a precursor to nucleotides or as   a carbon and nitrogen 
source. Nucleosides are able to freely diffuse across the E. coli outer membrane via the specific 
porin, Tsx (Bremer, Middendorf et al. 1990). In low concentrations however, nucleosides have 
to be actively translocated across the inner membrane via two unrelated families of 
transporters; the concentrative nucleoside transporters (CNT) and the nucleoside: 
H+ Symporter (NHS) family.  
NupC is a member of the CNT family of transporters and is a proton linked nucleoside 
symporter. Experimental evidence has highlighted the properties which nucleosides must have 
in order to be successfully translocated by NupC. Firstly, C-3’ on the sugar group must be in the 
α-configuration with a hydroxyl group. Secondly, the glyosidic bond must be in a β-
configuration. It has also been shown that, for as yet unknown reasons, NupC is unable to 
translocate guanosine or deoxyguanosine and is poor at translocating inosine. Due to NupCs 
22 and 26% sequence homology with the human CNT proteins (hCNT1 and hCNT2 
respectively), a crystal structure of NupC is more therapeutically relevant than any of its E.coli 
homologues, as it is the only E. coli nucleoside transporter which shows such a similarity (out 
of both the CNT and NHS families) (Patching, Baldwin et al. 2005, Vaziri, Baldwin et al. 2013). It 
also transports anti-viral drugs such as azidothymidine (AZT) which is used in the treatment of 
AIDS and gemcitabine which is a chemotherapy agent (Loewen, Yao et al. 2004).   
While there is no structure of NupC currently available, a crystal structure for its homologue in 
V. cholerae, designated VcCNT has been elucidated. Unlike NupC, VcCNT is a sodium linked 
concentrative nucleoside transporter which shows 39% sequence homology with hCNT3. The 
VcCNT structure suggests that the protein exists as a homotrimer composed of protomers with 
eight transmembrane helices each, two helix-turn helix hairpin motifs and three helices which 
run along the membrane known as interfacial helices (Johnson, Cheong et al. 2012).  
The VcCNT protomers are separated into different sub-domains based on the positions of the 
helices relative to the centre of the transporter. The first is located toward the outside of the 
protein and is known as the scaffold domain. It is responsible for maintaining the transporters 
structure and plays a role in the trimerization process. The domain is composed of four 
transmembrane helices and a single aliphatic interfacial helix. Secondly, each protomer has a 
transport domain toward the centre of the protein which is composed of two structural 
groups, each composed of two transmembrane helices, a single helix-turn-helix hairpin motif 
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and an interfacial helix. The two structural groups are separated from one another by the sixth 
transmembrane helix which sits at an axis across the membrane (Johnson, Cheong et al. 2012).  
Based on the high degree of conservation, the two turn-helix-turn motifs and the two 
transmembrane helices immediately adjacent to them (the 4th and the 7th respectively) are 
believed to be essential in substrate translocation. The substrate binding site is formed by the 
two structural groups within the transport which form deep clefts toward the centre of the 
protein (Johnson, Cheong et al. 2012).      
Both NupC and VcCNT were selected in this project due to the extensive amount of 
characterisation which had already been performed, including established expression and 
purification procedures for both proteins and a transport assay for NupC. As previously stated 
while a crystal structure is available of VcCNT, none yet exists for NupC. Therefore the 
selection of DARPins which could be subsequently used in co-crystallisation trails with NupC 
were also of interest. During this study, samples of NupC and VcCNT SMALPs were provided 
and compared with one another during a phage display screen using the aforementioned 
DARPin library, with the aim that DARPins capable of binding the targets could be used during 
future co-crystallisation trails.  
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1.4 In vitro selection strategies 
Several different examples of in vitro selection strategies currently exist and each strategy 
differs from one another in their efficiency and reliability (see below). In this study, phage 
display was chosen due to the technique’s robustness and in the extended literature that is 
available in which this technique is used for the selection of antibody mimetics. This includes 
antibody fragments such as scFvs and nanobodies as well as DARPins which are discussed in 
Section 1.5, and includes a wide array of targets like cell surface receptors and toxins. Finally, 
phage display often results in antibody mimetics with a sub-nanomolar affinity (Steiner, Forrer 
et al. 2008, Bazan, Calkosinski et al. 2012). For example, DARPins have been isolated against 
many membrane targets, for example, a DARPin inhibitor was used in the co-crystallisation of 
AcrB using ribosome display. This DARPin had a low nanomolar affinity and was isolated after 
four selection cycles on detergent solubilised AcrB immobilised via biotinylation (Sennhauser, 
Amstutz et al. 2007).  
1.4.1 Phage display 
In principle, phage display technology aims to fuse filamentous bacteriophage (viruses that 
infect bacterial cells) coat proteins (usually coat protein P3 from the bacteriophage M13) with 
proteins of interest (in this instance, Designed Ankyrin Repeat Proteins or DARPins), so that the 
phage is able to display them on its surface. This thereby links the phenotype of a particular 
peptide with its genotype. Once display has been achieved these phage particles can be 
selected for their ability to bind to an immobilised protein target (Smith 1985). As can be seen 
in Figure 1.4 a typical solid surface phage display selection, first requires the target protein of 
interest to be immobilised onto a solid surface. As is the case in this study, this immobilisation 
often relies on the biotinylation of target proteins and the use of streptavidin coated surfaces. 
In instances such as this, naïve libraries of putative binding partners displayed on the surface of 
phage particles are deselected against streptavidin in order to remove proteins capable of 
binding directly. Phage which does not bind during the deselection are removed by washing 
and used to select against the immobilised target protein. The fusion proteins which fail to 
bind to the target are removed by washing and discarded, while those that successfully bind 
are subsequently eluted (phage elution can be achieved via several different methods such as 
a pH change with trimethylamine and glycine or by trypsinization) and used to infect a culture 
of host bacteria (most often E.coli). Once infected the cells can either be used to amplify the 
amount of phage (and thus the fusion protein which successfully bind to the target) with the 
use of ‘helper phage’ or the DNA which encode the binding protein fused to the bacteriophage 
coat protein (the phagemid) can be recovered from the bacterial cells and sequenced. If the 
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phage is amplified then it can be used in further rounds of selection against the immobilised 
target protein. If the DNA is recovered, the binding protein DNA can be sub-cloned into an 
expression vector and subsequently expressed and purified (see Figure 1.4). An very similar 
methodology is employed for solution based selections, the difference being that target 
proteins are immobilised on beads (for example streptavidin coated magnetic beads) as 
opposed to a plate as shown in Figure 1.4.          
 
Figure 1.4: The schematic of a typical phage display experiment: Initially libraries of potential binding proteins are 
deselected against streptavidin in order to remove any binding proteins capable of binding to it directly, target 
proteins also undergo biotinylation and subsequent immobilisation on a streptavidin coated surface. Phage that 
are incapable of binding streptavidin are washed used in a selection against the immobilised target protein. 
Phage incapable of binding the target are then washed while the binding phage are eluted and used to infect 
E.coli. The infected cells are then superinfected with helper phage which facilitates the amplification of the 
eluted phage. This eluted phage can then be used in subsequent rounds of selection against the biotinylated 
target protein. Alternatively infected E.coli can be used to isolate the phagemid DNA in order to express and 
purify the binding proteins. 
As mentioned above, the phagemid requires a ‘helper phage’ in order to produce full phage 
particles. This is because the phagemid lacks all of the genes required to produce viable phage 
molecules in order to avoid bacterial cell stress which can lead to unstable phage libraries. 
Hence these components are provided by the ‘helper phage’ which itself lacks the coat protein 
contained in the phagemid and thus facilitates the production of phage molecules and their 
subsequent presentation of binding protein on their surface (Baek, Suk et al. 2002, Soltes, Hust 
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et al. 2007). To this end, during phage display screens, bacterial hosts are transformed with 
both phagemid and ‘helper phage’. 
Premature folding of antibody mimetics has been shown to reduce the amount of protein 
successfully translocated to the phage surface. Therefore, their open reading frames are often 
preceded by the signal sequence from E.coli namely the signal recognition particle (SRP). The 
SRP ribonucleoprotein is required because (unlike the Sec pathway), upon binding nascent 
polypeptides containing the appropriate signal sequence, it arrests translation. In this way it 
prevents the premature folding of DARPins before they can be translocated to the plasma 
membrane (Valent, Scotti et al. 1998, Steiner, Forrer et al. 2008). The SRP sequence of DsbA is 
the most commonly used SRP in plasmids designed for phage display (phagemid) and has been 
previously shown to very effective in the co-translocation of mimetics to the periplasm 
(Schierle, Berkmen et al. 2003, Steiner, Forrer et al. 2008).  
An amber stop codon is also often included within the phagemid, separating the binding 
protein from the phage coat protein. This stop codon is only recognised by bacterial amber 
suppressor strains which are able to read through it due to a mutation in their tRNA. Therefore 
its presence confers a level of control over which form of binding protein is expressed (either 
the protein alone or the protein bound to the phage coat protein) by transforming particular 
strains of expression host (mostly E.coli) with the phagemid (Soltes, Hust et al. 2007).  
Phage display technology takes advantage of several fundamental characteristics of the 
filamentous bacteriophage genome, in particular, their tolerance to insertions within non-
essential regions and the fact that alterations to the phage coat proteins does not affect the 
organism’s pathogenicity toward its bacterial hosts (Russel, Lowman et al. 2004, Steiner, Forrer 
et al. 2008, Thie, Schirrmann et al. 2008). However, the fact that bacterial cells must be 
transformed during the phage display procedure lowers the diversity of the library which can 
be presented to immobilised targets.  
1.4.2 Bacterial display 
Bacterial display procedures are similar to phage display in that, peptides of interest are 
presented at the surface of bacterial cells by fusing them to anchoring motifs. Proteins of 
interest can either be inserted into the centre of the surface protein or as a terminal fusion. 
However, fusion of binding proteins onto surface proteins can have undesirable physiological 
effects on the host cells which may be detrimental to the selection process (Lee, Choi et al. 
2003).  
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Research has now highlighted a wide range of carrier proteins which are resistant to the 
integration of binding proteins and have thus been used to display peptides of interest on the 
surface of bacterial cells. Although, Gram negative bacteria are the most extensively used, 
particularly E.coli due to its rapid growth rate and ability to allow the presentation of larger 
libraries (Daugherty 2007). Carrier proteins which have been used in this manner include outer 
membrane proteins such as OmpA and OmpX or flagellar proteins such as FliC (Getz, Schoep et 
al. 2012). Selection experiments using bacterial display are usually linked with techniques such 
as fluorescence-activated cell sorting (FACs) in order to enrich clones which bind to an 
immobilised target. The use of FACs also provide a real time quantitative analysis of the library 
as it effects a target and increase the contexts in which bacterial display is applicable, for 
example the proteins’ stability in the presence of proteases can be monitored as can its 
binding affinity (Getz, Schoep et al. 2012). The size of an antibody mimetic is an important 
factor in the likelihood of an antibody mimetic to be successfully displayed on the surface of a 
bacterial host, as well as its disulphide bond content and charge (Lee, Choi et al. 2003).   
Despite the fact that high affinity binders to a variety of targets (which had been previously 
subjected to phage display) have successfully been isolated using this method, its applicability 
to this study is limited. For instance, with OmpA as the carrier protein and a library of 5 x 105 
small 15 residue monomer peptides, several high affinity binders were selected against five 
unrelated target proteins which have previously been used in phage display. These targets 
included human serum albumin, a monoclonal antibody (mAb) against an epitope on T7, 
human C-reactive protein, the HIV-1 surface protein GP120 and streptavidin (Bessette, Rice et 
al. 2004). However, due to the unpredictable consequences displaying full length fusion 
proteins such as DARPins may have on the host cell and the fact that smaller libraries of 
proteins give rise to lower quality binders, this selection strategy is not appropriate for this 
study.        
1.4.3 Yeast display 
Yeast display has many conceptual similarities to both bacterial and phage display in that 
proteins of interest are fused to the surface of yeast cells and used as binding probes during 
selection experiments. As with bacterial display, a wide variety of surface proteins can have 
binding proteins integrated within them in order to display them on the cell surface, the 
original being α-agglutinin, a cell wall protein in Saccharomyces cerevisiae involved in mating. 
Many members of the glycosylphosphatidylinositol (GPI) family such as  of cell wall proteins 
can also be used for display procedures in yeast (Pepper, Cho et al. 2008). The most commonly 
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used carrier protein is a C-terminal fusion with the α-agglutinin protein Aga2p which is 
anchored to the yeast surface via a disulphide bridge with Aga1p and is also involved in mating 
(Pepper, Cho et al. 2008, Gera, Hussain et al. 2013). However, it has recently been shown that 
use of this surface protein may have many negative effects on the cells including either 
altering its growth kinetics or the hydrophobicity of its cell wall (Andreu and Del Olmo 2013). 
S. cerevisiae cells produce Aga2p fusions through the use of shuttle plasmid vectors, while 
Aga1p is stably integrated within the chromosome. Both proteins are under the control of the 
GAL1 promotor, therefore the protein of interest is only displayed in the presence of galactose 
(Gera, Hussain et al. 2013).     
The major benefit of yeast display is that the selection is performed in a eukaryotic system. 
This allows any complex post-translational modifications to be performed to the antibody 
mimetic. Also, like bacterial display, they are compatible with FACs analysis, although neither 
display technologies are able to present as large a library as phage display (Gera, Hussain et al. 
2013).  
1.4.4 Ribosome display  
Phage display has become one of the fundamental methods for the elucidation of both 
antagonistic and agonistic drug candidates against a wide variety of target proteins. The 
robustness of the technique when compared to other screening methods makes it particularly 
useful. Ribosome display, however, is superior in certain key aspects, namely the ease with 
which binding protein libraries can be altered through the use of error prone PCR and the 
removal of the transformation efficiency of a bacterial host cell as a factor in the success of 
selections (thereby allowing the display of larger libraries). Phage display on the other hand 
depends upon the in vivo production of the binding proteins and their presentation on the 
surface of phage particles (Schaffitzel, Hanes et al. 1999, He and Khan 2005). The main 
limitations with ribosome display lie with its dependency on stable mRNA as well as the 
ribosome itself and reaction conditions must therefore be closely monitored with regard to the 
presence of RNases, denaturing conditions and temperature (Steiner, Forrer et al. 2008); 
issues which are exacerbated when the target under test is a membrane protein.   
In principle, ribosome display relies on the in vitro translation of an mRNA molecule encoding 
an antibody mimetic of interest. In order to stabilise the ribosome/mRNA/ folded polypeptide 
complex, the mRNA is designed with a C-terminal spacer sequence without a stop codon. 
When translated, this spacer sequence remains bound to the appropriate tRNA and thus 
remains within the ribosome, while the correctly folded binding protein protrudes from the 
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ribosomal surface. These complexes can thus be used as binding probes to an immobilised 
target creating a direct link between the phenotype and genotype (Zahnd, Amstutz et al. 2007, 
Pluckthun 2012). The mRNA of binding proteins can then be easily recovered and its cDNA 
found via reverse transcription and PCR amplified so they can be used in subsequent rounds of 
screening (Pluckthun 2012).   
DNA constructs for ribosome display are designed with a strong promotor upstream from 
either a prokaryotic ribosome binding site or a eukaryotic Kozak sequence, depending upon 
the subsequent expression system that is required. The DNA constructs are also designed to 
place a ‘stemloop’ at both the 3’ and 5’ ends of the RNA in order to increase its resistance to 
RNase mediated degradation (Pluckthun 2012).  
1.4.5 mRNA display 
mRNA display is a conceptually similar selection technology to ribosome display in so far as it 
takes advantage of the translation process. However, while ribosome display aims to form 
complexes between the ribosome, the mRNA and the fully folded polypeptide (Zahnd, Amstutz 
et al. 2007), mRNA display is designed to form polypeptide/mRNA fusions which are released 
from the ribosome and subsequently used as screening probes. This is achieved through the 
use of the 3’ tRNA analogue puromycin which is able to prematurely terminate translation due 
to its structural similarity to adenosine. This similarity allows puromycin to occupy one of the 
binding sites within the ribosome after which it is incorporated into the polypeptide and 
translation is immediately terminated resulting in proteins covalently linked to the mRNA 
which encodes it (Keefe 2001).  
In order to perform mRNA display, DNA libraries are first established with constant regions at 
both ends of the DNA which provide features such as the promotor region, affinity tags and 
ribosome binding sites. Once the DNA is transcribed, the 3’ end of the mRNA is modified with 
an oligonucleotide which houses the puromycin binding site as well as a poly-adenosine tail. 
The oligonucleotide acts as a spacer, which ensures the puromycin properly fuses to the 
protein while the adenosine tail facilitates protein/mRNA purification (Keefe 2001, Seelig 
2011).    
Like ribosome display, mRNA display shares several distinct advantages over other display 
strategies, namely the ease with which libraries of binding proteins can be altered via error 
prone PCR or mutagenesis, the large libraries which can be screened and the option to include 
unnatural amino acids. However, due to the fact that mRNA display does not need to maintain 
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the ribosome protein complex, the experimental conditions required are less stringent 
compared to ribosome display. 
Despite their benefits, neither ribosome nor mRNA display are appropriate selection strategies 
for this study due to their reliance on in vitro translation. This expression technique requires 
the inclusion of Mg2+ ions as they prevent the undesired hydrolysis of tRNA and are therefore 
added during both ribosome and mRNA display procedures (Keefe 2001, Pluckthun 2012). 
Observational data has shown that magnesium ions are detrimental to the stability of SMALPs, 
which are one of the solubilisation methods under test in this study.                 
 
Table 1.1: A comparison of the different display technologies  
Display Technology Maximum Library 
size 
Suitability Example of its use 
Phage Display 1010 - 1011 Suitable Affibody against 
EGFR (Friedman, 
Nordberg et al. 
2007) 
 
Bacterial display 
 
109 
Unsuitable as the 
library under test is a 
commercial phage 
display DARPin 
library 
Higher affinity 
binders found 
against human C-
reactive protein, the 
HIV-1 surface 
protein GP120 
(Bessette, Rice et al. 
2004) 
 
Yeast 
 
107- 109 
Unsuitable as the 
library under test is a 
commercial phage 
display DARPin 
library 
Affinity maturation 
of a scFv against 
the Vβ8 T cell 
receptor (Kieke, Cho 
et al. 1997) 
 
Ribosome 
 
>1012 
The presence of Mg2+ 
makes this 
unsuitable for 
SMALPs 
A DARPin 
crystallization 
chaperone for AcrB 
(Monroe, 
Sennhauser et al. 
2011) 
 
mRNA 
 
>1012 
The presence of Mg2+ 
makes this 
unsuitable for 
SMALPs 
88 amino acid 
peptide apatamer 
against streptavidin 
(Wilson, Keefe et al. 
2001)  
 41 
1.5 Antibody mimetics 
Antibodies are involved in the immune response and are responsible for binding to foreign 
particles, highlighting them for degradation by components of the immune system such as the 
phagocytes. Antibodies come in several different classes, but the class that is typically used for 
research and therapeutics is known as Immunoglobulin G (IgG). IgGs are Y-shaped molecules 
consisting of 2 long heavy chains associated with 2 shorter light chains by disulphide bonds 
(Ruigrok, Levisson et al. 2011). These chains are made up of several units known as 
immunoglobulin folds composed of several anti-parallel β-sheets (Bork, Holm et al. 1994). Both 
the heavy and light chains are separated into constant and variable regions. The constant 
regions are found in all classes of antibody within a particular species and play roles in 
antibody stability and signal transduction. The variable regions determines antibody specificity 
through the complementarity determining region (CDR) (Ruigrok, Levisson et al. 2011).  
With regard to the drug discovery pipeline, any antibody or antibody mimetic which has been 
isolated against a target of interest via a selection experiment are subject to extensive 
characterisation using a wide array of techniques. These techniques include ELISA and size 
exclusion chromatography, which aim to confirm its ability to bind to target as well as identify 
which epitope the antibody or antibody mimetic binds to. ELISAs with potential drug 
candidates also try to use a wide enough range of concentrations in order to establish an IC50 
and thereby estimate an affinity of the binding protein for its target. This can then be 
subsequently confirmed using techniques such as Isothermal titration calorimetry (ITC). These 
binding affinities can then be optimised via site directed mutagenesis if desired, although 
identification of the essential residues is a time consuming process which requires the random 
substitution of several residues. Once binding has been confirmed and a desirable affinity has 
been obtained, the in vivo pharmacokinetics and efficacy of the candidate are investigated. In 
the case of bio conjugates, residues in the candidate can once again be altered via site directed 
mutagenesis in order to introduce residues amenable to biochemical alteration such as a 
cysteine residue (Simon, Frey et al. 2013). Pharmacokinetics can be explored via the use of GFP 
fusion proteins or the use of fluorophores and fluorescence microscopy. If a cell surface 
receptor has been targeted, the level of receptor at the surface of the cell can also be 
monitored (Boersma, Chao et al. 2011).     
Antibody mimetics are small proteins which replicate the binding activity and specificity of full 
length antibodies, while being smaller and, typically, more stable. They also have the added 
benefit of relatively easy expression and purification system, with a short production time that 
does not require the use of animals. As such, antibody mimetics are of particular interest to 
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the pharmaceutical industry. Typically, they are protein constructs that utilise the 
immunoglobulin fold. However, in recent years a range of mimetics based upon different 
protein scaffolds which facilitate protein-protein interactions have arisen. These stable scaffold 
motifs can be used as a starting point onto which diversity can be introduced in the sections of 
the protein which actually bind targets. For example, in the case of DARPins, they each have 
the same ankyrin motif but the actual residues responsible for binding differ from one another 
(Steiner, Forrer et al. 2008). As previously mentioned, the displayed antibody mimetics also 
often have the SRP signal sequence which is recognised by the Escherichia coli (see section 
1.3.1) (Steiner, Forrer et al. 2008). In this section, we will discuss a number of the most 
common antibody mimetics.   
1.5.1 Single chain variable fragments 
As previously stated, antibodies are composed of a heavy and light chain separated into 
modules known as immunoglobulin domains. Single chain variable fragments (scFv) are 
antibody mimetics made up of the variable regions of the light (VL) and heavy chains (VH) 
linked with one another by either a disulphide bridge or a flexible linker peptide which 
stabilizes them (Glockshuber, Malia et al. 1990, Jung, Pastan et al. 1994). The length of this 
linker is important; a linker above 3.5 nm ensures that the scFv will fold correctly. A linker that 
is shorter than this is used to produce diabodies, in which the variable regions dimerize 
(Holliger, Prospero et al. 1993). Stretches of glycine and serine are often employed in order to 
maximise the linker’s flexibility. Similarly, it is important that the linker is hydrophilic in order 
to avoid intercalation with the variable domains. Therefore, they are often designed with a 
large number of lysine and glutamic acid residues thereby maximising the proteins solubility. 
scFvs are therefore able to maintain the specificity of fully formed antibodies while being 
easier to produce as they can be produced within bacteria such as E. coli (Ahmad, Yeap et al. 
2012).  
Typically, the construction of scFVs utilises the VH and VL produced by hybridomas, the spleen 
cells from immunised mice or from human B lymphocytes. Their construction involves the 
isolation of the VH and VL mRNA and its subsequent conversion to cDNA via reverse 
transcription. This cDNA is then used as a template for PCR amplification, thus resulting in a 
library of VH and VL genes, which can then be randomly combined via PCR assembly and 
expressed in, for instance, phagemids in order to perform subsequent binding analysis via 
phage display or other display techniques are described above (McCafferty, Griffiths et al. 
1990, Marks, Hoogenboom et al. 1991). Alternatively, naïve scFvs can be formed by isolating 
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the variable region mRNA of non-immunised animals and subjecting the subsequent cDNA to 
error prone PCR in the VH and VL CDR regions (Silacci, Brack et al. 2005).  
Several applications of scFVs have been demonstrated and of particular interest are their 
potential as cancer therapies. For example, cytotoxic effects could be engineering by using a 
scFV capable of binding the interleukin receptor CD123, a common marker of acute myeloid 
leukaemia. By conjugating the scFVs with a truncated form of the immunotoxin Pseudomonas 
exotoxin-A, targeted cell death was observed (Stein, Kellner et al. 2010). To this end, scFVs 
have also played an important role in the development of immunocytokines. These are a class 
of promising therapeutic agents, which fuse antibodies or antibody mimetics with immune 
mediators such as interleukins, resulting in the selective removal of targets by the hosts own 
immune system. Immunocytokines can be classified in two distinct groups; firstly the large 
fusion proteins in which cytokines are fused to the entire heavy chain of an antibody. 
Secondly, the small fusion proteins in which cytokines are fused to antibody fragments such as 
scFvs or diabodies. While the large immunocytokines have a longer half-life in blood, the 
increased concentration of cytokines can result in dangerous side effects which can be avoided 
by the use of the small fusion immunocytokines. A fusion of IL-15 and a human antibody scFv 
specific for an angiogenesis marker which is upregulated in solid tumours (EBD domain of 
fibronectin) showed potent anti-cancer activity when tested in mice (Kaspar, Trachsel et al. 
2007, List and Neri 2013).  
1.5.2 Nanobodies 
Nanobodies are another class of antibody fragments which are significantly smaller than full 
length antibodies. They are composed of a single variable immunoglobulin domain and exhibit 
a significant increase in thermostability, as well as an increased resistance to denaturants 
compared to full length antibodies and scFvs. Nanobodies are typically derived from camelids 
due to their atypical immunoglobulins which do not have light chains. Instead, camelid 
immunoglobulins are produced as heavy chain homodimers (VHH) and have the smallest 
antigen binding site of all natural antibodies (Goldman, Anderson et al. 2006, Fridy, Li et al. 
2014).  
The isolation and selection of nanobodies capable of binding a single target is similar to that 
off scFVs, in that it relies on phage display (or other display techniques). Generally, in order to 
produce nanobodies, camelids (typically a llama) are first immunised and the variable gene 
repertoire from the resultant blood lymphocytes are sub cloned into phagemids. Alternatively, 
if a naïve library of nanobodies is required, the variable gene regions of non-immunized 
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camelids can be isolated, subjected to reverse transcription and sub-cloned into phagemid 
vectors. In order to maximise the number of clones within the library, the genes are subjected 
to hypermutation (using error prone PCR within the CDR region) in order to account for the 
diversity which is usually introduced by exposure to an antigen in a similar fashion as is 
performed to produce naïve scFv libraries (Goldman, Anderson et al. 2006, Monegal, Ami et al. 
2009).  
Nanobodies have been demonstrated to be proficient candidates for many applications, 
mainly due to their high specificity and stability. Their small size means that they are more 
susceptible to renal clearance than either scFvs or whole antibodies, but it also increases their 
tissue permeability. Nanobodies against GFP conjugated with fluorophores have been 
described which allow single molecule localisation experiments to be carried out on GFP 
tagged proteins (Ries, Kaplan et al. 2012). As potential therapeutic agents, nanobodies have 
been demonstrated to exhibit a high neutralisation activity in the presence of bacterial toxins 
and snake venom. Similarly, bispecific nanobodies (two nanobodies capable of binding two 
different epitopes bound to one another with a peptide linker) have been engineered which 
provided a high degree of protection to mice treated with lethal doses of Androctonus 
australis hector scorpion venom (Aah venom) compared with the commonly used polyclonal 
antibody based anti-venom. Bispecific nanobodies were of particular use, as the Aah venom is 
composed of three different small basic toxins the pharmacokinetics of which have shown that 
they can rapidly spread throughout the body compared to its anti-venom. Thus bispecific 
nanobodies capable of targeting the two most toxic elements the venom were desirable. 
Previous attempts to neutralise this venom used scFvs derived from mouse hybridomas, 
however their therapeutic use opens the possibility of anti-mouse antibodies limiting their 
efficacy. Nanobodies are able to avoid this shortcoming due to the similarity between camelid 
and human antibody variable regions and their small size suggests that their pharmacokinetics 
should be similar to the venom (Hmila, Saerens et al. 2010).  They have also shown some 
promise in the treatment of inflammation and due to their rapid clearance from blood they 
have some potential as in vivo imaging tools (Muyldermans 2013).          
1.5.3 Designed ankyrin repeat proteins and antibody fragments  
Designed Ankyrin Repeat Proteins (DARPins) are small binding proteins which benefit from 
lower production costs (as they can be produced in bacteria) and increased robustness (they 
can be used in chemically harsh environments) when compared to full length antibodies. Their 
structure is based upon the widespread ankyrin repeat, a 30-34 residue protein motif arranged 
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in two antiparallel alpha helices, separated by an outward projecting loop. It facilitates many 
protein-protein interactions (Li, Mahajan et al. 2006) and occurs as several tandem repeats 
which bundle with one another in a similar fashion as a β-hairpin sheet within proteins. 
Typically, proteins contain 4 – 6 ankyrin repeats which form a grooved, solenoid structure with 
a hydrophobic core (Pluckthun 2015).     
One of the main benefits of DARPins is their high degree of stability which is a result of several 
different factors. The most important being the coupling between the internal repeats, which 
arises due to a combination of electrostatic interactions and hydrophobic shielding 
(Tamaskovic, Simon et al. 2012). DARPins can contain any number of ankyrin repeats, it has 
been shown that the more repeats present, the more stable the DARPin is. Once a DARPin has 
a minimum of three internal repeats, there is a marked increase in its thermal stability as well 
as its resistance to denaturants. These internal repeats are flanked by an essential C- and N-
terminal cap which ensure proper folding and prevent aggregation of the DARPin in bacterial 
cells (see Figure 1.5). The C-terminal cap also plays a role in DARPins high degree of stability 
due to its close packing with the internal repeats, which is a consequence of their sequence 
similarity. This stability and robustness allow them to withstand conditions which would be 
considered too harsh for antibodies - such as in the presence of a reducing agent (antibodies 
are held together by disulphide bonds) or a detergent. Their complete denaturation requires 
incubation at high temperature in 5 M guanidine hydrochloride. The diversity of DARPin 
libraries comes from the randomization of residues located within a single repeat. Depending 
on the number of repeats within a DARPin it may become grooved (like ankyrin bundles) 
therefore complementing folded proteins and increasing the likelihood of correct binding 
(Gronwall and Stahl 2009, Milovnik, Ferrari et al. 2009, Boersma and Pluckthun 2011, 
Tamaskovic, Simon et al. 2012). The DARPin library under test is composed of three internal 
repeats capped with an N and C-terminal cap and 21 randomised residues in the loop regions 
(see Figure 1.5).         
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Figure 1.5:  The 3D structure of a DARPin: The model depicts three internal ankyrin repeat units flanked by an N-
terminal cap in green and a C-terminal cap in cyan. Randomised residue side chain are highlighted in red. The 3D 
structure has been placed over a generalised sequence of the DARPins used in this study which has been colour 
coded according to the structure. Each of the DARPins have three internal repeats and 21 randomised residues. 
Picture taken from the Chapter five “Designed Ankyrin Repeat Proteins (DARPins): From Research to Therapy” of 
the book “Methods in Enzymology” (Tamaskovic, Simon et al. 2012) 
DARPins have shown promise in several different aspects of therapeutics in recent years. For 
example, a DARPin with pico-molar affinity to the human epidermal growth receptor 2 (HER2) 
was able to detect elevated levels of the receptor in complex tissue with a specificity that 
surpassed a pre-existing therapeutic antibody, while showing a very similar level of sensitivity 
(Theurillat, Dreier et al. 2010). Thus highlighting its potential as either a powerful diagnostic 
tool or a therapeutic in patients with breast cancer, as elevated levels of HER2 occurs in 20 – 
30% of cases. The specificity of DARPins also made them suitable components as biological 
recognition elements in biosensors. For instance, the DARPins were shown to be capable of 
differentiating between non-phosphorylated and phosphorylated extracellular signal-regulated 
kinase (ERK), thus allowing the protein activation to be monitored in mouse embryo fibroblasts 
when the DARPins were conjugated with a thiol-reactive merocyanine dye (Kummer, Hsu et al. 
2013, Pluckthun 2015). 
1.5.4 Adhirons 
Adhirons are a novel class of antibody mimetic based upon a scaffold derived from a cysteine 
protease inhibitor in plants called phytocystatin. This inhibitor is a member of the cystatin 
family, all of which are identified by a highly conserved fold, comprised of a central α-helix 
with four anti-parallel β-sheets wrapped around it (see Figure 1.6). In order to construct 
adhirons, the N-terminal of the scaffold is truncated and its two inhibitory loops (one of which 
contains a QXVXG active site) are altered with a random sequence of nine residues. This 
insertion gives rise to two variable regions in the loops located between the β-sheets. Like 
DARPins, adhirons exhibit a vastly superior degree of thermostability compared to full length 
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antibodies with melting temperatures of 101°C and high level of expression in E. coli (Tiede, 
Tang et al. 2014).    
 
Figure 1.6: The X-ray crystal structure of an adhiron:  The structure is at a resolution of 1.75 Å and depicts a 
truncated adhiron, from residue 11 – 89. The positions of the randomised amino acid residue insertions are 
marked in black. Original image was taken from the paper “Adhiron: a stable and versatile peptide display 
scaffold for molecular recognition applications” (Tiede, Tang et al. 2014). 
  
Phytocystatin is a very important protein in plants and has been shown to play roles in plant 
defence against proteases released by pathogens as well as environmental stress such as 
drought. It also plays a role in the regulation of proteases during seed maturation and is 
involved in programmed cell death (Chan, Abu Bakar et al. 2014). Its small size, stability and 
natural lack of either cysteines or glycosylation sites, make it ideal for the development of a 
protein library capable of binding targets of interest. 
Adhirons have been shown to bind several different targets specifically, such as a chemically 
biotinylated yeast small ubiquitin-like modifier (SUMO) protein with low nanomolar affinity. 
They have also been shown to bind magnetite nanoparticles with high affinity in the presence 
of casein (Rawlings, Bramble et al. 2015).    
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1.6 Project Aim 
As this chapter has discussed, detergent solubilisation is the most common method of 
membrane protein solubilisation, however the effect that detergent micelles have on in vitro 
selection experiments with antibody mimetics is poorly understood.  Therefore this study, 
aims to compare the potential of different methods of membrane protein immobilisation and 
solubilisation with regard to their ability to select an antibody mimetics using a panel of 
membrane proteins. The methods of membrane protein immobilisation under test were (a) 
the cloning of a streptavidin binding protein (SBP) tag into the C-terminal of a model 
membrane protein, for binding to a streptavidin coated surface (a staple of the pharmaceutical 
industry); (b) the cloning of a C-terminal avitag which can undergo enzyme-catalysed 
biotinylation of its lysine residue and subsequently bind to streptavidin via this biotin moiety; 
(c) the introduction of an accessible cysteine residue by mutagenesis into the C-terminus of 
the model membrane protein, enabling chemical biotinylation with the reagent biotin 
maleimide; and (d) aspecific biotinylation of a model membrane protein by the biotinylation 
reagent NHS-biotin.  
The methods of solubilisation under test included typical detergent solubilisation with DDM 
compared with detergent free methods of solubilisation such as (a) the encapsulation of 
purified membrane protein in nanodiscs; and (b) the use of the co-polymer SMA on bacterial 
membranes in order to purify membrane proteins in styrene-maleic acid lipid particles 
(SMALPs).  
The panel of membrane proteins discussed in section 1.3 were used as models in this study 
and were subjected to two rounds of phage display on a streptavidin coated surface, using a 
naïve library of DARPins. DARPins which successfully bound to the targets were further 
characterised via phage ELISA with the hope that they may be used in future co-crystallisation 
trails. In a typical phage display experiment a minimum of 3 rounds would be used and the 
cross-reactivity of the proteins which successfully bound the target would be tested, however 
this was not possible due to time constraints.  
Ultimately this study aimed to determine which method of membrane protein immobilisation 
and solubilisation is the best in regard to their ability to isolate DARPin binders using phage 
display.   
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Chapter 2  
 
Materials and Methods 
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2.1 Materials and Suppliers 
All solutions (including growth media) where made using ultrapure water, which had been 
purified and deionized with a resistivity of 18.2 MΩ cm in a Milli-Q Plus system manufactured 
by Millipore Corporation. Where appropriate, buffers were sterilised either by autoclaving at 
121°C or by filtering through a 0.22µM filter.  Suppliers from which each chemical was 
purchased have been outlined in Appendix 1  
2.2 Bacterial strains, Growth and Expression Media 
2.2.1 Bacterial strain genotypes 
E.coli strains served several functions including plasmid amplification and manipulation, 
protein expression and phage amplification. The genotypes of each strain used are listed 
below: 
Omnimax™2 - F- [proAB+ lacIq lacZΔM15 Tn10(TetR) Δ(ccdAB)] mcrA Δ(mrr-hsdRMS-mcrBC) 
φ80(lacZ)ΔM15, Δ(lacZYA-argF) U169, endA1, recA1, supE44 thi-1, gyrA96, relA1, tonA, panD 
BL21 star™ - F- ompT, hsdSB (rB-, mB-) gal dcm rne131 (DE3) 
BL21™ - F– ompT gal dcm lon hsdSB(rB- mB-) λ(DE3)  
AVB101 (Avanti) -  
TG1 - F' [traD36 proAB+ lacIq lacZΔM15]supE thi-1 Δ(lac-proAB) Δ(mcrB-hsdSM)5, (rK-mK-) 
 
2.2.2 Growth media 
 
Bacteria were routinely grown in either LB (1% Tryptone, 1% NaCl, 0.5% w/v yeast extract) 
or2xTY (1.6% Tryptone, 0.5% NaCl, 1% w/v yeast extract) media. They were adjusted to pH7 
with NaOH prior to their sterilisation by autoclaving. LB agar was prepared by adding 1.5 g agar 
powder per 100 mL LB media prior to sterilisation.   
LB agar plates were then prepared by melting pre-prepared stock LB agar in a microwave. 20 
mL of the molten agar was then poured into a falcon tube and (once it had sufficiently cooled) 
1/1000th of the required antibiotic was added (i.e. 20 µL). The agar was then poured into a 
petri dish and allowed to set for 30 mins. 
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2.2.3 Buffers and Media for expression via auto-induction 
Expression of recombinant proteins via auto-induction was typically carried out in SB media 
(3.2 % Tryptone, 2% w/v yeast extract) supplemented with 1x auto-induction phosphate buffer 
(25 mM Na2HPO4, 25 mM, KH2PO4, 5 mM Na2SO4, 50 mM NH4Cl) adjusted to pH 6.7, 1 mM 
MgSO4, 1x 5052 (0.01% glycerol, 0.001% glucose, 0.04% α-lactose). Each constituent was 
sterilised by autoclave with the exception of the 5052 which was sterilised by filtration through 
a 0.22 µm filter. In order to avoid precipitation the MgSO4 was added before the phosphate 
buffer. Once complete the media was immediately inoculated with bacterial culture and 
antibiotic was added at 1/1000th the total volume of media.       
 
2.2.4 Media for expression via Isopropyl β-D-1-thiogalactopyranoside 
(IPTG) induction 
Expression of protein via IPTG used autoclaved 2YT media (1.6% Tryptone, 1% yeast 0.5% w/v 
NaCl) with antibiotic added. IPTG was added to a final concentration of 0.6 mM after E.coli pre-
cultures had reached the desired OD600nm.    
2.3 Recombinant DNA techniques 
2.3.1 Amplification of plasmid DNA via the Polymerase Chain Reaction 
(PCR) 
PCR was performed using KOD hot start polymerase from Novagen. This amplification usually 
had a final volume of 50µL and uses a maximum of 50ng of template DNA. A typical reaction 
was set up as follows: 
  5 µL 10 x KOD hot start buffer (Final concentration of 1x)  
  1 µL Forward Primer (100 µM) (Final concentration 2 µM) 
  1 µL Reverse Primer (100 µM) (Final Concentration 2 µM) 
  3 µL 25 mM MgSO4 (Final concentration 1.5 mM) 
  5 µL 2 mM dNTPs (Final concentration 0.2 mM) 
  1 µL Template DNA (~ 50 ng/µL) (Final quantity 50 ng) 
1 µL KOD hot start polymerase, 1U/µL (Final concentration 0.02 U/µL) 
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33 µL ultrapure, deionized water  
Once mixed, the PCR samples were loaded into a DNA engine Dyad™ peltier thermal cycler 
from MJ research and subjected to the following thermal cycles: 
  94 ˚C, 3 minutes 
94 ˚C, 30 seconds 
50 ˚C, 30 seconds 32 cycles 
72 ˚C, 105 seconds 
72 ˚C, 5 minutes 
10 ˚C, hold 
 
In order to assess the success of the PCR, DNA samples were then analysed electrophoretically 
on an agarose gel (see section 2.3.4).  
2.3.3 Restriction digestion of plasmid DNA 
Typically a restriction digestion included 5 – 10 µg of DNA mixed with 2 µL of the appropriate 
10x restriction digest buffer (NEB 1 – 4), 1 µL of the desired restriction enzyme (purchased 
from New England Biolabs) and ultrapure deionized water to a final volume of 20 µL. The 
restriction digestion was then incubated at 37°C for a minimum of 3h. 
In the case of PCR products quick digest enzymes (from Thermo scientific) were utilized. During 
these restriction digests the final volume of the solution was typically 100 µL and involved 
mixing the entire 50 µL DNA fragment, recovered using the Promega Wizard SV® Gel and PCR 
clean up system (see section 2.3.9), with 10 µL of 10x green fast digest buffer, 2 µL of the 
desired fast digest enzyme and ultrapure deionized water up to 100 µL. The fast digest 
reactions were then incubated for a minimum of 1h at 37°C. The resultant DNA fragments 
were then analysed via electrophoresis on an agarose gel (see section 2.3.4).           
2.3.4 Separation of DNA fragments via electrophoresis on an agarose 
gel 
All agarose gels were performed in the Embi Tec RunOne™ electrophoresis cell using tris acetic 
acid EDTA (TAE) buffer diluted to 1x from a 50x stock, a litre of which was made with: 
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 242g Tris 
 2.92g EDTA 
 57.1 mL acetic acid 
 Up to 1L ultrapure H2O 
In order to make the agarose gels, 1 – 2% (w/v) agarose was added to 30 mL TAE buffer in a 
250 mL conical flask. Due to the insoluble nature of agarose at room temperature, the mixture 
needed to be heated in a microwave for approximately 1.5 minutes. Once all agarose had 
dissolved the flask was cooled under cold water before 2 µL SYBR® safe DNA gel stain was 
added and mixed by swirling. The agarose mixture was then poured into a gel cassette with an 
attached comb and allowed to set for 20 minutes.  
DNA samples were mixed with 6x MassRuler™ DNA loading dye and loaded into the gel 
alongside 5 µL Fermentas MassRuler™ DNA ladder mix and run at 100V for approximately 35 
minutes. The gel was then quickly visualised using the Invitrogen Safe Imager™ and the size of 
DNA confirmed by comparison with the ladder. The quantity of DNA was confirmed by slicing 
the desired DNA fragment from the gel, purifying it using the Promega Wizard SV® Gel and PCR 
clean up system (see section 2.3.9) and spectrophotometrically analysing the fragment with a 
microspectrophotometer.                  
2.3.5 Dephosphorylation of DNA fragments 
In order to prevent DNA from self-ligating, phosphate groups were removed from their 5’ end. 
This process required the use of the Antarctic phosphatase enzyme from New England Biolabs. 
Typically a dephosphorylation reaction consisted of adding 6 µL 10x Antarctic phosphatase 
buffer (diluted down to 1 x) was added to the entire 50 µL DNA sample followed by 3 µL of 
dH2O and  1 µL (5 units) Antarctic phosphatase enzyme prior to incubation for 1 hour at 37°C. 
The phosphatase enzyme was then heat inactivated by incubation at 65°C for 5 mins. The 
newly dephosphorylated DNA could then be used in subsequent ligations (see section 2.3.6).             
2.3.6 Ligation of DNA fragments 
A typical ligation reaction had a maximum of 10 ng of restriction vector DNA (the 
concentration of which was determined via micro-spectrophotometer either the ND-1000 
Nanodrop from Thermo Scientific or the DS-11 from DeNovix) mixed with enough restriction 
insert DNA (dephosphorylated if compatible restriction enzymes were used) to have a molar 
ratio of 1:4, 1:10 or 1:15 (vector: insert). Ligations were typically performed in a total volume 
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of 10 – 20 µL in the presence of 1x T4 DNA ligase buffer and 1 µL T4 DNA ligase (Invitrogen 1 
U/µL). The ligations were then incubated for a minimum of 16 hours at 16°C. 
In the case of quick ligase (New England Biolabs), the ligation reaction typically had a final 
volume of 20µL and the vector and insert were mixed with 10 µl 2x quick ligation buffer 
followed by 1 µL quick T4 ligase. The ligation was then incubated at 20°C for 30 minutes. Once 
the ligation was complete the resultant DNA was used to transform Omnimax cells (see 
section 2.3.8).         
2.3.7 Preparation of competent bacterial cells 
The production of competent cells used two buffers designated transformation buffer 1 (Tfb1- 
3 mM, potassium acetate, 100 mM RbCl2, 10 mM CaCl2, 50 mM MnCl2, 15% glycerol) and 
transformation buffer 2 (Tfb2 – 10 mM MOPs, 75 mM RbCl2, 10 mM CaCl2, 15% glycerol. The 
pH of Tbf1 was adjusted to 5.8 using 0.2 M acetic acid prior to filter sterilisation using a 0.2 µm 
filter. Tbf2 was adjusted to 6.5 with KOH prior to filter sterilisation with a 0.2 µm filter. Tbf1 
was stored in 20 mL aliquots while Tbf2 was stored in 5 ml aliquots, both buffers were stored 
at 4°C 
Bacterial host cells were made chemically competent with a rubidium chloride based 
procedure. Firstly glycerol stocks of the required cells were streaked aseptically onto a LB-agar 
plate (see section 2.2.2) and grown overnight at 37°C in a stationary incubator. A single colony 
from the plate was then used to inoculate 5 mL of LB media (see Table 2.1) and grown 
overnight at 37°C in an orbital shaker at 200 rpm (1 g). Depending on the strain used the agar 
plate and media were sometimes supplemented with an appropriate antibiotic. 100 µL of the 
pre-culture was then used to inoculate 50 mL of pre-warmed LB media in a 250 mL conical 
flask (with antibiotic if required) and incubated at 37°C with shaking at 200 rpm until an 
OD600nm of 0.4 – 0.6 was attained. The culture was then transferred to a 50 mL falcon tube and 
left on ice for 5 minutes, followed by centrifugation for 10 minutes at 3000 rpm and the 
removal of the supernatant. The cell pellet was gently resuspended in 20 mL of ice cold Tbf1 
buffer (see Table 2.8) so as not to damage the cells a 5 mL pipette was used instead of 
vortexing. Once resuspended the cells were stored on ice for 5 minutes, before being once 
again subjected to centrifugation for 10 minutes at 3000 rpm. Once the supernatant was 
discarded for the second time the cells were once again resuspended gently in 2 mL Tbf2 
buffer (see Table 2.9) and stored on ice for 15 minutes. 50 µL aliquots of the cells were then 
transformed to pre-cooled Eppendorf tubes (which had been sterilised by auto-clave) and snap 
frozen in liquid nitrogen and stored at -80°C.                        
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2.3.8 Transformation of competent bacterial host cells 
In order to transform bacterial host cells, 1 µL of DNA was mixed with 10 µL of competent cells 
freshly thawed on ice. The cells were then incubated for 30 minutes at 4°C before being 
subjected to heat shock at 42°C for 30 seconds and returned to 4°C for an additional 2 
minutes.  100 µL of LB media was then added to the cells before incubating them for 1 hour at 
37°C.  
Once the 1 hour incubation was complete the entire bacterial culture was spread on an LB agar 
plate supplemented with the required antibiotic and incubated overnight at 37°C.  
Resultant colonies were then either picked and grown in 5 mL LB media for plasmid 
purification (see section 2.3.8); or grown in 50 mL pre-cultures for protein expression (see 
section 2.4.1) overnight at 37°C with shaking (200rpm).    
2.3.9 Purification of plasmid DNA 
The desired plasmids were purified from the 5 mL cultures described above using the Promega 
Wizard® SV miniprep kit. The concentration of the isolated plasmids was determined via micro-
spectrophotometer prior to characterisation by either restriction analysis or sequencing.    
2.3.10 Site directed mutagenesis of plasmid DNA 
Site directed mutagenesis was performed using the QUICKCHANGE® procedure from 
Strategene. A typical reaction had a final volume of 100 µL and was set up as follows:  
 10 µL of 10× KOD buffer – Final concentration 1x 
 50-100 ng of template DNA  
 3 µL  Forward primer (10µM)- Final concentration 0.3 µM 
 3 µL Reverse primer (10µM) – Final concentration 0.3 µM 
 10 µL of dNTP mix (2mM) – Final concentration 0.2 mM 
 6 µL MgSO4 (25 mM) – Final concentration 1.5 mM 
 Ultrapure water up to 99 µL 
 1µL of KOD polymerase (1 U/µL) – Final Concentration 0.02 U/µL  
 
The reaction was separated into 5x 20 µL aliquots in 0.2 mL PCR tubes, placed into the DNA 
engine Dyad™ peltier thermal cycler set to provide a temperature gradient between 50 - 70°C 
within a single block. In order to find the optimal temperature for the site-directed 
mutagenesis a temperature screen was established by incubating one of the five 20 µL 
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mutagenesis aliquots at a single 5°C incremental temperature within the aforementioned 
gradient: 
 
95 °C 4 min 
94 °C 30 s 
Gradient from 50 → 70 °C 30 s       30 cycles 
72 °C 6 min 
72 °C 10 min 
4 °C continuous 
In order to remove the template DNA a DpnI restriction digestion was used as it only the 
enzyme is only able to digest methylated DNA. Therefore 5 µL of each reaction was analysed 
electrophoretically while the remaining 15 µL was mixed with 2µL 10x NEB restriction buffer 4, 
2 µL ultrapure water and 1 µL DpnI from New England Biolabs once the cycles were complete. 
The restriction digest was then incubated for a minimum of 3 hours at 37°C and used to 
transform competent ‘Omnimax™2’ cells selected by the appropriate antibiotics. The 
mutagenized plasmids were then purified as discussed in section 2.3.8.   
2.3.11 DNA sequencing 
Sequencing was performed by the Source Bioscience DNA sequencing service. The reaction 
required a minimum of 15 µL of 100 ng/µL template DNA and 15 µL of 3.2 pmol/µL sequencing 
primer. Typically one of the following primers were used: 
 pTACF: TTGACAATTAATCATCGGC 
 pTACR: CGCCAGCTGGCGAAAGGGG   
 pC6F: CAGCTATGACCATGATTACG 
 pC6R: GAATTTTCTGTATGAGTTTTG 
 T7Fwd: TAATACGACTCACTATAGGG    
 57 
2.4 General protein techniques 
2.4.1 Expression of proteins in a bacterial host strain via auto-
induction 
To perform an auto-induction the 50 mL bacterial cultures described in section 2.3.8 were 
used as a pre-culture for large scale protein expression. 3 - 4L of SB-5052 was prepared (see 
table 2.6) and separated into 500 mL aliquots in 2 L baffled conical flasks. These aliquots were 
then inoculated with enough pre-culture to have a starting OD600nm of 0.1. To determine the 
volume of pre-culture a 1/10 dilution was made in LB media and the OD600nm measured 
spectrophotometrically. The inoculated 500 mL culture was then incubated for a minimum of 
20 hours at 37°C with shaking (200 rpm / 1 g). The cells were harvested via centrifugation at 
2634 g for 30 minutes and the pelleted cell paste was transferred to falcon tubes. Before 
storage at -80°C their weight was determined.  
2.4.2 Expression of proteins in a bacterial host strain via IPTG 
IPTG inductions were performed in a similar manner as described in section 2.4.1, except that 
after inoculation of either LB or 2x TY (typically 3 – 4L in 500 mL aliquots, the OD600nm  was 
continually monitored until it reached  between 0.6 and 0.8. At this point IPTG was added to a 
final concentration of 1 mM and the culture was incubated at 37°C with shaking (200 rpm/ 1 g) 
for a minimum of 4 hours. The cells were then pelleted, weighed and stored as described in 
section 2.4.1.   
2.4.3 Disruption of bacterial cells and isolation of membrane extract  
In order to disrupt bacterial cells harvested from induction experiments, the pellets were first 
resuspended in a volume of buffer (20 mM Tris, 0.5 mM EDTA, pH 7.4) five to six times the 
weight of the harvested cells. Once resuspended the cells were homogenized firstly with a 
hand held homogenizer, followed by the use of the Ultra-Turrax®. Once the cell solution was 
completely homogenous it was subjected to two runs through a TS5/40/AB/GA cell disrupter 
(from Constant Systems) at 30 Kpsi in order to break the bacterial cells. Once complete the 
disrupter and Ultra-Turrax® were cleaned with Teepol™.     
 
The lysed cells were then centrifuged at 14,000 gav for 45 minutes in order to remove 
unbroken cells and cellular debris. The supernatant was then ultracentrifuged at 131,000 gav 
for 2 hours to isolate the bacterial membranes. Trace amounts of EDTA were removed from 
the membrane pellets by resuspending them in a 20 mM Tris buffer (pH 7.4) prior to 
ultracentrifugation at 131,000 gav this wash was repeated twice. The membrane pellet was 
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then finally resuspended in a minimum of 2 mL 20 mM Tris (pH 7.4) and snap frozen in liquid 
nitrogen as beads. The beads were produced by syringing droplets of resuspended membrane 
directly into liquid nitrogen. The concentration of the protein in the membrane extracts was 
determined with a BCA assay (section 2.4.9.1) and typically would result with concentrations 
between 20 – 50 mg/mL.         
2.4.4 Chemical Biotinylation of proteins 
The following biotinylation reagents were used: 
 EZ-Link® NHS-Biotin (Thermo scientific) 
 EZ-Link® NHS-SS-Biotin (Thermo scientific) 
 EZ-Link® Maleimide-PEG11-Biotin (Thermo scientific)  
The procedure for protein biotinylation followed the manufacturer’s instructions and was 
identical for all the biotinylation reagents used. Once a molar excess of biotin reagent to 
protein had been selected (typically 2.5 – 5 times), the amount of reagent was calculated 
following the equations set out in the manufacturers instruction. 
The biotinylation reagents were equilibrated to room temperature before a 10 mM stock 
solution (250 mM for biotin maleimide) was prepared in an appropriate volume in dimethyl 
sulfoxide (DMSO) immediately before use. For biotinylation with the maleimide reagent, 
proteins were first incubated for 30 minutes in 5 mM tris(2-carboxyethyl)phosphine (TCEP) at 
room temperature in order to reduce any cysteine residues. TCEP was then removed either by 
desalting column or dialysis (section 2.5.1.1).  
An appropriate volume of biotinylation reagent (based on the earlier calculations) was then 
added to the protein and the protein solution was incubated for a minimum of 2 hours on ice 
(in the case of NHS-biotin and NHS-SS-Biotin more stable proteins such as the DARPins were 
incubated at room temperature for 30 mins). Excess or unreacted biotinylation reagent was 
then removed either by desalting column or by dialysis (section 2.5.1.1). 
The labelling efficiency of biotin maleimide was tested using 4'-hydroxyazobenzene-2-
carboxylic acid (HABA). Due to HABA’s natural affinity for avidin, it can be used as a reporter 
molecule for biotin labelling efficiency. The presence of biotin will displace the HABA causing 
its adsorption at 500nm to decrease proportionally. To this end, a 10 mM stock solution of 
HABA was prepared by dissolving 24.2 mg in ultrapure water followed by 100 µL NaOH. This 
solution was then filtered through a 0.22 µm filter and stored at 4°C. In order to prepare the 
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HABA avidin solution 10 mg of avidin was added to 600 µL of the aforementioned HABA stock 
and 19.4 mL of PBS was added prior to storage at 4°C.  
In order to test the labelling efficiency, the A500nm of 900 µL of HABA/avidin was measured in a 
spectrophotometer and recorded. 100 µL of biotinylated protein was then added and mixed 
well before the A500nm was measured once every 15 seconds until it remained constant 
(samples with A500nm over 0.3 were diluted). The two absorbance readings were then used to 
calculate the number of biotin molecules per protein, in a series of calculations based upon the 
Beer Lambert law: A = ε x bC (where A is the absorbance, ε is the molar extinction coefficient – 
67443 cm-1M-1 for MPSIL0294, b is the cell path length and C is the concentration in M) 
(https://tools.lifetechnologies.com/content/sfs/manuals/MAN0011200_HABA_UG.pdf).                     
  
2.4.5 Separation of proteins electrophoretically via sodium dodecyl 
sulphate polyacrylamide electrophoresis (SDS-PAGE) 
SDS-PAGEs were run using the Bio-rad protean 2 system; typically with 12% (w/v) SDS-PAGE 
separating gels made with 3.3 mL ultrapure water mixed with 4 mL acrylamide/Bis-acrylamide 
(30% w/v solution), 2.5 mL separating buffer (1.4M Tris-HCl, pH 8.8), 100 µL 10% (w/v) SDS, 
100 µL 10% (w/v) freshly prepared ammonium persulphate and 5 µL 
tramethylethylenediamine (TEMED). Once mixed, the separating gel was then left for 30 
minutes at room temperature to polymerise within the gel apparatus. The stacking gel, 
composed of 3.025 mL ultrapure water, 625 µL acrylamide/bis-acrylamide (30% w/v), 2.5 mL 
stacking buffer (0.5M Tris-HCl, pH 6.8), 100 µL 10% (w/v) SDS, 100 µL 10% (w/v) ammonium 
persulphate and 5 µL TEMED was then made and overlaid atop the separating gel and left for 
30 minutes to set with an appropriate comb. 
SDS-PAGE protein samples were prepared by adding loading buffer (0.5M Tris-HCl, 10% w/v 
SDS, 10 mM EDTA, 5.4M glycerol, 10 mg/mL pryonin Y). The pH of the loading buffer was 
adjusted to 6.8 using 1M NaOH and stored at -20°C in 1 ml aliquots. For a 20 µL sample, 4 µL of 
loading buffer was added and 1 µL of DTT, for the SDS-PAGE of membrane proteins the sample 
were left at room temperature for a minimum of 20 minutes before loading. For globular 
proteins, the samples were incubated at 95°C for 15 minutes using the DNA engine Dyad™ 
peltier thermal cycler. The gels were then submerged in either 1x running buffer (19 mM 
glycine, 2.5 mM Tris, 0.01% w/v SDS) or 1x MOPs running buffer (2.5 mM 3-(N-morpholino) 
propanesulfonic acid, 2.5 mM Tris, 0.005% SDS, 50 µM EDTA, pH 7.7). ) prior to sample loading 
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and run at a constant voltage of 90 V for 100 minutes until the dye front reached the bottom 
of the gel.  
Protein bands were visualised by Coomassie staining using four solutions the first of which was 
a fixing solution (10% acetic acid and 25% isopropanol) which aimed to denature and entrap 
proteins within the gel matrix. Gels were incubated in this solution for a minimum of 4 hours 
before they were transferred to staining solution 1 (10% acetic acid, 25% isopropanol and 
0.025% Coomassie). Once again the gels were incubated for a minimum of 3 hours before 
transfer to staining solution 2 (10% acetic acid, 10% isopropanol and 0.0025% Coomassie) for a 
minimum of 2 hours. Finally the gels were transferred to destaining buffer (10% acetic acid). 
This destain buffer was continuously replaced until all extraneous dye was removed. 
 
2.4.6 Electrophoretic transfer and detection of proteins on an 
nitrocellulose membrane via western blotting  
Six pieces of filter paper and a piece of nitrocellulose membrane were incubated in transfer 
buffer (25 mM Tris, 192 mM glycine, 20% v/v methanol) for a minimum of 1 hour. Once the 
SDS-PAGE gel had finished it was also incubated for a minimum of 30 minutes in the same 
buffer. Electrotransfer of protein samples was achieved using the TE77x semi-dry transfer unit 
(Hoefer Inc®) at a constant amplitude of 43 A for a minimum of 1 hour. The membrane was 
then blocked in 10 mL 3% BSA dissolved in TBST (50 mM Tris, 150 mM NaCl, 9, 2% w/v 
Tween®20) buffer for a minimum of 1 hour. After blocking the membranes, they were treated 
with the required antibody diluted to an appropriate dilution (as outlined in the 
manufacturer’s instructions) in the same buffer used to block the membrane for 1 hour. After 
three 15 minute washes in 10 mL TBST buffer, the membrane was incubated in a freshly 
prepared equal volume mixture of  SuperSignal® West Pico (Pierce) Luminol/Enhancer Solution 
and Stable Peroxide Solution for precisely 1 minute. The chemiluminescent bands of the blot 
were then visualized using a G-box from SynGene. Quantification by densitometry was 
performed using ImageJ.      
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2.4.7 Protein quantification  
2.4.7.1 BCA assay 
The concentration of membranes and purified protein was determined via the bicinchoninic 
acid (BCA) assay with a range of 0 – 10 µg of BSA used to determine the standard curve. All 
samples (and standards) had a final volume of 10 µL and were done in duplicate in a 96-well 
plate. Once all samples had been loaded, BCA assay reagent A (Pierce)   was mixed with 4% 
CuSO4 in a ratio of 50:1 and 200 µL was added to each well of the plate. In order to facilitate 
the BCA/peptide bond reaction the plate was incubated at 37°C for a minimum of 30 minutes 
before its absorbance at 570 nm was analysed using a plate reader (ICN Biomedical Titertek).        
2.4.7.2 Spectrophotometric measurement  
Alternatively protein samples could be quantified by analysing it’s absorbance at 280 nm. This 
method relies on the ability of aromatic amino acids to absorb light at this wavelength and the 
protein concentration can be determined using the Beer-Lambert law (see 2.4.6). This method 
of quantification was used for several membrane proteins, namely AcrB (an extinction 
coefficient of 89855 cm-1M-1 was used), NupC (32890 cm-1M-1) and VcCNT (39545 cm-1M-1). 
DARPins (4470 cm-1M-1) were also quantified in this manner. Protein concentration was 
determined in this manner using either the Biowave II spectrophotometer (Biochrome WPA), 
the ND-1000 Nanodrop™ micro-spectrophotometer (Thermo scientific) or the DS-11+ 
spectrophotometer (DeNovix) 
2.5 Purification of proteins via Immobilized metal ion affinity 
chromatography 
2.5.1 Purification of MPSIL0294 variants 
2.5.1.1 Purification of MPSIL0294-SBP  
MPSIL0294-SBP was expressed using auto-induction with SB-5052 media (see Table 2.6) in 
BL21 star (DE3); the resultant membranes were isolated using a cell disruptor as discussed in 
section 2.4.3. MPSIL0294-SBPs subsequent purification typically involved taking less than 5 mL 
of membrane and solubilising them with 66.7 mL of solubilisation buffer (1.5% n-Dodecyl-β-D-
maltoside (DDM), 50 mM HEPES, 20% glycerol, 150 mM NaCl, 10 mM Imidazole and protease 
inhibitor cocktail (EDTA free), pH 8), resulting in a final protein concentration of approximately 
3 mg/mL. The membranes were then incubated at 4°C for 1 hour after a 100 µL sample was 
taken for later analysis. The solubilised membranes were then ultracentrifuged at 110,000gav 
 62 
for 1 hour, after which the insoluble pellet was resuspended in 1% SDS and a sample was taken 
for SDS-PAGE analysis. After a 100 µL samples was taken for further analysis, the supernatant 
was added to a BV of 1 mL of Hispur™ cobalt resin pre-equilibrated in wash buffer 1 (50 mM 
HEPES, 20% glycerol, 150 mM NaCl, 10 mM imidazole and 0.05% DDM, pH 8). The MPSIL0294 
was bound to the resin by incubating at 4°C for 2 hours on a roller. The resin was packed into a 
disposable filtered column (Thermo-Pierce) by allowing the buffer to flow through it. A sample 
of this buffer was then taken for later analysis. The packed resin was then washed twice, 
initially with 10BV (i.e. 10 mL) wash buffer 1, followed by 7.5 BV wash buffer 2 (50 mM HEPES, 
20% glycerol, 150 mM NaCl, 40 mM imidazole and 0.05% DDM pH 8); samples of each wash 
were taken for subsequent SDS-PAGE analysis in order to evaluate their effectiveness. 'Finally 
the protein was eluted from the resin in 1 mL fractions using elution buffer (50 mM HEPES, 5% 
glycerol, 150 mM NaCl, 200 mM imidazole and 0.05% DDM, pH 7.4). The amount of protein in 
each fraction was measured spectrophotometrically at 280 nm with the most proteinaceous 
fractions being pooled and subsequently dialyzed against dialysis buffer (50 mM MES, 5% 
glycerol, 150 mM NaCl and 0.05% DDM, pH6) with a minimum 333.3 fold excess in volume. In 
order to ensure a maximal amount of imidazole was removed a minimum of two rounds of 
dialysis was performed on MPSIL0294-SBP samples, after which the samples were 
concentrated in a Vivaspin® concentrator (Sartorius) with a 50 kDa molecular weight cut off. A 
10 µL sample of the concentrated protein was then analysed on a 12% SDS-PAGE gel and 
western blotting (see section 2.4.7 and 2.4.8) alongside all of the other samples taken 
throughout the purification. The remaining protein was snap frozen in liquid nitrogen and 
stored at -80°C.                
2.5.1.2 Purification of MPSIL0294-Avitag  
Purification of MPSIL0294-avitag was identical to MPSIL0294-SBP. To biotinylate this protein in 
vivo, the avitag construct was, however, expressed in AVB101 with 50 µM biotin added to the 
auto-induction media (see Table 2.6).  
2.5.1.3 Purification of MPSIL0294-V532C  
MPSIL0294-V532Cs expression was identical to MPSIL0294-SBP also; it was however, 
solubilised and purified with 0.5 mM TCEP in all buffers. The addition of TCEP was designed to 
prevent MPSIL0294-V532C forming disulphide bridges with arbitrary endogenous E.coli 
proteins with an accessible cysteine leading them to co-purify. The TCEP was also useful as it 
reduces the cysteine residues thereby making them suitable for labelling with biotin-
maleimide.          
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2.5.2 Purification of AcrB  
Membranes of AcrB were prepared by Dr. Pete Roach using a 30 L culture of C43 (DE3) 
produced in a fermenter. The AcrB gene was present in the plasmid pBPT0480-C0H which has 
been detailed previously (Glover, Postis et al. 2011).  In order to purify AcrB, typically less than 
5 mL of the membranes were diluted in 20 mL of ice cold 2x solubilisation buffer (2x PBS, 15 
mM imidazole, 20% glycerol and EDTA free protease inhibitor cocktail, pH 7.4) and ice cold 
ultrapure water to a final volume of 38.4 mL. The membrane solution was then homogenised 
before 1% DDM was added (1.6 mL of a 25% stock), thereby resulting in a final protein 
concentration of approximately 2.5 mg/mL. The solubilising membranes were incubated on a 
roller mixer at 4°C for 1 hour before a sample was taken for further analysis. To remove any 
insoluble material the solubilised membranes were then ultracentrifuged at 100,000 gav for 1 
hour and samples of the pellet and supernatant were taken. The supernatant was then added 
to a BV of 0.6 mL of Hispur™ cobalt resin pre-equilibrated in wash buffer 1 (1x PBS, 7.5 mM 
imidazole, 10% glycerol, 0.05% DDM, pH 7.4) and incubated for 2 hours at 4°C on a roller 
mixer. The bound resin was then centrifuged in an Eppendorf 5804R centrifuge at 700 gav for 5 
minutes and the supernatant was discarded (after a sample was taken). The resin pellet was 
then washed twice in 10BV (6 mL) wash buffer 1 via centrifugation at 700 gav for 5 minutes 
before resuspension in 3 mL of this same buffer and packing into a disposable column. The 
resin was then washed by gravity flow in 30BV (18 mL) wash buffer 1 followed by the same 
volume of wash buffer 2 (1x PBS, 20 mM imidazole, 10% glycerol, 0.05% DDM, pH 7.4). The 
wash buffers were discarded once samples were taken for further analysis. AcrB was then 
eluted in 1 mL fractions using elution buffer (1x PBS, 250 mM imidazole, 10% glycerol and 
0.05% DDM, pH 7.4) in an identical manner as MPSIL0294-SBP (see section 2.5.1.1). The peak 
fractions of AcrB were then pooled and extensively dialysed in 1x PBS supplemented with 10% 
glycerol and 0.05% DDM, before they were concentrated in a vivaspin protein concentrator 
with a 100 kDa molecular weight cut off and snap frozen in liquid nitrogen. All of the samples 
taken throughout the purification were then analysed via SDS-PAGE and western blotting.          
2.5.3 Purification of VcCNT  
Once again membranes of VcCNT were provided by David Sharples from a 30 L E.coli culture 
using the plasmid pET26-MPSIL0206-VcCNT. The plasmid is designed to place a pelB signal 
sequence followed by a 10x polyhistidine tag and a maltose binding protein at the N-terminal 
of VcCNT.  The protein and tags are separated by a HRV3C cleavage site. Purifying VcCNT was 
similar to AcrB in that less than 5 mL of membrane was diluted in 25 mL ice cold solubilisation 
buffer (100 mM Tris, 300 mM NaCl, 10 mM imidazole, 20% glycerol, pH 7.4) and made up to a 
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final volume of 47 mL in ice cold ultrapure water. The solution was then homogenised and 
1.5% DDM (3 mL from a 25% stock) was added, bringing the final concentration of 
solubilisation buffer to 1x and the protein concentration to approximately 2 mg/mL. The 
membrane solution was then incubated for 2 hours at 4°C on a roller mixer.  Once 
solubilisation was complete the insoluble fraction was isolated via ultracentrifugation at 
100,000 gav for 1 hour; the resultant supernatant was added to a BV of 1 mL HisPur™ cobalt 
resin pre-equilibrated in wash buffer (50 mM Tris, 150 mM NaCl, 15 mM imidazole, 10% 
glycerol and 0.05% DDM, pH 7.4). VcCNT was then allowed to bind to the resin by incubating 
the supernatant/resin solution at 4°C for 2 hours on a roller mixer, after which the resin was 
pelleted, washed in wash buffer and eventually eluted in elution buffer (50 mM Tris, 150 mM 
NaCl, 250 mM imidazole, 10% glycerol and 0.05% DDM, pH 7.4) in an identical manner as 
described in section 2.5.1. Peak fractions of VcCNT were dialysed in 50 mM Tris supplemented 
with 150 mM NaCl, 10% glycerol and 0.05% DDM (pH 7.4). The protein was then concentrated 
in a vivaspin concentrator with a 30 kDa molecular weight cut off. Samples were taken 
throughout the VcCNT purification and were once again analysed with SDS-PAGE and western 
blotting.               
2.5.4 Purification of membrane protein via Styrene Maleic Acid co-
polymer (SMA) 
In order to produce styrene maleic acid lipid particles (SMALPs) 1.5g of bacterial membrane 
with a concentration of 20 – 40 mg/mL, was diluted in 32 mL of a buffer containing 50 mM tris, 
10% glycerol, 500 mM NaCl (pH 8) and mixed with 2.5% (w/v) SMA co-polymer (provided by 
Tim Dafforn in the university of Birmingham). Once the entire SMA polymer was dissolved, the 
solution was incubated at room temperature for 2 hours on a rocker before it was subjected to 
ultracentrifugation at 145,000gav for 45 minutes. The supernatant was then incubated with a 
bed volume (BV) of 2 mL pre-equilibrated cobalt resin overnight at 4°C. Once the SMALPs were 
bound to the resin, it was washed in 10 BV (i.e. 20 mL) of the previously described tris buffer 
supplemented with 10 mM imidazole. The protein SMALPs were then eluted from the resin in 
6.25 BV (i.e. 12.5 mL) elution buffer (500 mM NaCl, 10% glycerol, 50 mM Tris and 250 mM 
imidazole, pH 8). The eluted SMALPs were collected in fractions and their A280nm were 
monitored spectrophotometrically using a micro-spectrophotometer.        
2.5.5 Preparation of protein nanodiscs 
In order to construct nanodiscs, a precise molar ratio of membrane scaffold protein (MSP): 
membrane protein: lipid is required. To determine this ratio, a calculation which takes into 
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account the amount of lipid that is encapsulated in a single nanodisc, its occupancy, the area 
of the target protein and the subsequent amount of lipid displaced upon its entry into the 
nanodisc must be performed.  
Once an appropriate ratio is estimated, the membrane protein must first be purified in 
detergent micelles. A stock solution of POPC lipid was also prepared by drying chloroform lipid 
stock (25 mg/mL) in a glass tube under a gentle stream of nitrogen gas until all chloroform was 
removed. The 100 mg of dry lipid was then solubilised in 657.83 µL of lipid solubilisation buffer 
(20 mM Tris-HCl pH 8, 150 mM NaCl and 400 mM sodium cholate) resulting in a 200 mM lipid 
solution in 400 mM sodium cholate. The lipid was the subjected to vortexing, incubation at 
60°C and sonication in water bath sonicator until the solution was transparent, at which point 
it was stored at -80°C.  
The membrane protein, lipid and membrane scaffold protein were then mixed according to 
the previously determined molar ratio. It was vital that the final concentration of sodium 
cholate remained between 12 mM and 40 mM (CMC = 9.5 mM). If required, extra sodium 
cholate was added from a 1M stock solution prepared prior to nanodisc construction. The 
nanodisc solution was then incubated at 4°C for 2 hours before the detergent was removed 
using pre-equilibrated bio-beads and gentle agitation in order to keep the bio-beads 
suspended. Detergent removal was continued until all detergent was removed (the level of 
detergent was tested by gently passing air through the solution) and the bio-beads were 
replaced with a fresh stock twice a day. Typically this process took a minimum of 1 week. Once 
complete the nanodiscs were stored at 4°C and analysed by gel filtration and western blotting 
(see section 2.4.8). 
Alternatively nanodiscs were analysed via sucrose density gradient and involved adding 250 µL 
of nanodiscs to 250 µL 60% sucrose buffer (20 mM Tris-HCl pH 8, 150 mM NaCl, 60% sucrose). 
The resultant 30% nanodisc solution was then applied to a Beckman TLS-55 centrifuge tube 
(max capacity 2.2 mL) and gently overlaid successively with 0.5 mL samples of buffer 
containing 20%, 10% and 5% sucrose. The samples were centrifuged for 16 hours at 259,000 
gav before each fraction was collected and analysed via western blotting (see section 2.4.6).  
In order to biotinylate the MSP, a buffer exchange is required in order to remove the protein 
from the Tris buffer it is eluted in (40 mM Tris, 0.3 M NaCl, 0.4 M Imidazole, pH 8) into PBS. 
This was accomplished via extensive dialysis and was necessary in order to avoid competition 
between the primary amines on lysine residues and the Tris for the biotinylation reagent. 
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Biotinylation was then carried out as described in section 2.4.4. The resultant biotinylated MSP 
was then used in the construction of AcrB nanodiscs.                 
2.5.6 Sub-cloning the DARPin gene into expression vector pET16b 
The sub-cloning of the DARPin gene was designed to remove the gene from pC6 (Figure 2.1) 
into the expression vector pET16B, thereby removing the reliance on the DsbA signal sequence 
and the requirement of the amber stop codon and placing a His-tag on the N-terminal of the 
DARPin. In order to achieve this, an N-terminal NdeI and a C-terminal BamHI cut site were 
inserted at the two ends of the DARPin gene in the pC6 via PCR (see section 2.3.1) using the 
following primers: 
 Forward primer (introducing the NdeI site) pET16b_DP_Fwd: 
 5’ – CGATCATATGGATCTGGGAAAAAAACTGCTGGA – 3’ 
 Reverse primer (introducing the BamHI site) pET16b_DP_Rev: 
 5’ – ATCGGGATCCTCACTACAGTTTCTGCAGG – 3’ 
The amplified DARPin was inserted into an empty pET16B vector via double restriction digest 
with NdeI and BamHI followed by ligation (see section 2.3.3 and section 2.3.6). The newly 
constructed plasmids were then used to transform the E.coli strain Omnimax™2 thereby 
amplifying the concentration of DNA. 
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Figure 2.1 Plasmid map of the DARPin phagemid pC6: A diagrammatic cartoon of plasmid pC6 in which all 
DARPins are originally inserted after the PCR which places a novel BamHI cut site (676) as well as a novel NdeI 
(197) cut site at each end of the DARPin. The DARPin (represented by the smaller purple arrow) is fused to the 
coat protein pIII of the bacteriophage M13 (the larger purple arrow) thereby allowing its presentation on the 
surface of a phage particle. The two proteins are separated by a polyhistidine tag, a myc tag and an amber stop 
codon. The N-terminal of the DARPin has a DsbA signal sequence which facilitates its rapid translocation to the 
periplasm thereby preventing premature folding of the DARPin in the cytoplasm.  
 
2.5.7 Periplasmic extraction of cells expressing DARPins 
 As previously mentioned the plasmid in which the DARPin was placed, was designed to 
facilitate its co-translational release into the periplasm therefore periplasmic extractions were 
carried out on the cultures. They were first pelleted and resuspended in 1 mL TSE buffer (20% 
(w/v) sucrose, 30 mM Tris/HCl, 1 mM EDTA, pH 8.3) before incubation at room temperature 
for 15 mins with gentle mixing on a roller. The samples were then centrifuged at 5000 gav for 
15 min and the supernatant removed and stored as periplasmic fraction 1. The pellet was then 
resuspended once again in a minimal amount of TSE buffer before being immediately diluted 
in 1 mL ice cold ultrapure water before being stored on ice for 15 min. The solution was then 
centrifuged at 16,000 gav for 30 min and the supernatant taken and stored as periplasmic 
fraction 2. The resultant pellet was finally resuspended in 1 mL ice cold MilliQ water and stored 
as the cytoplasmic fraction. This procedure was performed on both IPTG induced and non-
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induced samples and each fraction was subjected to SDS-PAGE and analysis by western 
blotting alongside a positive control of MPSIL2094.  
2.5.8 Expression and purification of Designed ankyrin repeat proteins 
(DARPins)  
DARPins were expressed in BL21 cells via IPTG induction in 500 mL of 2xTY media (see Table 
2.2). The expression was done in a slightly modified form from that described in section 2.4.2. 
Initially 30 mL pre-cultures of transformed BL21 cells were grown overnight at 37°C with 
shaking at 280 rpm. 25 mL of this culture was then used to inoculate 500 mL of 2xTY media 
supplemented with 100 µg/mL carbenicillin resulting in a 1:20 dilution. The 500 mL cultures 
were then incubated for 2 hours at 37°C with shaking at 200 rpm, after which IPTG was added 
to a final concentration of 0.6 mM. Upon the addition of IPTG, the cultures were incubated for 
a further 4 hours at 37°C with shaking. The cells were then pelleted at 4,000 rpm for 20 
minutes and resuspended in 2x PBS with 5 mM imidazole before immediate disruption in the 
cell disruptor (see section 2.4.3). In order to pellet the membranes, the output from the cell 
disrupter was then centrifuged at 150,000 gav and the supernatant was added to 500 µL (BV) 
pre-equilibrated (in 2x PBS, 5 mM imidazole) Hispur™ Cobalt resin. The mixture was then 
incubated at 4°C overnight on a roller mixer. Once DARPin binding was complete the resin was 
packed into a disposable gravity flow column by allowing the buffer to flow through it. The 
resin was then washed in 10BV (i.e. 5 mL) 2x PBS buffer with 20 mM imidazole. The DARPin 
was then eluted (in 2xPBS with 250 mM imidazole) and dialyzed (in 2x PBS) in an identical 
manner a described in section 2.5.1.1. The DARPin was then concentrated in a vivaspin 
concentrator with a 10 kDa molecular weight cut off before its concentration was determined 
spectrophotometrically, the protein was snap frozen in liquid nitrogen and stored at -80°C.     
2.6 Quality control of MPSIL0294 samples 
The three MPSIL0294 protein constructs were designed to immobilise onto a solid surface via a 
biotin binding protein. In the case of the phage display this was streptavidin coated plates 
(Thermo scientific). Verification of the proteins ability to bind via their various tags used 
manually produced neutravidin coated plates in an ELISA procedure.       
2.6.1 Producing Neutravidin Coated plates  
In order to test the quality of protein samples in relation to their ability to present an epitope 
for binding they were tested in an ELISA on neutravidin coated plates. Initially a 10 mg/mL 
Neutravidin (Thermo scientific) stock solution was prepared in 50% glycerol. This stock solution 
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was then used to make a 2 µg/mL working solution, 100 µL of which was used to coat the wells 
of a Nunc Maxisorp® plate. The plate was then sealed with an adhesive cover and incubated 
overnight at 4°C, after which it was washed three times in 1xPBS and stored at 4°C.  
2.6.2 Indirect ELISA of MPSIL0294 samples on Neutravidin Coated 
plates 
A serial dilution of MPSIL0294 from 100 to 0.098 µg/mL was established in the 96-well 
neutravidin coated plate. The protein dilutions were then allowed to bind to the surface by 
incubating the plates (which were sealed with an adhesive cover) for 1 hour at 4°C. Once 
binding was complete the plates were washed three times in PBS before they were blocked in 
200 µl 3% (w/v) dried skimmed milk (Marvel) in PBS for 1 hour at room temperature, after 
which the plates were washed three times once again in PBS. The plates were then probed 
with 50 µL of an anti-polyhistidine tag antibody conjugated with HRP diluted 1:10,000 in the 
3% (w/v) milk block buffer.  The plates were once again incubated for 1 hour at room 
temperature before it was washed three times in PBS supplemented with 0.05%Tween (PBST). 
50 µL of tramethylbenzidine (TMB) was added and the plates were incubated at room 
temperature for a maximum of 20 minutes after which 50 µL of 0.5 M H2SO4 was added to stop 
the reaction. The absorbance at 450 nm was then measured using the Multiskan Ascent 
96/384 plate reader (Thermo scientific).              
2.6.3 Fluorescence-activated cell sorting (FACs) analysis of detergent 
solubilised MPSIL0294 samples immobilised on streptavidin coated 
magnetic beads 
FACs analysis was performed in order to show that the MPSIL0294 detergent solubilised 
variants had the ability to bind to a streptavidin coated surface. In order to perform this 
analysis 10 µg/mL of protein was bound to streptavidin coated Dynabeads® (Thermo Scientific) 
and incubated for 1 hour at room temperature.  The beads were then washed three times in 
PBS (using a magnetic Eppendorf stand) before being blocked in 3% (w/v) skimmed milk 
(Marvel) in PBS for 1 hour at room temperature. After blocking, the beads were once again 
washed 3 times in PBS before being probed with a mouse polyhistidine antibody (at a dilution 
of 1:1000) in block buffer and incubated at room temperature for 1 hour; after which the 
beads were washed three times in 0.05% PBST. A goat anti-mouse antibody conjugated with 
DyLight 488 was used as a secondary antibody (Jackson ImmunoResearch Ltd). The beads were 
then treated in an identical manner as they were after incubation with the primary antibody. 
Blank beads with no bound MPSIL0294 and a biotinylated and polyhistidine tagged control 
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protein (which had been characterised by MedImmune) was also prepared in an identical 
manner in order to act as a negative and positive control, respectively. The beads were then 
washed again in FACs buffer (10% FBS (Fetal bovine serum), 1 mM EDTA, 0.01% Azide in 1x 
PBS) prior to analysis with a FACs machine which measured the fluorescence at 488 nm and 
plotted the results on an overlay histogram.    
 2.7 Assay for Zn2+ uptake by MPSIL0294 via Fluozin-1  
2.7.1 Preparing a stock solution of small unilamellar vesicles   
An assay was developed in order to test MPSIL0294s ability as a divalent metal cation 
transporter. Initially a 50 mg/mL stock solution of small unilamellar vesicles (SUV) was 
prepared by drying 100 mg of E.coli polar lipids dissolved in chloroform in a round bottom 
Corex glass tube under a gentle stream of nitrogen. In order to remove any residual traces of 
chloroform the tubes were left in a desiccator under continuous vacuum overnight. The lipids 
were then rehydrated in 1x Bis-Tris-Mes (BTM - 20 mM Bis(2-hydroxyethyl)amino-
tris(hydroxymethyl)methane with the pH adjusted to 6.8 with 20 mM Mes) supplemented with 
2 mM 2-mercaptoethanol by vigorous vortexing. The lipid solution was then sonicated in a 
bath sonicator until it became a translucent suspension of SUVs. 
2.7.2 Reconstitution of MPSIL0294 for stopped flow analysis 
 The reconstitution of MPSIL0294 was based of the work performed by Dax Fu (Chao and Fu 
2004), as such detergent solubilised MPSIL0294 was diluted in protein dilution buffer (20 mM 
BTM, pH 6.8, 2 mM 2-mercaptoethanol, 1% (w/v) n-Octyl-β-D-Glucoside (β-OG), 50 mM K2SO4) 
down to a concentration between 0.26 and 0.52 mg/mL. Lipids were prepared by adding 100 
µL 10% β-OG to 130 µL (6.5 mg) of the 50 mg/mL SUV stock solution in BTM buffer. The 
complete transparency of the lipid solution was indicative of complete lipid solubilisation. 770 
µL of diluted MPSIL0294 was added and the protein-lipid-detergent mixtures were incubated 
at 4°C for 20 minutes. The samples were then applied to a PD-10 column pre-equilibrated in 
assay buffer (20 mM BTM, pH 6.8, 50 mM K2SO4) and the cloudy void volume was collected 
and ultracentrifuged at 140,000 gav for 45 minutes. The pellet was then resuspended in 200 µL 
of assay buffer and 22 µL of the Zn2+ sensitive dye Fluozin-1. In order to maximise the amount 
of dye uptake into the proteoliposomes, the proteoliposome/dye solution was sonicated in a 
bath sonicator for 10 seconds, subjected to a single freeze thaw cycle in liquid nitrogen, 
subjected to extrusion through a 1 µm filter and finally sonicated for an additional 10 second. 
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The dye loaded proteoliposomes were then applied to a second PD-10 column in order to 
remove excess dye and the cloudy void fraction was once again collected.  
The proteoliposomes (and control liposomes which were formed in an identical manner in the 
absence of MPSIL0294) were then tested against varying concentrations of ZnCl2 in a stopped 
flow machine (Applied photophysics) measuring the fluorescence at 490 nm (F). The 
background readings were also measured by measuring the fluorescence when no Zn was 
present (F0) and the maximum possible amount of fluorescence (Fmax) was measured by mixing 
the proteoliposomes with 20 µM pyrithione (a Zinc ionophore) in the stopped flow mixing cell. 
Due to the fact that Fmax and F0 should be a single figure the mode of each data set was used as 
the true Fmax and F0. The data was then analysed using the following formula and ΔF/ΔFmax was 
plotted on a graph as a function of time: 
  Fraction Zn2+ uptake (%) = 100 x F- F0/Fmax - Fo 
2.8 Screening of immobilised membrane protein samples via 
phage display 
 
2.8.1 First round selections on streptavidin coated plates 
Phage display was carried out onsite in MedImmune’s screening labs in Cambridge. In order to 
screen immobilised proteins against a library of potential binding partners expressed on the 
surface of bacteriophage, a culture of TG1 cells were first prepared. This culture was 
established by inoculating 50 mL 2xTY media with a single colony and incubated at 37°C with 
shaking at 300 rpm (3 g). This incubation was maintained until the culture had an OD600nm of 
0.5 – 1 (i.e. exponential phase), this typically took 4 -5 hours and once the required OD00nm was 
obtained the culture was placed on ice until it was needed.  
For a single phage display screen against a single target protein, one 50 µL aliquot of the naïve 
DARPin library (which had a size of 7.5 x 109) was blocked in an equal volume of ‘phage 
blocking buffer’ (2x PBS, 6% w/v skimmed milk powder). Simultaneously a 100 µL aliquot of 
streptavidin coated Dynabeads® were vortexed in order to resuspend the beads. The beads 
were then captured using a magnetic Eppendorf stand and subsequently blocked in 100 µl 
‘well blocking buffer’ (1x PBS, 3% w/v skimmed milk powder). The aliquots of phage and beads 
were then placed separately in an orbital mixer for 1 hour at room temperature, after which 
the beads were once again placed in a magnetic stand (in order to separate the beads from the 
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blocking buffer) and the supernatant was discarded. The entire 100 µL blocked phage aliquot 
was then added to the beads, vortexed gently and placed back into the orbital mixer for an 
additional hour at room temperature in order to deselect the phage against streptavidin.  
125 µL of target protein diluted to a concentration of 50 - 100 µg/mL in PBS (with an 
appropriate concentration detergent if necessary) was added to a single well of a streptavidin 
coated plate (Pierce™) and incubated for 1 hour at 4°C. After the target protein had been 
immobilized on the plate’s surface, it was washed three times with PBS (with detergent if 
required), blocked in 300 µL of ‘well blocking buffer’ and incubated once again at 4°C for 1 
hour. After blocking, the plate was washed once in PBS, then the beads were placed in a 
magnetic stand once again and the 100 µL deselected phage in the supernatant was pipetted 
onto the appropriate well of the streptavidin coated plate. The plate was then incubated at 4°C 
for 1 hour in order to allow any phage capable of binding to do so.   
The plates were then washed 5 times in PBST (1x PBS, 0.05% Tween) prior to elution of the 
phage via trypsinization (Thomas and Smith 2010). This was achieved with a 10 µg/mL working 
solution of trypsin (made from a 5 mg/mL stock diluted in 0.1M sodium phosphate buffer) 
0.001 µg of which (100 µL) was pipetted onto the appropriate well on the plate. The eluted 
phage was then used to inoculate a 5 mL aliquot of the exponential phase TG1 cells. An 
additional 100 µL of 0.1 M sodium phosphate buffer was then used to wash out the well and 
added to the culture as well. This 5 mL culture was then incubated for 1 hour at 37°C with 
shaking at 150 rpm. 100 µL of a serial dilution of the TG1 cells (from pure to 10-5) were plated 
on 2x TY agar plates supplemented with 100 µg/ml ampicillin in order to calculate the phage 
titre.  
The remainder of the inoculated TG1 culture left was centrifuged for 5min at 2000 gav after 
which the cells were resuspended in 1ml TY media. This entire 1ml sample was then spread on 
a large 24.5 cm x 24.5 cm square bio-assay plate, onto which 2x TY agar supplemented with 
100 µg/mL ampicillin had been poured. The plates were then incubated overnight at 37°C. 
2.8.2 Phage rescue of selection output 
In order to recover the phage produced by the TG1 cells spread on the bio-assay plate, a phage 
rescue was necessary. Firstly 2xTY media was mixed with 50% (v/v) glycerol in a 2:1 ratio and 
supplemented with ampicillin. 10 mL of this 2x TY-glucose media (TYAG) was then spread 
across the surface of the bio-assay plate (in a sterilised hood) and the cells (and phage) were 
gently scraped using a disposable cell scraper. The cells were then transferred into a 50 mL 
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falcon tube and fully resuspended by placing the tubes into an orbital mixer for 10 minutes.  
Two 1 mL aliquots were taken from this cell suspension, pipetted into cryotubes (Nunc) and 
stored at -80°C as a selection backup. The OD00nm of the undiluted cell suspension was then 
calculated by spectrophotometrically analysing a 1/100 dilution in 2x TY media and used to 
inoculate 25 mL of TG1 culture in 2x TYAG media (2x TY media as before, 2% w/v glucose, 100 
µg/mL ampicillin) at an OD600nm of 0.1.  This 25 mL culture was grown in a 250 mL conical flask 
at 37° with shaking at 280 rpm until it reached an OD600nm of 0.5 – 1. At this point the cultures 
were superinfected with 2.5 µL M13K07trp helper phage (from a stock containing 7.5 x1010 
pfu)  which carries essential genes for the production of fully formed phage particles (Carmen 
and Jermutus 2002). The cultures were then incubated for an additional hour at 37°C with 
gentle shaking 150 rpm. 
In order to express the DARPin proteins on the surface of the phage particles, due to glucoses 
ability to repress the lacZ promoter it needed to be removed from the growth media in order 
to allow expression of the DARPin, coat protein fusion (Carmen and Jermutus 2002). To this 
end the cultures were transferred into 50 mL falcon tubes and centrifuged at 2000 gav for 10 
minutes. The supernatant was subsequently discarded and the pellet was resuspended in 25 
mL 2x TYAK media (2xTY as before, 100 µg/mL ampicillin, 50 µg/mL kanamycin). The cultures 
were then grown overnight in 250 mL conical flasks at 37°C with shaking at 280 rpm (1 gav). 
Once the overnight incubation was complete 1 mL of this culture was centrifuged at 27,000 gav 
(max speed) in a microfuge and the phage contained within the supernatant was stored on ice 
for the second round of selection (see section 2.8.4).            
2.8.3 Calculating phage input and output titres  
The input and output titre acts as a preliminary measure of the success of a phage display 
screen. A typical output titre is between 103 – 106 cfu (colony forming units) and was 
calculated by counting the colonies on the serial 2x TY dilution plates which were grown 
alongside the bio-assay plate after a round of phage selection (see section 2.8.1). Colonies 
were counted using the Acolyte automated colony counter and the output titre was calculated 
using the following formula: 
 Number of colonies x dilution factor of plate x 10 = cfu/mL        
A typical input titre on the other hand measures the number of phage particles which enter a 
subsequent cycle of phage display. The input titre is typically between 5 x 1011 – 1013 and was 
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calculated at the same time as the second round of selection using the phage solution isolated 
from the selection rescue as follows (see section 2.8.2).  
A colony of TG1 cells is established in an identical manner as discussed in section 2.8.1. Once 
the TG1 cells reached exponential phase (OD600nm = 0.5 – 1) a 990 µL aliquot was placed in a 
single well of a sterilized Greiner Masterblock® (Sigma), 10 µL of 10-4 dilution of the phage was 
then added to this aliquot (giving a 10-6 dilution) and the block was incubated for 1 hour at 
37°C with shaking at 150 rpm. After preparing further dilutions of the TG1/phage mixture, 100 
µL of the 10-8 – 10-10 dilutions were then spread on 2x TY agar plates supplemented with 100 
µg/mL ampicillin and incubated at 30°C overnight. The resultant colonies and subsequent titre 
was calculated in an identical manner as discussed for the output titre.  
2.8.4 Second Round selections on streptavidin coated plates 
The second round of selection was performed simultaneously with the input titre; a 50 µL 
aliquot of the isolated phage solution from the selection rescue (see section 2.8.2) was 
blocked in an equal volume of ‘phage blocking buffer’ (Table 2.14). The selection was then 
performed in an identical manner as discussed in section 2.8.1. 
Once the second round of selection was complete, a 96-well master plate was established for 
the output. To do this, 120 µL aliquots of 2xTYAG was pipetted into a 96 well round bottomed 
plate (Costar). 88 colonies were used to inoculate 88 of the wells (the final row was left with 
media alone in order to act as a negative control). The plate was then sealed and stored in a 
box with a moist tissue to prevent evaporation and placed in a slow rotating incubator at 30°C 
overnight. Once incubation was complete 40 µL was transferred to a fresh 96 well plate 
(ensuring that each culture was transferred to the same well) and sent for sequencing by 
MedImmune’s internal sequencing lab. 40 µL 50% glycerol was added to the remaining 
cultures in the first plate (henceforth known as the master plate) and the plate was 
subsequently stored at -80°C.                
2.9 Analysing the phage outputs via phage ELISA 
2.9.1 96 well phage preparation 
Master plates (see section 2.8.4) were removed from storage and thawed at room 
temperature. A separate 96 deep well plate was loaded with 500 µL 2xTYAG media and (once 
the master plate was completely thawed) inoculated with all 96 TG1 cultures of the master 
plate (including the negative control) using a sterile 96 well plate inoculator. The master plate 
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was returned to storage while the ‘daughter’ plate was incubated at 37°C at 280 rpm for 5 
hours.  The helper phage was then prepared by adding 5 µL M13K07 per 10 mL 2xTYAG media 
(a single daughter plate requires 10 mL). Once the 5 hour incubation was complete the plate 
was visually checked for growth in each well before 100 µL of diluted helper phage was added 
in each well thereby superinfecting the cultures. It was then incubated at 37°C for 1 hour at 
150 rpm. Once again in order to develop binding partners on the surface of the phage, glucose 
needed to be removed from the media. Therefore the plates were centrifuged in a benchtop 
centrifuge for 10 mins at 2000 gav at room temperature. Following centrifugation the 
supernatants of each well were discarded and the pellets were resuspended in 500 µL 2xTYAK 
media. The plate was then incubated overnight at 25°C, 280 rpm. Finally the phage cultures 
were blocked in 500 µL ‘well blocking buffer’ and incubated for 1 hour at room temperature. 
The plate was then centrifuged for a second time at 2000 gav and the supernatants were ready 
to be used in phage ELISAs (see section 2.9.2).                 
2.9.2 Phage ELISAs on blank streptavidin plates 
Despite deselecting the phage against streptavidin during each round of selection, an ELISA 
was still performed to ensure that any potential binding partners which showed an ability to 
bind directly to streptavidin were removed. Streptavidin coated plates were first blocked in 
300 µL ‘well blocking buffer’ for one 1 hour at room temperature. Once blocking of the plate 
was complete the buffer was discarded and the plate was washed three times in PBS. 50 µL of 
each phage supernatant described in section 2.9.1 was then transferred from the daughter 
plate to their corresponding positions on the streptavidin coated plate which was then 
incubated at room temperature for 1 hour.  Once phage binding was complete the plates were 
washed three times with PBS then treated with 1/5000 anti-M13-HRP antibody conjugate 
(Thermo scientific) diluted in well blocking buffer, capable of binding to the surface of 
bacteriophage particles. The plates were once again incubated for 1 hour at room temperature 
before being subsequently washed three times in 0.1% PBST.  The presence of phage was then 
detected via 5- 20 minute incubation with 50 µL tetramethylbenzidine (TMB) solution followed 
by the addition of 50 µL 0.5 M H2SO4 to stop the reaction, A450nm was then measured in a plate 
reader.  
2.9.3 Phage ELISAs on streptavidin coated plates in the presence of 
target protein 
Following the ELISAs described in section 2.9.2 all binding proteins which showed an ability to 
bind directly to streptavidin were removed from further analysis. ELISAs were then repeated in 
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an identical manner on the remaining binding candidates in the presence of the immobilized 
target protein. The procedure for these ELISAs was identical as those described in section 2.9.2 
with the exception that the streptavidin coated plates were first coated in 50-100 µg of target 
protein prior to blocking.   
2.10 Confirming the DARPins ability to bind the various target 
proteins via ELISA 
After the DARPins were subcloned, expressed and purified (see section 2.5.6 and 2.5.7), ELISAs 
were designed to confirm the ability of the most promising DARPins to bind to their various 
targets. In order to do this they were first biotinylated using the reagent NHS-biotin (the 
procedure for which was described in section 2.4.6) with a 2.5 – 5: 1 molar excess of biotin.   
 The actual ELISA was performed by adsorbing 10 µg of purified detergent solubilized target 
protein onto Nunc Maxisorp plates. This was accomplished by diluting the various proteins 
down to the desired concentration in 2x PBS supplemented with 0.05% DDM, pipetting 50 µL 
into the required wells of the plate and incubating them overnight at 4°C. Once adsorption was 
complete the plates were washed three times in 200 µL wash buffer (2 x PBS, 0.05% DDM) 
prior to incubation at 4°C for 1h in 200 µL blocking buffer (2 x PBS, 3% BSA, 0.05% DDM). 
During the blocking process, a serial dilution of the biotinylated DARPin ranging from 10 µM to 
1 pM was performed in wash buffer. Once the incubation was complete the plates were once 
again washed three times in 200 µL wash buffer before they were incubated for 1h at 4°C in 
the presence of 50 µL of the biotinylated DARPin. The plates were then washed for a third time 
in 200 µL wash buffer after which 50 µL streptavidin-HRP (diluted to a concentration of 
1:20,000 in blocking buffer) was added to each well and the plate was incubated at 4°C for 1h. 
The plates were then washed in 200 µL 0.1% PBST three times before 50 µL TMB solution was 
added and the plates were incubated for 15 mins at room temperature. To end the ELISA 
reaction 50 µL of 0.5 M H2SO4 was added before the A450nm was measured using a plate reader. 
For a negative control, the methodology was identical as just described except no target 
protein was adsorbed to the plates initially.  
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Chapter 3 
 
A comparison of alternative methods 
of protein immobilisation using 
phage display with a DARPin library 
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3.1 Introduction 
The production of novel therapeutic agents against membrane proteins is difficult, in part due 
to their amphipathic natures. One of the main requirements for the elucidation of a 
therapeutic agent is their specificity to the target. Therefore prior to screening against binding 
protein libraries, membrane proteins must be over-expressed in an appropriate expression 
host, solubilised using detergents such as n-Dodecyl β-D-maltoside (DDM), thereby placing 
them into micelles and subsequently purified.   
In regard to their over-expression Escherichia coli has been shown to be a robust host for the 
production of a wide variety of prokaryotic membrane proteins. This is due to its high growth 
rate and our extensive understanding of its physiology (Makino, Skretas et al. 2011). Studies 
have shown however that the success of this over-expression can be influenced by factors such 
as the topological characteristics of the membrane protein and the position and length of the 
tag which has been used (Mohanty and Wiener 2004).  
During phage display, typically a target protein will be first immobilised onto a solid support, 
often by a tag. There are several problems with immobilising membrane proteins, primarily 
due to their propensity to unfold and adopt non-native conformations. Or the adsorption of 
non-specific proteins to the surface as seen with earlier attempts to immobilise membrane 
proteins via a Histidine-nitrilotriacetic acid (NTA) interaction (Friedrich, Kirste et al. 2008, 
Vaish, Silin et al. 2013).   
To this end, this chapter shall focus on the development of two membrane proteins which 
were prepared for phage display screening trails. A single model membrane protein from the 
BBSRC funded membrane protein structure initiative at Leeds (MPSIL) designated MPSIL0294 - 
a divalent metal ion transporter from Enterococcus faecalis and part of the MntH family of 
transporters. It was chosen due to the fact that topological predications show that it has 12 
transmembrane helices thereby making it more structurally similar to its human homologue 
when compared to the other bacterial members of this transporter family. Its human 
homologue - the natural resistance associated macrophage protein (NRAMP), shares a 35% 
sequence homology with MPSIL0294 and plays a pivotal role in the transport of iron in the 
body. Due to the12th helix of MPSIL0294 predictive models place its N and C- termini within the 
cytoplasm therefore making it more amenable to tagging, unlike its homologue MntH from 
E.coli. It has been shown that tagging an extracellular N-terminal can hinder membrane 
proteins insertion into the plasma membrane and their expression even with a short 
polyhistidine tag (Rahman, Ismat et al. 2007, Kang, Lee et al. 2013). These three variants of 
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MPSIL0294 were designed to compare alternative methods of protein immobilisation in regard 
to their ability to isolate DARPins capable of binding to them after selection with phage 
display.  
In order to compare alternative methods of membrane protein immobilisation, three different 
C-terminal tags which immobilised MPSIL0294 via a biotin/streptavidin interaction were 
added. The first being a streptavidin binding peptide (SBP) tag, the second an avitag which was 
subjected to in vivo biotinylation and finally the inclusion of an accessible cysteine via site 
directed mutagenesis which allowed the protein to be biotinylated chemically at a specific site 
using biotin maleimide.  
AcrB was used as a second model membrane protein, designed to compare alternative 
methods of membrane protein immobilisation. It was chosen because topological analysis of 
its crystal structure shows a large extracellular loop, most likely a part of the TolC docking 
domain (Murakami, Nakashima et al. 2002), is present within the proteins natural 
conformation. This thereby gives it a higher chance of isolating binding partners than 
MPSIL0294 which doesn’t have any particularly large extracellular components according to 
topological predictions. AcrB was also chosen due to its natural affinity to bind to IMAC resin 
due to a cluster of histidine residues in its C-terminus which make extensive tagging 
unnecessary and its purification simpler (Veesler, Blangy et al. 2008).          
3.2 Cloning of MSIL0294 variants  
Three MPSIL0294 variants were designed to allow for a consistent method of expression and 
purification to be utilised. Restriction sites were chosen which allowed the inclusion of a C-
terminal polyhistidine tag consisting of 8 histidine residues in tandem downstream from the 
various newly introduced tags on all three proteins. The MPSIL0294 open reading frame was 
placed under the control of the lac operon thereby allowing its expression to be controlled via 
IPTG or auto-induction. A human rhinovirus 3C protease (HRV-3C) motif was engineered 
downstream of the polyhistidine and other tags. All of these features were included in plasmid 
construct pBPT0294-CVH designed by Dr. Cheng Ma (Ma 2013).        
Two of the three MPSIL0294 constructs were derived from pBPT0294-CVH along with two 
commercially purchased open reading frames for AtPH01_SPX_Avitag and TaALMT1-CTD 
which provided the avitag and SBP tag via sub-cloning. Initially a double restriction digest using 
Hind III and AvrII was performed on pBPT0294-CVH, AtPH01_SPX_Avitag and TaALMT1-CTD 
(see section 2.3.3). The resultant pBPT0294-CVH fragment was then ligated with either the 
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AtPH01_SPX_Avitag fragment or the TaALMT1-CTD fragment thereby creating the 
intermediate plasmids pL50 and pL51 respectively (see Figure 3.2). 
While the original pBPT0294-CVH plasmid has two BamHI cut sites PL50 and PL51 have a single 
unique BamHI site (see Figure 3.2). Therefore a BamHI restriction analysis was used as a 
method to confirm the construction of pL50 and pL51 on a 1% agarose gel (see section 2.3.4). 
When digested by BamHI, pBPT0294-CVH produced two DNA fragments while pL50 and pL51 
produced only one (see Figure 3.3).  
 
 
 
 
 
 
 
 
 
Figure 3.1: Plasmid maps of pBPT0294-CVH, AtPH01-SPX avitag and ALMT CTD SBP: The plasmid constructs of 
pBPT0294-CVH developed by Dr. Cheng Ma, and the purchased open reading frames of AtPH01_SPX_Avitag and 
TaALMT1-CTD. In order to produce the two of the three MPSIL0294 variants, a HindIII/ AvrII double restriction 
digest was performed initially upon pBPT0294-CVH and a resultant fragment was ligated with those produced by 
AtPH01_SPX_Avitag and TaALMT1-CTD.  Within the blue box are the fragments of each DNA construct which 
were used after digestion with HindIII and AvrII. For clarity all restriction cut sites other than HindIII, AvrII, BamHI 
and PstI in pBPT0294-CVH have been removed.     
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Figure 3.2 Plasmid Maps of pL50 and pL51: The resultant plasmids produced as a consequence of the ligation 
between AvrII/HindIII fragments of pBPT0294-CVH and AtPH01_SPX_Avitag resulting in pL50 or those of 
pBPT0294-CVH and TaALMT1-CTD resulting in pL51. All restriction cut sites have been removed except for those 
relevant to the cloning strategy.  These intermediate plasmids successfully place an avitag (in the case of pL50) 
and a SBP tag (pL51) into the expression vector but also unwanted genes such as AtPH01 SPX domain (pL50) and 
ALMT C-terminal domain (pL51). They also no longer contain the reading frame of MPSIL0294.         
 
Figure 3.3 BamHI analysis of pBPT0294, pL50 and pL51: A BamHI digestion was carried out on samples of the 
newly constructed intermediate plasmids pL50 (A) and pL51 (B). The resultant DNA fragments were analysed on a 
1% agarose gel stained with SYBR®SAFE from life technologies and visualised with the G-Box from SynGene.    
pL50 contained the open reading frame for AtPH01_SPX domain which plays a role in 
phosphatase homeostasis in eukaryotes (Secco, Wang et al. 2012) and is not relevant to this 
study but introduced an avitag sequence upstream from the polyhistidine-tag. pL51 on the 
other hand contained the open reading frame of ALMT, a transporter in plants, which plays a 
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role in aluminium tolerance (Ma and Furukawa 2003). Once again this protein is not relevant 
to this study but provided the SBP tag (see Figure 3.2).   
In order to construct plasmids in which the MPSIL0294 gene was upstream from the desired 
tags, the irrelevant genes were switched with MPSIL0294 using an AvrII and PstI double 
restriction digest on pBPT0294-CVH, pL50 and pL51. The enzymes removed the open reading 
frames of MPSIL0294, the AtPH01 SPX domain and the ALMT from the plasmids (see Figure 3.1 
and 3.2). The MPSIL0294 fragment was then ligated with the PL50 fragment (thereby creating 
PVA1 MPSIL0294-avitag) and the PL51 fragment (creating PVA2 – MPSIL0294-SBP) (see Figure 
3.4).  
The insertion of the MPSIL0294 fragment re-introduced a BamHI site thereby allowing pVA1 
and pVA2 to be distinguished from pL50 and pL51 once again via BamHI restriction analysis 
(see Figure 3.5). 
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Figure 3.4 Plasmid maps of pVA1 and pVA2: The final plasmids which place MPSIL0294 upstream from either an 
avitag (pVA1) or a SBP tag (pVA2), while removing the unwanted genes from pL50 and pL51. For clarity all 
restriction sites other those used throughout the cloning strategy have been removed.     
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Figure 3.5 BamHI analysis of pL50, pL51, pVA1 and pVA2: Plasmids pVA1 (A) and pVA2 (B) were digested with 
BamHI in order to check that the two MPSIL0294 constructs had successfully been made. The plasmid fragments 
were analysed on a 1% agarose gel stained with SYBR®SAFE from life technologies and visualised under UV with 
the G-Box from SynGene.      
In the case of the MPSIL0294-V532C, site directed mutagenesis was used in order to replace a 
C-terminal valine with an accessible cysteine residue. The original MPSIL0294 plasmid - 
pBPT0294-CVH was used as the template DNA (see section 2.3.10) and utilised the following 
mutagenic primers: 
    Forward: 5' GAGCAACAAGTAGAGGAGTGTAAACCTGCAGGACTAG 3' 
    Reverse: 5' CTAGTCCTGCAGGTTTACACTCCTCTACTTGTTGCTC 3'          
(Mismatched nucleotides have been highlighted in red; their melting temperature was 78.3°C 
and had a GC content of 48.65%) 
Samples from the mutagenesis experiment were analysed and found to only produce an 
amplification product when the mutagenesis procedure was carried out at 60 or 65°C (see 
Figure 2.3.10). Once the methylated template DNA was removed via DpnI digestion, the newly 
mutagenized DNA was amplified in OmniMax2 (see section 2.3.8).  
Samples of each pVA1, pVA2 and pVA3 were then sent for sequencing via Source Bioscience 
using primers pTACF and pTACR (see section 2.3.11). While sequencing confirmed the correct 
construction pVA1 and pVA2, it showed that all of the pVA3 plasmids suffered from random 
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insertions of nucleotides into the plasmid thus rendering them unusable. Fortunately the 
desired codon substitution in MPSIL0294 had been successful while the arbitrary nucleotide 
insertions occurred upstream of a PstI/Sbf-I cut site. Therefore a double restriction digestion 
with AvrII and Sbf-I and subsequent ligation was performed on pVA3 and pBPT0294-CVH in 
order to switch the wild type MPSIL0294 gene with the mutant.  The correct construction of 
pVA3 was confirmed via sequencing with the pTACF and pTACR sequencing primers (see 
section 2.3.11).  
3.3 The purification of MPSIL0294 constructs and AcrB 
3.3.1 The purification of C-terminal SBP tagged MPSIL0294 
MPSIL0294-SBP membranes were prepared via auto-induction in BL21 star (DE3) transformed 
with pVA2 and subsequently isolated via disruption using a cell disruptor. Samples taken 
throughout the purification described in section 2.5.1.1 were analysed electrophoretically via 
SDS-PAGE followed by staining with Coomassie blue and western blotting (see Figure 3.6). This 
analysis provides a reliable insight into the behaviour of MPSIL0294-SBP throughout the 
purification. The sample taken from the ‘Total’ provides an indication of the expression level of 
the protein. Analysis of the ‘supernatant’ sample shows the amount of protein successfully 
solubilised by the DDM; while samples taken from the ‘pellet’ represent the protein which 
failed to do so. The ‘Flow-through’ samples give an indication of how much protein fails to bind 
to the cobalt resin. Finally the 10 and 40 mM imidazole wash samples shows if any MPSIL0294 
is prematurely stripped from the column as a result of imidazole exposure.    
Firstly the noticeable lack of prominence of the protein resolved at approximately 55 kDa in 
the ‘Total’ sample indicates a poor expression level of MPSIL0294-SBP. The similarity of this 
protein in the ‘supernatant’ sample however, (as well as its disappearance in the ‘Pellet’) 
shows that the majority of the MPSIL0294-SBP was successfully solubilised. Minimal amounts 
of protein appear to have been lost in the 10 and 40 mM imidazole washes however they 
successfully remove part of the 25 kDa impurity. The protein was successfully eluted in 1 mL 
200 mM fractions of elution buffer. The majority of MPSIL0294-SBP came off the column after 
exposure to 10x bed volume of elution buffer (i.e. 10 mL). The final eluate sample produced 
after the peak fractions were pooled, dialysed and concentrated is relatively pure, except for 
the presence of some low molecular weight proteins which appear at 20 kDa and below. These 
observations are given further credence by the western blot of the same samples probed with 
an anti-polyhistidine tag antibody conjugated with HRP (see Figure 3.6). A single His-tagged 
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protein is shown in the total and supernatant samples, therefore confirming that the protein is 
almost completely solubilised in 1.5% DDM. The lack of His-tagged protein in the ‘Flow-
through’ confirms that the protein was completely bound to cobalt resin. As before samples of 
the 40 mM wash shows that some protein is lost however this sample represents 0.1% of the 
total 40 mM wash while the total and supernatant represents 0.01% therefore a direct 
comparison would not be accurate. Aside from this the same sample is undetectable when 
analysed by SDS-PAGE stained with Coomassie.  
Several protein bands also appear on the blot once the elution is initiated. These bands occur 
between 25 and 30 kDa as well as below 10 kDa. After concentration in a 100 kDa cut off 
vivaspin column, bands also appear at approximately 170 kDa. As can be seen in Figure 3.6 the 
majority of these extra bands are not easily detectable by Coomassie stain however. The fact 
these bands have a lower mass suggest that they are not aggregates and they do not appear in 
every sample therefore are most likely not artefacts of the SDS-PAGE. Instead they are likely 
minor degradation products from a protease resistant to inhibitor cocktail used during the 
purification procedure. Analysis via micro-spectrophotometer showed that 0.76 mg of 
MPSIL0294-SBP was purified from 200 mg of mixed membrane. Samples of MPSIL0294-SBP 
were then used to form protein filled nanodiscs and SMALPs as shown in the next chapter. 
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Figure 3.6: IMAC Purification of MPSIL0294-SBP: Samples taken throughout the purification of MPSIL0294-SBP 
were analysed via 12% SDS-PAGE gel subjected to staining with Coomassie blue and western blotting probed with 
an anti-polyhistidine tag antibody conjugated with HRP. Each sample was normalised to a volume of 10 µL and 
represent different relative amounts of their total samples. The total, supernatant and flow-through represent 
0.01% of their respective total samples. The pellet as well as both the 10 and 40 mM washes represents 0.1%, 
while all of the elution fractions as well as the final concentrated protein represent 1%.   
3.3.2 The purification of C-terminal Avitag MPSIL0294 after in vivo 
biotinylation 
Membranes were prepared in an identical manner than those used to purify MPSIL0294-SBP 
except the E.coli strain AVB101 was used thereby allowing in vivo biotinylation of MPSIL0294-
avitag. Once again samples were analysed by SDS-PAGE and western blotting probed with an 
anti-polyhistidine tag antibody conjugated with HRP (see Figure 3.7). The fact that no other 
protein’s had a polyhistidine tag means that the band which has been produced on the blot is 
most likely MPSIL0294-avitag.  
It is once again clear that MPSIL0294-avitag does not express to a particularly high level based 
on the Coomassie stained ‘Total’ sample. Nonetheless it can be concluded that the protein is 
successfully solubilised and subsequently bound to the resin, based on the protein bands 
shown in the blot in conjunction with those resolved on the Coomassie stained SDS-PAGE in 
Figure 3.7. A small amount of MPSIL0294 is visible in the lane loaded with material that did not 
solubilise in DDM (Lane ‘pellet’, Figure 3.7). However, 10 times as much of the total material 
A) 
B) 
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was loaded on this lane compared to the other lanes, indicating that only 10% of MPSIL0294 
did not solubilise  
Like the MPSIL0294-SBP purification shown previously, some of the His-tagged protein has 
been lost after washing with the 40 mM imidazole buffer, in this instance however none of the 
25 kDa impurity was removed, therefore this wash could have been omitted from the 
purification procedure. The protein is of a reasonably high quality in regard to its purity after 
elution with 200 mM imidazole and was subjected to concentration in a 100 kDa vivaspin 
concentrator.  Spectrophotometry was used to estimate the final amount of protein at 0.35 mg 
from 200 mg of mixed membranes after the final eluate was subjected to dialysis and 
concentration.    
 
Figure 3.7: IMAC Purification of MPSIL0294-avitag: Samples taken throughout the MPSIL0294-avitag purification 
were analysed on a 12% SDS-PAGE gel with subsequent staining in Coomassie blue and by Western blotting 
probed with an anti-polyhistidine tag antibody conjugated with HRP. Each sample represents a different amount 
relative to the original sample they were taken from; the total, supernatant and flow-through represents 0.01%. 
A) 
B) 
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The pellet, 10 and 40 mM washes all represent 0.1% and the elution fraction and final elution represent 1% of the 
total samples size.   
3.3.3 The purification and subsequent labelling of MPSIL0294-V532C 
Membranes of MPSIL0294-V532C were prepared by David Sharples using a 30L fermenter via 
auto-induction. The protein was produced in BL21 star (DE3) and the membranes were 
isolated using the cell disruptor (see section 2.4.3). Once again samples taken throughout the 
purification protocol provide a clear profile of MPSIL0294-V532Cs behaviour throughout the 
procedure.  These samples were analysed by SDS-PAGE and western blotting probed with anti-
histidine antibody conjugated with HRP (in an identical manner as MPSIL0294-SBP and 
MPSIL0294-avitag) resulting in the data shown in Figure 3.8.  
Once again the majority of MPSIL0294-V532C was solubilised by 1.5% DDM. As described for 
the two other MPSIL0294 variants, relative to the total sample, ten times more was loaded for 
the non-solubilised protein fraction (‘pellet’) and the second wash step of the affinity column 
(’40 mM’, Figure 3.8) and relative small amounts of the protein yield was lost in these steps. 
However as is clear from Figure 3.8 a large fraction of the protein was lost due to its failure to 
bind to the resin and instead was found in the ‘flow-through’. The protein produced through 
elution with 200 mM imidazole has a highly pure. 
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Figure 3.8: IMAC purification of MPSIL0294-V532C: Samples from the purification of MPSIL0294-V532C were 
analysed by SDS-PAGE and western blotting with anti-polyhistidine tag antibody conjugated with HRP. As with 
the previous two purifications, samples from the total, supernatant and flow-through represent 0.01% of their 
respective fractions. The pellet, 10 and 40 mM washes represent 0.1% while the eluted protein fractions and final 
dialyzed protein represents 1%. 
Once purified the MPSIL0294-V532C was biotinylated with EZ-Link® Maleimide-PEG11-Biotin. 
The labelling efficiency (estimated via the HABA method) (see section 2.4.6) was shown to be 
0.46 biotin molecules per MPSIL0294 molecule. After spectrophotometric analysis, the final 
protein yield was determined to be 0.28 mg of MPSIL0294-V532C from 200 mg of mixed 
membrane.   
B) 
A) 
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3.3.4 The purification of AcrB 
AcrB was purified according to the procedure described in section 2.5.2 and the samples taken 
were analysed in a similar manner as described for MPSIL0294 resulting in the data presented 
in Figure 3.9.  AcrB has a high level of expression which is typified by the large protein band 
which has resolved at approximately 100 kDa in the ‘Total’ sample (see Figure 3.9A). The vast 
majority of this protein was successfully solubilised in 1% DDM hence no bands are present in 
the ‘Pellet’ sample when it is analysed by western blotting (see Figure 3.9B). A faint protein 
band has been produced on the blot in the ‘Flow-through’ sample indicating that some AcrB 
failed to bind to the cobalt resin and was lost. Despite this the protein is very pure once eluted 
via 200 mM imidazole. Spectrophotometric analysis showed that 0.5 mg of AcrB was purified 
from 100 mg of mixed membrane. While the final purified protein purer, based upon the blots 
shown in figures 3.6B and 3.9B, the purification of AcrB shows several similarities to that of 
MPSIL0294-SBP.    
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Figure 3.9: IMAC Purification of AcrB: Samples taken throughout the AcrB purification were analysed via 12% SDS-
PAGE and western blotting. The blot was treated with an anti-polyhistidine tag antibody conjugated with HRP 
while the SDS-PAGE gel was stained with Coomassie blue. The samples were normalized by volume to 10 µL 
therefore the total, supernatant and flow-through represent 0.01% of their original fractions while the pellet and 
washes represent 0.1%.       
 
B) 
A) 
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3.6 Transport of Zinc by MPSIL0294 
The transport of metal ions by MPSIL0294 was tested by reconstituting purified samples into 
liposomes loaded with the zinc sensitive dye fluozin-1 and measuring the intake of Zn ions via 
stopped flow analysis as described in section 2.7.2 (Chao and Fu 2004). The Fmax (i.e. the 
maximum amount of fluorescence which can be produced by the dye within the 
proteoliposomes) was determined with the use of 20 µM of the zinc ionophore pyrithione. The 
background fluorescence, F0, was measured by mixing proteoliposomes with assay buffer 
without any zinc, and subtracted from F (the fluorescence produced by the test sample) and 
Fmax to give ΔF and ΔFmax of which the ratio (ΔF/ΔFmax) is plotted as a function of time. However 
the transport assay was limited, no validation of the protein reconstitution was performed and 
neither the extent with which protein successfully integrated into the liposomes or the 
orientation of the successfully reconstituted protein were tested.      
3.6.1 Transport of Zn2+ ions in MPSIL0294-SBP 
Transport assays of MPSIL0294-SBP (and other mutants, see below) were also performed in 
order to prove functionality of this mutant and, by implication, to provide evidence that the 
protein is properly folded. Assays were carried out using two concentrations of Zn2+ ions (31.25 
and 3.905 µM). Figure 3.10 shows that MPSIL0294-SBP is functional as indicated by the rise of 
fluorescence in the presence of Zn (shown by the red and blue traces). The time trace shows a 
rapid increase in fluorescence for approximately 5 seconds, after which the signal plateaus and 
remains relatively constant. The sample mixed with 20 µM pyrithione produced more than 
twice the amount of fluorescence compared to MPSIL0294-SBP proteoliposomes. The 
pyrithione is expected to equilibrate the intravesicular compartments of the MPSIL0294-SBP 
proteoliposomes with zinc. However it is not clear why the samples analysed in the presence 
of pyrithione produce such a significant increase in fluorescence relative to those treated with 
zinc alone. This increase may be a consequence of empty liposomes in the proteoliposomal 
fraction which are able to produce fluorescence in the presence of the ionophore.  
The second zinc concentration (3.905 µM) which was tested produced a peak fluorescence 
reading of 0.290 almost instantaneously and is approximately 1.3 times smaller than the peak 
fluorescence produced in the presence of 31.25 µM Zinc. Finally F0 (proteoliposomes mixed 
with assay buffer in which no zinc was included) produces approximately the same level of 
fluorescence as the negative control as expected. 
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Figure 3.10 Zinc uptake assay with MPSIL0294-SBP proteoliposomes: Samples of purified MPSIL0294-SBP were 
reconstituted in liposomes loaded with the Zn2+ sensitive dye fluozin-1 and tested against two concentrations of 
ZnCl in order to assay the transport activity of MPSIL0294 using stopped flow analysis. The readings which have 
been plotted as result of mixing proteoliposomes with assay buffer containing 31.25 µM (red) and 3.905 µM 
(blue) Zinc are a result of dividing ΔF/Δ Fmax. Fmax of MPSIL0294-SBP was identified by the use of 20 µM of the zinc 
ionophore, pyrithione. The resultant Fmax reading for MPSIL0294-SBP is shown in black and represents the 
maximum possible fluorescence produced by the proteoliposomes. F0 is also shown in pink and was identified by 
mixing proteoliposomes with an assay buffer lacking Zn. A negative control was also carried out using empty 
liposomes mixed with 31.25 µM ZnCl (green), once again the readings on the graph represent the ΔF/Δ Fmax for 
the empty liposomes.            
3.6.2 Transport of Zn2+ ions in MPSIL0294-Avitag 
The transport assay was performed in an identical manner as described for MPSIL0294-avitag 
which undergone in vivo biotinylation in the E.coli strain AVB101 (see section 2.5.1.2). Analysis 
of the fluorescence produced by fluozin-1 loaded liposomes containing MPSIL0294-Avitag 
were analysed via stopped flow as before and were plotted as a function of time. The resultant 
graph shown in Figure 3.11 shows that the MPSIL0294-Avitag protein is not able to transport 
Zinc ions. It is unlikely that this is due to misfolding as the protein exhibited similar behaviour 
as the other two MPSIL0294 constructs during their purification (see section 3.3). While the 
SBP and avitag are quite different from one another, in regard to the method by which they 
bind streptavidin and their length (the avitag is 15 residues while the SBP tag is 38) as 
discussed below, the reason for this constructs lack of function is not understood at this 
moment.  
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There also appears to be an initial ‘spike’ in fluorescence in the proteoliposomes, the reason 
for this is not clear and experimental data has shown that it occurs in an unpredictable 
manner. Therefore I hypothesis that it is indicative of particularly leaky vesicles which either 
leak Zn2+ ions (once transported) or the dye itself causing an instant peak of fluorescence 
followed by immediate quenching.          
 
Figure 3.11 Zinc uptake assay with MPSIL0294-avitag proteoliposomes: The stopped flow analysis of samples of 
MPSIL0294-Avitag which had been subjected to in vivo biotinylation prior to the assay. The protein was 
reconstituted into liposomes loaded with the zinc sensitive dye flouzin-1 and mixed with an assay buffer 
supplemented with 31.25 µM ZnCl. The readings shown on the graph represent ΔF/ΔFmax (red), with the 
maximum amount of fluorescence(black) analysed with the use of pyrithione(a zinc ionophore). The same 
transport assay was carried out on empty liposomes which acted as a negative control (blue).    
  
3.6.3 Transport of Zn2+ ion in MPSIL0294-V532C 
The zinc uptake assay described above was also carried out on samples of MPSIL0294-V532C 
which had been biotinylated chemically with biotin maleimide. The amount of fluorescence 
produced by the proteoliposomes loaded with fluozin-1 (see Figure 3.12), were recorded by 
stopped flow and plotted as a function of time. As was the case with the MPSIL0294-avitag 
plot, an initial sharp ‘spike’ of fluorescence is observed in the sample when mixed with 31.25 
µM ZnCl. The MPSIL0294-V532C trace shows an initial surge similar to that displayed by 
MPSIL0294-avitag. The major difference between the two is in their respective Fmax traces. 
While MPSIL0294-V532C peaks at approximately the same point as the Fmax, MPSIL0294-avitag 
produces a very large trace which plateaus just below 5 A.U.  While it is not clear what is 
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causing this initial spike, it could be due to a rapid influx of Zn ions which saturate the 
encapsulated dye, therefore producing fluorescence, which is then rapidly quenched, possibly 
due to leaky vesicles allowing Zn2+ to leave once again, until the florescence remains constant. 
The fact that the level of florescence remains approximately 0.75 times higher than the 
negative control, suggests that the MPSIL0294-V532C is active, however a more reliable 
transport assay would be required to confirm this. 
 
Figure 3.12 Zinc uptake assay with MPSIL0294-V532C proteoliposomes: Stopped flow analysis of samples of 
MPSIL0294-V532C which had undergone chemical biotinylation of its accessible cysteine with biotin maleimide 
prior to the assay. The protein was reconstituted into liposomes loaded with flouzin-1 and mixed with an assay 
buffer supplemented with 31.25 µM ZnCl. The readings shown in red on the graph represent ΔF/ΔFmax. The 
maximum amount of fluorescence is shown in black and was analysed with the use of 20 µM pyrithione (a zinc 
ionophore). The same transport assay was carried out on empty liposomes which acted as a negative control and 
are shown in blue.    
3.6 Quality control of phage display samples 
3.6.1 Indirect ELISA of MPSIL0294 variants on neutravidin coated plates 
In order to show that the various MPSIL0294 variants could bind a solid streptavidin coated 
surface no matter the method of immobilisation employed, the various forms of MPSIL0294 
were subjected to ELISA probed with an anti-polyhistidine tag antibody as described in section 
2.6.2. These ELISAs involved immobilising the various proteins onto the surface of manually 
produced neutravidin coated plates thereby providing a useful analogue for the subsequent 
phage display procedure, except here we use neutravidin instead of streptavidin. Due to their 
structural similarities, neutravidin is often used interchangeably with streptavidin (the 
difference between the two being the removal of streptavidin glycosylation sites). Especially as 
they both have very similar affinities for biotin and isoelectric points. While it was highly 
probable that MPSIL0294-avitag and MPSIL0294-V532C would successfully bind to the 
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neutravidin surface (as they are both biotinylated). It was unclear if MPSIL0294-SBP would also 
be able to do so, however due to neutravidin and streptavidin’s extreme functional similarity 
the SBP/neutravidin interaction was presumed.   
The ELISA results for each of the three MPSIL0294 formats are represented graphically in 
Figure 3.13 and show that while each of the protein formats follow a similar trend when 
subjected to this test they have different magnitudes. MPSIL0294-V532C produces the highest 
A450nm trace and the highest reading in the presence of 50 µg/mL antigen. Intriguingly both the 
chemically biotinylated MPSIL0294-V532C and the in vivo biotinylated MPSIL0294-avitag 
appear to suffer from a hook affect at the highest concentration (100 µg/mL) which would 
suggest a very high concentration of analyte on the surface. While this was deemed sufficient 
for this study due to time constraints, the success of these two proteins could be tested by 
repeating this ELISA with non-biotinylated samples. This effect doesn’t appear in the trace for 
MPSIL0294-SBP, possibly due to the fact that neutravidin was used as opposed to streptavidin. 
Nevertheless it appears as if each of the three detergent solubilised variants saturate the 
neutravidin coated plate at 50 µg/mL and is therefore suitable for phage display screening. 
  
 
Figure 3.13 Quality control ELISA with detergent solubilised samples of the three MPSIL0294 variants: Each 
different MPSIL0294 variant was immobilised on a neutravidin coated plate in a serial dilution from 100 to 0.098 
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µg/mL and subjected to ELISA probed with an anti-polyhistidine tag antibody conjugated with HRP. Each 
concentration was performed in duplicate and the absorbance readings were measured spectrophotometrically 
after treatment with TMB stop solution followed by 0.5M H2SO4.   
3.6.2 Analysis of detergent solubilised MPSIL0294 variants by Fluorescence-
activated cell sorting 
As a secondary method of assessing the three different MPSIL0294 variants ability to 
immobilize on a streptavidin coated surface they were each subjected to FACs analysis as 
described in section 2.6.3 using streptavidin coated magnetic Dynabeads® (Thermo scientific). 
A mouse anti-polyhistidine tag antibody was used as a primary while a goat anti-mouse 
antibody conjugated with DyLight 488 was used as a secondary for this analysis. The overlay 
histograms shown in Figure 3.14 show that there is distinctively more intense fluorescence on 
the Dynabeads® incubated with the MPSIL0294 variants compared with the negative control 
(which were blank beads). This increase in fluorescence represent an increase in secondary 
antibody and thus an increase in MPSIL0294 material immobilised on the Dynabeads®.  
It is therefore clear that all three of the detergent solubilised MPSIL0294 are successfully able 
to immobilise on the surface of the streptavidin coated beads, while maintaining the 
accessibility of the polyhistidine tag to the antibody as they all show an increase in 
fluorescence when compared with the negative control (the blank beads). Two of the 
detergent solubilised MPSIL0294 variants performed particularly well in this assay (in regard to 
their ability to immobilise on beads), namely MPSIL0294-SBP and MPSIL0294-avitag as they 
produce an identical level of fluorescence that almost matches the positive control (a 
biotinylated, his-tagged protein extensively worked on by MedImmune which shall be referred 
to as ‘protein x’ from here on). ‘Protein x’ was bound to the beads at the same molar 
concentration as the MPSIL0294 variants, however it is considerably smaller, therefore it is 
possible that the increase in fluorescence which ‘protein x’ exhibits in the FACs analysis is due 
to an increased amount of packing on the surface of the beads.  
The overlay histogram in Figure 3.14 shows that the MPSIL0294-SBP peak is higher than the 
MPSIL0294-avitag, thus suggesting that it was better able to pack on the beads; although it 
appears that both are almost able to saturate the beads in a similar manner as the positive 
control. The Dynabeads modified with this variant exhibit a more homogeneous fluorescence 
profile with less of the Dynabeads exhibiting a lower fluorescence compared to MPSIL0294-
avitag. MSPIL0294-V532C shows the least binding to streptavidin in this particular assay, but 
still shows that the protein is successfully able to immobilise onto the beads.  
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The three MPSIL0294 variants were immobilised onto the beads in the presence of 0.05% DDM 
as properly folded protein immobilised on the surface of the plate was required in order to 
isolate confirmation specific DARPins during phage display. However there is no evidence 
provided in this study that the protein, once immobilised, is in its native confirmation. 
  
 
Figure 3.14: FACs analysis of detergent solubilised samples of the three MPSIL0294 variants with streptavidin 
coated beads: FACs analysis was performed on each of the detergent solubilised variants of MPSIL0294 mixed 
with magnetic streptavidin coated DynaBeads® (Thermo scientific). The primary antibody was against the 
polyhistidine tag while a goat anti mouse antibody conjugated with DyLight 488 was used as the secondary. A 
biotinylated, his-tagged ‘protein x’ was the positive control. Blank streptavidin coated magnetic beads were used 
as the negative control.   
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3.7 A Comparison of different methods of membrane protein 
immobilisation using phage display 
Each of the samples was subjected to two rounds of phage display with a functional DARPin 
library of 7.5 x 109 (data provided by MedImmune) as described in section 2.8. In an attempt 
to retain the tertiary structure of the target protein during the phage display panning, 
selection was performed in the presence of 0.05% DDM throughout (see section 2.8) instead 
of the more commonly used Tween20. In chapter 4, experiments are described where 
different methods of membrane protein ‘solubilisation’ are compared. The experiments 
described here compared alternative methods of membrane protein immobilisation (and to 
obtain a high affinity DARPin binder). As such, ideally a minimum of three rounds of phage 
display would typically be employed, however due to time constraints only two rounds of 
panning could be performed, thereby increasing the risk of background noise in the selection 
output.  
As previously mentioned (see section 2.8.3) the input titre for a phage selection typically 
should fall between 5 x 1011 – 1013 while the output should be 103 – 106. Table 3.1 shows that 
all of the titres calculated for the detergent solubilised samples fall well within this remit, with 
MPSIL0294-avitag having the highest input titre (5 x 1012) while AcrB has the lowest output 
titre with 6.5 x 105.  
The selection diversity was calculated by aligning the DARPin amino acid sequences after the 
selection was complete and the 88 DARPins were sequenced. Any repeats within the selection 
output were removed and the remaining number of unique sequences divided by 88 to give 
the diversity in percentages). The sequence diversity can be used as an early indicator of the 
quality of the selection output. It is generally desirable for the diversity to be moderately high, 
as a very low percentage may be an indicator of sequence bias within the output, a common 
sign that the majority of DARPins are binding directly to the streptavidin. Conversely, a 
sequence diversity which is too high may be an indicator of a lack of selectivity in the output. 
The highest sequence diversity of the detergent solubilised samples has been attained by 
MPSIL0294-SBP, while the output with the lowest diversity is the in vivo biotinylated 
MPSIL0294-Avitag (see Table 3.1). Despite this, all of the samples fall within an acceptable 
range.          
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 Sample Method of 
immobilisation 
Input Titre 
(cfu/mL) 
Output Titre 
(cfu/mL) 
Sequence 
Diversity 
MPSIL0294-SBP SBP binding 3.6 x 10
12 1.315 x 106 86% 
MPSIL0294-
Avitag 
In vivo 
biotinylation 
5 x 10
12 8.5 x 105 72% 
MPSIL0294-
V532C 
Biotinylation via 
Cys residue 
2.6 x 10
12 1.145 x 106 81% 
AcrB Lysine 
biotinylation 
4 x 10
12 6.5 x 105 77% 
 
Table 3.1 An overview of the titres produced after phage display carried out on the detergent solubilised 
members of the membrane protein panel: All samples were solubilised in DDM and were immobilised within the 
resultant micelles. They subsequently subjected to two rounds of phage display against a DARPin library. All of 
the selections were also carried out in the presence of DDM and at 4°C. The input titre was calculated after round 
one of phage display while the output titre was calculated after round two.  
3.7.1 Removing streptavidin binding DARPins via Phage ELISAs on 
blank streptavidin plates 
 
3.7.1.1 The Three Detergent solubilized MPSIL0294 variants  
During the selection the phage were deselected against streptavidin in a single deselection 
step using streptavidin coated beads, however as previously stated two rounds of selection 
carries a high risk of background noise in selection outputs. Therefore phage ELISAs against 
streptavidin were carried out on the selection outputs of the detergent solubilised MPSIL0294 
as described in section 2.9.2 in order to exclude any DARPins that bind directly to streptavidin. 
A threshold A450nm value of 0.1 was used in order to reduce the large amount of data to a more 
manageable level. Any DARPin which crossed this threshold was deemed capable of binding to 
directly to streptavidin to some extent and was no longer studied. Table 3.2 shows that 
between the three methods of immobilising MPSIL0294 there is a vast difference in the 
number of DARPins which appear to cross the threshold. The SBP tagged MPSIL0294 only has 
19 sequences which did not produce a signal in the presence of streptavidin thereby making it 
the worst of the three as the avitagged protein produced 85 potential binders while V532C 
produced 67.  
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Interestingly within the DARPins capable of binding to streptavidin, V532C was the only version 
of MPSIL0294 which produced DARPins capable of binding streptavidin strongly (i.e. DARPins 
which produced an A450nm value above 1.0). In total 14 of the 21 DARPins which were rejected 
at this point showed a strong ability to bind, this is a characteristic unique to the V532C output 
as neither the SBP or the avitagged protein produced any strong streptavidin binders. In regard 
to the other two detergent solubilised MPSIL0294 samples, the 3 rejected DARPins from the 
avitagged protein are actually relatively close to the threshold and thus are considered weak 
streptavidin binders. The SBP tagged protein on the other hand mainly produced DARPins with 
a moderate streptavidin binding ability with A450nm values ranging between 0.5 and 0.7 (see 
Table 3.2).    
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            MPSIL0294-SBP 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 0.188 0.189 0.381 0.438 0.071 0.059 0.081 0.728 0.394 0.669 0.354 0.075 
B 0.554 0.222 0.367 0.694 0.454 0.406 0.338 0.244 0.214 0.876 0.255 0.051 
C 0.046 0.13 0.728 0.16 0.087 0.191 0.514 0.118 0.477 0.684 0.432 0.025 
D 0.1 0.081 0.22 0.29 0.637 0.325 0.433 0.278 0.439 0.587 0.462 0.057 
E 0.22 0.147 0.08 0.133 0.109 0.447 0.36 0.408 0.152 0.598 0.478 0.051 
F 0.059 0.268 0.107 0.227 0.148 0.304 0.535 0.455 0.149 0.74 0.53 0.041 
G 0.047 0.166 0.071 0.161 0.198 0.089 0.095 0.054 0.232 0.142 0.411 0.048 
H 0.057 0.094 0.085 0.086 0.274 0.305 0.135 0.129 0.439 0.065 0.076 0.062 
 
MPSIL0294-Avitag 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 0.08 0.073 0.082 0.064 0.055 0.082 0.064 0.055 0.067 0.05 0.063 0.082 
B 0.072 0.053 0.054 0.09 0.047 0.051 0.073 0.054 0.046 0.053 0.053 0.049 
C 0.057 0.06 0.053 0.048 0.068 0.047 0.064 0.05 0.058 0.055 0.051 0.056 
D 0.052 0.059 0.08 0.057 0.052 0.061 0.061 0.07 0.053 0.05 0.057 0.044 
E 0.044 0.062 0.058 0.065 0.059 0.062 0.062 0.172 0.287 0.049 0.068 0.056 
F 0.057 0.078 0.061 0.06 0.061 0.065 0.063 0.048 0.053 0.056 0.048 0.044 
G 0.058 0.068 0.292 0.06 0.062 0.061 0.055 0.066 0.054 0.051 0.054 0.054 
H 0.06 0.051 0.057 0.051 0.054 0.049 0.054 0.051 0.07 0.054 0.05 0.042 
 
MPSIL0294-V532C 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 0.044 0.068 0.087 0.076 0.072 0.081 0.061 0.071 0.062 0.075 1.11 0.056 
B 0.055 0.06 0.31 0.08 0.088 0.09 0.073 0.078 0.063 0.071 1.415 0.046 
C 0.041 0.055 0.096 1.12 0.07 0.077 1.411 0.226 0.077 1.487 0.098 0.052 
D 0.047 0.068 0.08 0.095 0.073 0.059 0.083 0.067 0.083 0.094 0.088 0.061 
E 0.075 1.281 0.104 0.094 0.441 0.069 0.064 0.067 0.066 1.322 0.075 0.057 
F 1.025 0.086 1.235 1.484 1.279 0.061 0.055 0.069 0.067 0.089 0.073 0.044 
G 0.062 0.057 1.141 0.111 0.113 0.065 0.52 0.06 0.058 0.076 0.072 0.05 
H 0.052 0.052 0.309 1.174 1.355 0.048 0.047 0.049 0.048 0.049 0.048 0.041 
 
Table 3.2 Quality control of the selection outputs generated against the three MPSIL0294-variants performed on 
blank streptavidin coated plates: The data produced after the selection outputs from each detergent solubilised 
form of MPSIL0294 is analysed via phage ELISA on blank streptavidin plates with an M13 antibody conjugated 
with HRP followed by treatment with TMB solution and 0.5M H2SO4. All DARPins which do not show an ability to 
bind directly to streptavidin are highlighted in green, weak streptavidin binders are highlighted in yellow while 
DARPins which bind streptavidin moderately are highlighted in orange. Finally, DARPins which strongly bind to 
streptavidin are highlighted in red and the negative control values are written in blue text.  
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3.7.1.2 Detergent solubilized AcrB  
Detergent solubilised AcrB protein was immobilised via chemical biotinylation with NHS-Biotin 
(see section 2.4.4) and subjected to two rounds of phage display as previously described. The 
selection output was then analysed so that any DARPins with a capability to bind directly to 
streptavidin could be identified via phage ELISA carried out in an identical manner as described 
previously (see section 2.9.2). Table 3.3 shows the results of the AcrB phage ELISA and 
resulted in 33 DARPins which did not produce an A450nm reading above 0.1 in the presence of a 
blank streptavidin plate and were therefore taken for further study. Of the 55 DARPins which 
did show an ability to bind, one produced a signal over 1.0 while the rest were moderate in a 
similar vein as MSIL0294-SBP (see Table 3.2).              
Detergent solubilised AcrB 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 0.096 0.059 0.379 0.097 0.071 0.087 0.063 0.062 0.28 1.985 0.171 0.058 
B 0.076 0.067 0.334 0.13 0.709 0.272 0.081 0.372 0.076 0.109 0.073 0.045 
C 0.121 0.097 0.269 0.501 0.273 0.182 0.433 0.181 0.058 0.161 0.207 0.052 
D 0.11 0.137 0.241 0.054 0.119 0.12 0.49 0.09 0.104 0.431 0.148 0.096 
E 0.048 0.061 0.123 0.183 0.35 0.937 0.395 0.071 0.149 0.201 0.537 0.065 
F 0.054 0.519 0.052 0.098 0.114 0.74 0.476 0.097 0.142 0.093 0.641 0.047 
G 0.056 0.391 0.064 0.075 0.357 0.132 0.28 0.33 0.073 0.13 0.064 0.056 
H 0.063 0.052 0.073 0.07 0.319 0.079 0.231 0.053 0.135 0.27 0.073 0.046 
 
Table 3.3 Quality control phage ELISA of selection output generated against detergent solubilised AcrB:  The data 
produced after a phage ELISA on a blank streptavidin plate using the selection output isolated against AcrB 
solubilised and presented within DDM micelles. The plates were probed with an anti M13-HRP antibody 
conjugate and visualised with TMB solution followed incubation with 0.5 M H2SO4. The absorbance of the plate 
was then analysed at 450 nm and all DARPins with a reading over 0.1 were no longer studied. DARPins 
highlighted in green were taken on for further validation; those which bind streptavidin weakly are highlighted in 
yellow. DARPins which bind streptavidin moderately are highlighted in orange while those that bind strongly are 
highlighted in res. Finally, A450nm readings in blue were the negative control in which no phage was added.          
3.7.2 Refining selection outputs via Phage ELISA in the presence of 
target protein 
3.7.2.1 The three detergent solubilized MPSIL0294 variants 
 A phage ELISA was performed the phage identified in Section 3.7.1. These ELISAs were done 
against the same MPSIL0294 variant used during the screening (panning) procedure in order to 
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validate the selection outputs against each target and confirm the DARPins ability to bind 
them. In this repeat 100 µg of target protein was first immobilised onto the streptavidin 
coated surface and tested against the DARPins which did not produce a signal in the previous 
phage ELISAs (see Table 3.2) as described in section 2.9.3. In order to attain a more 
manageable amount of data, a threshold A450nm value of 1.0 was selected for these phage 
ELISAs. The resultant 96 well plates shown in Table 3.4 shows that the vast majority of DARPins 
failed to produce a strong signal in the presence of the various detergent solubilised 
MPSIL0294 variants. The majority of the phage isolated against MPSIL0294-avitag (66 out of 
the 85 DARPins of interest) produced a signal between 0.1 and 0.5 which could be considered 
very weak binders. This pattern is unique to this variant as MPSIL0294-V532C and MPSIL0294-
SBP only produced 6 and 4 DARPins respectively which were capable of producing a similar 
signal. However MPSIL0294-V532C was able to produce two DARPins which appeared to 
strongly bind the target at positions E6 and G6 respectively (see Table 3.4, MPSIL0294-V532C).  
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 Detergent solubilised MPSIL0294-SBP 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 0.061 0.043 0.038 0.041 0.083 0.091 0.096 0.04 0.044 0.042 0.04 0.067 
B 0.054 0.044 0.047 0.048 0.049 0.05 0.055 0.053 0.05 0.052 0.046 0.054 
C 0.089 0.038 0.035 0.039 0.082 0.043 0.041 0.049 0.039 0.038 0.039 0.064 
D 0.051 0.107 0.048 0.05 0.046 0.049 0.055 0.051 0.049 0.049 0.048 0.059 
E 0.031 0.037 0.078 0.038 0.039 0.037 0.04 0.041 0.039 0.039 0.039 0.067 
F 0.125 0.049 0.047 0.048 0.048 0.049 0.05 0.045 0.048 0.054 0.046 0.061 
G 0.072 0.035 0.076 0.036 0.038 0.069 0.081 0.071 0.039 0.041 0.044 0.076 
H 0.1 0.094 0.095 0.1 0.049 0.048 0.05 0.046 0.049 0.109 0.095 0.058 
 
Detergent solubilised MPSIL0294-Avitag 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 0.089 0.108 0.159 0.144 0.103 0.112 0.163 0.13 0.092 0.126 0.115 0.099 
B 0.119 0.153 0.217 0.151 0.183 0.136 0.199 0.218 0.135 0.184 0.148 0.093 
C 0.089 0.106 0.125 0.11 0.099 0.096 0.116 0.157 0.152 0.125 0.159 0.079 
D 0.095 0.133 0.145 0.111 0.145 0.131 0.166 0.175 0.149 0.143 0.145 0.061 
E 0.067 0.1 0.124 0.092 0.114 0.136 0.108 0.042 0.039 0.125 0.112 0.074 
F 0.103 0.114 0.131 0.144 0.139 0.133 0.143 0.138 0.152 0.153 0.147 0.069 
G 0.066 0.096 0.037 0.104 0.078 0.083 0.098 0.094 0.075 0.078 0.093 0.072 
H 0.107 0.107 0.101 0.105 0.1 0.101 0.105 0.106 0.106 0.114 0.098 0.062 
 
Detergent solubilised MPSIL0294-V532C 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 0.058 0.087 0.068 0.059 0.062 0.065 0.064 0.068 0.045 0.063 0.041 0.065 
B 0.089 0.095 0.044 0.082 0.079 0.084 0.082 0.072 0.055 0.086 0.061 0.069 
C 0.059 0.083 0.065 0.038 0.059 0.07 0.04 0.038 0.043 0.037 0.207 0.068 
D 0.089 0.104 0.106 0.091 0.088 0.095 0.085 0.092 0.054 0.09 0.097 0.071 
E 0.062 0.037 0.039 0.052 0.041 1.233 0.177 0.062 0.042 0.038 0.081 0.065 
F  0.091 0.048 0.049 0.046 0.089 0.087 0.08 0.05 0.08 0.114 0.066 
G 0.054 0.068 0.039 0.038 0.063 1.31 0.041 0.06 0.045 0.115 0.071 0.065 
H 0.092 0.079 0.048 0.049 0.048 0.091 0.079 0.075 0.052 0.074 0.084 0.056 
Table 3.4 The Secondary quality control phage ELISA against the three detergent solubilised MPSIL0294 variants 
selection outputs:  Phage ELISAs were performed on streptavidin coated plates on which 100 µg of the three 
detergent solubilised MPSIL0294 variants had been immobilised. The ELISAs were probed with anti- M13 
antibody conjugated with HRP, they were visualised by incubation with TMB followed by treatment with 0.5 M 
H2SO4 and analysis of it absorbance at 450 nm. Values which have been redacted in black denote the DARPins 
which showed an ability to bind streptavidin directly while green values are DARPins which showed an ability to 
bind to MPSIL0294. Values highlighted in red represent DARPins which failed to bind to the target while those in 
yellow represent DARPins considered very weak binders.           
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3.7.2.2 Detergent solubilized AcrB  
The phage ELISAs were also carried out on samples of detergent solubilised AcrB which had 
been chemically biotinylated. These ELISAs were performed in an identical manner as 
described above for the detergent solubilised MPSIL0294 variants and were once again 
designed to further validate the selection output. As shown in Table 3.5 no DARPins were able 
to produce a reading which surpassed the 1.0 A450nm threshold. Unlike MPSIL0294 none of the 
tested DARPins (of the 39 DARPins which did not show any activity on blank streptavidin 
coated plates) were able to cross 0.1, with the highest being DARPin B1 with an A450nm of 0.096. 
Detergent solubilised AcrB 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 0.061 0.053 0.045 0.048 0.045 0.043 0.044 0.036 0.037 0.036 0.04 0.049 
B 0.096 0.088 0.046 0.045 0.045 0.047 0.071 0.045 0.067 0.049 0.07 0.04 
C 0.032 0.053 0.035 0.037 0.035 0.036 0.037 0.036 0.045 0.037 0.038 0.051 
D 0.052 0.047 0.046 0.052 0.046 0.048 0.053 0.069 0.047 0.05 0.047 0.044 
E 0.061 0.062 0.056 0.035 0.038 0.035 0.038 0.045 0.036 0.037 0.04 0.054 
F 0.083 0.048 0.082 0.048 0.044 0.047 0.049 0.069 0.046 0.08 0.048 0.047 
G 0.049 0.05 0.051 0.051 0.036 0.036 0.035 0.039 0.052 0.038 0.048 0.048 
H 0.075 0.068 0.075 0.078 0.05 0.075 0.051 0.074 0.048 0.056 0.074 0.042 
 
Table 3.5 The secondary quality control phage ELISA of the detergent solubilised AcrB selection output: The data 
produced by the phage ELISA performed on streptavidin coated plates on which 100 µg AcrB in DDM micelles 
which had been immobilised via chemical biotinylation. The plates were probed with anti-M13 antibody 
conjugated with HRP and visualised using TMB. Incubation with H2SO4 stopped this reaction and allowed for its 
absorbance at 450 nm to be analysed. Black squares have been used to represent the DARPins which were 
removed due to their ability to bind directly to streptavidin in the previous phage ELISAs.     
3.7.3 An overview of phage display on different methods of membrane 
protein immobilisation 
Each of the immobilised target proteins was subjected to the identical regimen of procedures 
in order to isolate DARPins capable of binding and subsequently validate them. These 
procedures included the initial two rounds of phage display which were performed on a 96 
well plate and resulted in the isolation of 88 DARPins (stage 1). Followed by the initial phage 
ELISAs aimed at identifying DARPins capable of binding directly to streptavidin (stage 2). 
Thirdly, the phage ELISAs were repeated in the presence of immobilised target protein in order 
to validate their ability to bind (stage 3) and finally the DARPins with A450nm readings above the 
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threshold were taken on for further study (stage 4). The outcome of this procedure is outlined 
in Table 3.6 and shows that neither the C-terminal avitag which had undergone in vivo 
biotinylation, the C-terminal SBP tag or the aspecifically biotinylated AcrB were able to isolate 
any DARPins after stage 3. MPSIL0294-V532 on other hand managed to isolate two DARPins 
(E6 and G6) which are seemingly able to bind the protein and were taken for further study (see 
Chapter 5). 
  
Target 
Method of 
Immobilisation 
Method of 
Solubilisation 
Stage 1 Stage 2 Stage 3 
MPSIL0294 
 
 
Avitag DDM 88 85 0 
SBP DDM 88 19 0 
Cys/Biotin 
maleimide 
DDM 88 67 2 
AcrB 
Lysine 
Biotinylation 
DDM 88 33 0 
 
Table 3.6 An Overview of the entire phage display and subsequent validation steps performed on all detergent 
solubilised target proteins: The detergent solubilised protein samples aimed to compare alternative methods of 
protein immobilisation via either different tags or aspecific biotinylation. The data has been compiled through 
the three stages of DARPin isolation: Stage 1 represents the initial two rounds of phage display carried out in 96 
well plates, in each instance 88 arbitrary DARPins were isolated prior to sequencing. Stage 2 was the phage 
ELISAs performed on blank streptavidin plates while Stage 3 was the second round of phage ELISAs performed in 
the presence of immobilised target protein. The two DARPins which seemingly bound to MPSIL0294-V532C were 
further characterised in chapter 5. The numbers in each cell of denote the number of DARPins available for the 
subsequent stage of validation.      
3.8 Discussion and conclusion 
In this chapter two model membrane proteins were prepared in a variety of different formats 
for phage display, in order to compare different methods of membrane protein immobilisation 
and presentation and generate successfully binding DARPins. The different immobilisation 
methods under test are all based around the interaction between streptavidin and biotin and 
involve the use of different C-terminal tags on a model membrane protein – MPSIL0294. The 
tags were placed on its C-terminal because Dr Cheng Ma has previously shown that a C-
terminal His tag does not affect its expression or ability to transport metal ions. However when 
the expression levels of MPSIL0294-CVH produced by Dr. Cheng Ma are compared with those 
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of MSPIL0294-SBP, avitag and V532C (shown by the ‘Total’ samples of Coomassie stained SDS-
PAGEs in Figure 3.5, Figure 3.6 and Figure 3.7) it is clear that there is a sharp decrease, 
therefore resulting in lower yields of protein (Ma 2013). Also zinc uptake assays appear to 
suggest that MPSIL0294-avitag is not active. This lack of function is not caused by the 
polyhistidine tag as the other constructs have this tag and are functional, although a more 
consistent transport assay would help to clarify this (see section 3.6). Despite this, enough 
protein was obtained for phage display as demonstrated by the fact that each of the 
MPSIL0294 variants successfully saturated a neutravidin coated plate probed with an anti-
polyhistidine tag antibody conjugated with HRP in Figure 3.13. This ELISA result alongside the 
FACs analysis shown in Figure 3.14 provides evidence that the proteins can be immobilised 
while retaining their accessibility to a binding probe, which in both of these instances was an 
antibody against the C-terminal polyhistidine tag.   
The purifications for two of the differently tagged forms of MSIL0294 (SBP and the biotinylated 
avitag) exhibit what appear to be degradation products on the blots shown in Figure 3.5 and 
Figure 3.6. These superfluous bands cannot definitively be identified as MPSIL0294, but the 
fact that they appear on the blot shows that they must have a polyhistidine tag therefore it is 
very likely that they are. The fact that the MPSIL0294-V532C does not exhibit the same 
behaviour suggests that this is not being caused by a protease, as all three MPSIL0294 variants 
were purified in an identical manner with the exception of 0.5 mM TCEP in all buffers for the 
MPSIL0294-V532C purification (see section 2.5.1). The addition of TCEP prevented the 
undesired formation of disulphide bridges with endogenous E.coli proteins and subsequent co-
purification. Potentially degraded protein relative to the full length MPSIL0294 is barely 
detectable on Coomassie stained SDS-PAGEs.  
AcrB was included as a second model membrane protein in the comparison of alternative 
immobilisation strategies. Like MPSIL0294 it was solubilised in DDM and presented to the 
DARPin library in the presence of 0.05% DDM (see section 3.3.4). As previously mentioned 
AcrB was chosen due to its large extracellular loop which is thought to form a TolC docking 
domain after the protein forms the functional trimer. This soluble loop could make the 
isolation of binding proteins against AcrB easier. A second reason for its inclusion is the fact 
that there is precedence for the isolation of DARPins against AcrB which were subsequently 
found to act as an inhibitor to the protein and were used as crystallisation partners 
(Sennhauser, Amstutz et al. 2007, Eicher, Cha et al. 2012, Du, Wang et al. 2014). Sennhauser et 
al, isolated DARPins using four rounds ribosome display on chemically biotinylated detergent 
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solubilised samples presented to the library in 0.03% DDM. The study presented here followed 
a very similar outline however despite this, no DARPins showed an ability to bind to the 
detergent solubilised AcrB. This inability to isolate DARPins is probably due to the fact that only 
two cycles of phage display were utilised during the selection and only 88 DARPins were 
selected arbitrarily as a result of it. Two rounds of phage display will suffer from a high level of 
background in the results, however the selection was designed in this manner because this 
study aims to compare immobilisation strategies rather than specifically isolate DARPins to 
particular targets. Therefore an increase in the number of cycles and the number of phage 
particles selected would most likely alleviate this problem. It must also be noted that due to 
time constraints, no validation was performed that looked at the ability of biotinylated AcrB to 
immobilise on a streptavidin coated surface however. Therefore, the lack of successfully 
binding DARPins to detergent solubilised AcrB due to its poor immobilisation on the surface 
cannot be ruled out. ELISAs should be performed in which streptavidin plates are coated with a 
titration of serially diluted biotinylated AcrB probed with an anti-His-HRP antibody conjugate.     
The FACs data in Figure 3.14 suggests that when compared with the other two, less 
MPSIL0294-V532C is able to immobilise to a streptavidin coated surface. However, the ELISA 
data shown in Figure 3.13 does not support this notion as it appears as though the MPSIL0294-
V532C is most able to saturate the plate. . It may be that while the MPSIL0294-avitag and 
MPSIL0294-SBP are able to saturate a streptavidin coated surface. On the other hand in the 
case of MPSIL0294-V532C it may be that its inability to do so may result in a population of 
DynaBeads® which do not produce fluorescence thus explaining the overlay histogram. 
However, the saturation of a streptavidin coated surface by MPSIL0294-avitag and MPSIL0294-
SBP may decrease the accessibility of the polyhistidine tag antibody conjugated with HRP 
leading to the decrease in magnitude of the fluorescent traces in the ELISA (see Figure 3.13). 
As a subsequent consequence of MPSIL0294-V532C’s decrease in immobilisation, it is possible 
that more bare streptavidin was exposed to the DARPin library during the phage display 
selections thus resulting in the increase in streptavidin binders observed in Table 3.2. While 
this is theoretically possible the fact that the ELISA was performed on neutravidin while the 
FACs and phage display were performed on streptavidin may also account for the differences 
between the ELISA and the FACs which are observed, particularly with MPSIL0294-SBP.    
The validation experiments highlighted several differences between all three MPSIL0294-
variants. Firstly MPSIL0294-SBP isolated far more DARPins capable of moderate binding to 
streptavidin (see Table 3.1) when compared with its two counterparts. While MPSIL0294-
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V532C was the only variant that isolated DARPins capable of binding to the target after the 
two validation tests (see Table 3.2). This unfortunately is not enough data to draw any 
meaningful conclusions. Although fundamental differences in the nature of the interaction 
which results in the immobilisation of the protein may be a factor. For instance, while 
MPSIL0294-avitag and MPSIL0294-V532C both rely on the biotin/streptavidin interaction, the 
SBP tag binds directly to streptavidin. Binding is dependent upon a HVV motif in the SBP N-
terminal and a HPQ motif in its C-terminal, thus occupying two of the four biotin binding 
pockets within streptavidin, while several of the central residues form an α-helix (SBP is 
comprised of 35 residues in total) which do not play a role (Barrette-Ng, Wu et al. 2013). While 
two SBPs can bind to a single streptavidin molecule, four biotins are able to bind with a single 
molecule occupying on of the aforementioned biotin binding pockets. This means that the 
MPSIL0294 variants differ from one another in regard to the density with which they can pack 
on a solid surface. A decrease in which may in turn be beneficial to the isolation of binding 
partners via phage display. However it is not clear if all four of these binding pockets are 
accessible once streptavidin has been immobilised onto a solid surface. Also, it is unlikely that 
a single streptavidin would be able to accommodate either two SBP tagged, or four 
biotinylated MPSIL0294 molecules due to steric hindrance, especially due to the large size of 
the DDM micelle. Nevertheless, if the density with which MPSIL0294 is able to pack on the 
streptavidin coated surface has an influence on the number of binding partners isolated after 
phage display, it could be tested by comparing different surface coverages in a comparative 
phage display screen in which the number of binding proteins isolated are compared.     
Alternatively the isolation of the two DARPins by MPSL0294-V532C may be due to the 
flexibility the protein is afforded by the presence of a PEG11 linker separating the maleimide 
group from the biotin in the biotinylation reagent. This seems unlikely however as the PEG 
linker separating the protein from the tag is similar in length to the amino acid linker which 
separates the protein from both the SBP and avitag (PEG11 is approximately the same length as 
an amino acid chain with 11 residues).  As mentioned earlier the SBP tag is 35 residues long 
but immobilises the protein by binding to the streptavidin directly via its terminals (Barrette-
Ng, Wu et al. 2013), the linker which separates the SBP from MPSIL0294 is 15 residues. 
Similarly the avitag is composed of 15 residues and biotinylation occurs at the lysine residue in 
the 10th position. Once again the linker which separates MPSIL0294 from the avitag is 15 
residues long. It is not clear if increasing the amount of flexibility that the linker provides to the 
target protein will improve the number of DARPins which are isolated by phage display. A 
potential method to test this would be to label MPSIL0294-V532C with a panel of biotinylation 
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reagents with alternative length PEG linkers separating the maleimide and biotin, while the 
amino acid linker separating the MPSIL0294 from the SBP or the avitag is increased. All of 
these altered variants could then be subsequently subjected to two rounds of phage display as 
described here.  
The amino acid sequences of the two DARPins (E6 and G6) which showed an ability to bind to 
MPSIL0294 are markedly similar to one another as can be seen in Figure 3.15. In several 
positions within the variable regions for example at positions 33, 64 and 77 of the DARPin 
either the same amino acid is present, amino acids with a similar side chain or residues with 
the same physical characteristics. When aligned with a third DARPin (DARPin H2 which 
produced an A450nm value of 0.079) from the same selection output it appears to confirm the 
proposition that the chemical nature of the amino acids at position 33, 64 and 77 are 
important for binding to MSPIL0294. 
 
 
 
 
Figure 3.15 MPSIL0294-V532C DARPin binders sequence alignment: An alignment of the two DARPins which 
showed an ability to bind detergent solubilised MPSIL0294-V532C when presented in DDM micelles, E6 in the 
central row and G6 on the bottom. These DARPins have been aligned with a third DARPin H2 from the same 
selection output which did not show any evidence of binding activity in the presence of MPSIL0294-V532C. The 
variable regions of the DARPins have been highlighted, residues in red differ from the reference but are not 
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related to one another, those in yellow are amino acids in the same group in regard to their side chains or their 
physical characteristics and those in green differ from the reference DARPin but are the same in both E6 and G6. 
Residues in H2 are highlighted in blue to emphasis the fact that they are not related to the residues in the 
corresponding positions in the two protein binding DARPins. Residues which are not highlighted are in the 
conserved region and have been removed in both E6 and G6.    
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Chapter 4 
 
Alternative methods of membrane 
protein solubilisation compared 
using Phage Display against a DARPin 
library 
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4.1 Introduction 
Membrane proteins are traditionally solubilised using strong surfactants as described in the 
previous chapter. However detergent solubilisation can result in the adoption of inactive 
conformations by the membrane protein under test due to its removal from the lipid bilayer 
(Bowie 2001). This thereby limits the applicability of any successful binding protein, both as a 
real world therapeutic and as a research tool for the elucidation of the membrane protein 
structure (see section 1.4.1).  Furthermore,  micelles can hide epitopes, affecting the success 
of phage display screening on membranous targets because  the micelle, depending on the 
carbon chain of the detergent (longer chain detergents result in larger micelles) can be bigger 
than the width of a lipid bilayer (Oliver, Lipfert et al. 2013). Larger micelles will alter the 
accessibility of surface epitopes to potential binding partners due to the hydrophobic 
mismatch between the protein and the detergent (i.e. the micelle does not properly align with 
the hydrophobic portion of the protein) thereby lowering the chances of a successful screen 
and potentially reducing the stability of the target protein (Kunji, Harding et al. 2008).            
In this chapter different methods of detergent free solubilisation, namely nanodiscs and 
styrene maleic acid lipid particles (SMALPs), were compared in regard to their ability to isolate 
DARPins screened using phage display. A panel of membrane proteins composed of 
MPSIL0294-SBP and AcrB (both of which were introduced in chapter 3) solubilised in nanodiscs 
and SMALPs were subjected to two rounds of phage display. Furthermore, two concentrative 
nucleoside transporters (CNT) were also included the first being NupC – from E.coli, and the 
second being VcCNT - NupCs homologue from Vibrio cholerae both of which were prepared in 
SMALPs. NupC and VcCNT were chosen due to the extensive body of work which has already 
been done with the aim of characterising them (see Chapter 1). This panel was chosen with the 
aim of isolating DARPins capable of binding. 
4.2 The preparation of membrane protein Nanodiscs 
 
As in chapter 1 nanodiscs are a novel method of membrane protein solubilisation which rely 
on a membrane scaffold protein (MSP) derived from apolipoprotein 1. There are several 
different MSPs that are commonly used, each of which differs from one another in their amino 
acid sequences and length which in turn alters the size of nanodiscs they can produce. All of 
them, however, are derived from apolipoprotein 1 and form nanodiscs in an identical manner 
(Bayburt and Sligar 2010). They are typically expressed in E.coli and purified in a similar 
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manner as described in section 2.5.4 with the help of a C-terminal His tag. The MSP are eluted 
in a buffer consisting of 40 mM Tris, 0.3 M NaCl, 0.4 M Imidazole, pH 8 and stored at -80°C. For 
this study the MSP was provided by Emily Caseley from the University of Leeds.      
In the case of MPSIL0294-SBP nanodiscs, samples of detergent solubilised MPSIL0294-SBP 
protein were mixed with the MSP1D1 (the membrane scaffold protein) and POPC (Avanti) in a 
ratio of 1:2:35, in a manner described in section 2.4.5. The pertinent information when 
deciding upon a molar ratio was the fact that a nanodisc composed of MSP1D1 and POPC is 
thought to contain 61 - 65 lipid molecules and have an occupancy of 69Å2 (Bayburt and Sligar 
2010). Secondly, the area of MPSIL0294 was determined to be 3216.99 Å2; this was estimated 
by working out the radius of the protein (which itself was estimated using a model built by 
Jocelyn Baldwin of the university of Leeds of MPSIL0294 based on the crystal structure of the 
amino acid exchanger ApcT using the software package Pymol from Schrödinger). By dividing 
MSIL0294s area by the occupancy of a single nanodisc it can be estimated that the proteins 
insertion will displace 46.6 lipid molecules. Because there are two lipid envelops within a 
nanodisc this is actually 93.2 lipid molecules; an empty nanodisc has a total of 130 lipids (1 
MSP1D1 to 65 POPC). Therefore in a MSIL0294 nanodisc it can be concluded that there should 
be an estimated 36.8 lipids (130 – 93.2), which was rounded down to 35.   
Once all detergent was removed (see section 2.5.5) nanodisc samples were analysed via ÄKTA 
explorer in a Superdex 200 10/300 GL column at a flow rate of 0.5 mL/min. The resultant 
chromatogram shown in Figure 4.1 shows a large peak in the void volume of the column, the 
cause of which is not clear. Several smaller absorbance peaks (280 nm) were visible at an 
elution volume of 20-25 mL, which suggested the presence of folded protein. Further analyses 
of these samples however by western blotting or SDS-PAGE followed by silver staining using 
the Pierce® Silver stain kit (Thermo scientific), showed no protein present (Figure 4.2). Samples 
from the void volume showed a very faint band at approximately 55 kDa which corresponds to 
an immunogenic band on the western blot which is most likely MPSIL0294. Conversely, on the 
SDS-PAGE, a clear 25 kDa band can be seen which corresponds to a very faint band of the same 
size on the western blot most likely the MSP (Figure 4.2). While the MPSIL0294 may fail to 
show up on the SDS-PAGE due to a lack of sensitivity (despite the fact that silver staining was 
used as opposed to conventional staining with Coomassie), it is not clear why detection of the 
MSP appears to have failed on the blot. The presence of both bands at their expected masses 
suggests the presence of protein filled nanodiscs, however nanodiscs typically have two MSPs 
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per disc therefore the intensity of the bands does not support this. It is therefore likely that the 
ratio used for the nanodiscs is not ideal.     
 
Figure 4.1: Gel filtration chromatogram of MPSIL0294-SBP nanodiscs: Samples of Nanodiscs produced with 
MPSIL0294-SBP were analysed using a Superdex 200 10/300 GL column at a flow rate of 0.5 mL/min in an AKTA 
explorer.  
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Figure 4.2: Analysis of MPSIl0294-SBP nanodisc samples recovered from the gel filtration analysis: Samples 
collected from the size exclusion chromatography of MPSIL0294-SBP filled nanodiscs run on a 12% SDS-PAGE 
before A) silver staining using the Thermo scientific silver staining kit on which a single protein band is resolved 
with a mass of 25 kDa. Or B) Western blotting probed with an anti polyhistidine tag antibody conjugated with 
HRP on which a single protein band has been resolved at 55 kDa. The numbers denote each peak from the 
chromatogram shown in figure 4.1 in order from left to right.     
Fresh samples of the nanodiscs were also analysed by sucrose density gradient (see Section 
2.5.5). Each fraction was analysed by western blotting probed with an anti-polyhistidine tag 
antibody conjugated with HRP. The blot shown in Figure 4.3 shows two bands with a mass of 
approximately 55 and 25 kDa, indicative of MPSIL0294 and the MSP respectively.  
Densitometric analysis via the software imageJ (National institutes of Health) shows that the 
25 kDa band is approximately 1.7 times brighter than the 55 kDa band. This relative difference 
between MPSIL0294 and the MSP is as expected for a homogenous population of nanodiscs 
due to the fact that a typical nanodisc has two MSPs for each disc.  
 
 119 
 
Figure 4.3 Sucrose density gradient analysis of MPSIL0294-SBP nanodiscs: Samples of freshly prepared nanodiscs 
were analysed via sucrose density gradient and subsequently analysed by western blotting probed with anti-
polyhistidine tag antibody conjugated with HRP. The resultant blot shows the presence of two distinct protein 
bands. Densitometric analysis of these bands shows that the 25 kDa protein band is 1.5 times brighter than the 
band at 55 kDa.  
Purified samples of AcrB were also used to form nanodiscs with POPC and MSP1E3 in a molar 
ratio of 2:3:101 in an identical manner as described above and in section 2.4.5. This 
formulation was performed by Dr. Vincent Postis of the University of Leeds. However the 
membrane scaffold protein was biotinylated using EZ-Link® NHS-SS-Biotin (Thermo scientific) 
as described in section 2.4.6.  
4.3 The preparation of styrene maleic acid lipid particles 
(SMALPs) 
 SMALPs are a novel alternative to the solubilisation of membrane proteins in detergent 
micelles, instead holding membrane proteins within discoidal structures which are 
conceptually similar to nanodiscs. SMALPs differentiate themselves, however, in several ways; 
firstly, they do not require the initial purification of the target membrane protein from its lipid 
environment. Instead, the styrene maleic acid co-polymer can be added directly to membranes 
as described in section 2.4.4. Therefore SMALPs are able to capture membrane proteins in 
 120 
their native environments, surrounded by their native lipids. Secondly, SMALPs do not require 
the use of any other proteins, unlike nanodiscs which require MSPs to encircle the 
phospholipid core. Inclusion of exogenous proteins such as MSP into phage display screens can 
be very problematic and requires extra precautions to be taken to ensure that isolated binding 
proteins are not binding directly to the exogenous protein. Thirdly, they can be purified in an 
identical manner as detergent solubilised membrane protein and can withstand multiple 
freeze-thaw cycles. A major drawback of SMALPs is that the maleic acid moiety on the polymer 
is very negatively charged which has negative implications for future assays and their 
purification as described in the next section.    
4.3.1 The production of MPSIL294-SBP SMALPs  
In order to maintain consistency between the different forms of protein presentation 
MSPIL0294-SBP was chosen to be placed within a SMALP. The procedure was performed as 
described in section 2.4.4 on inner membrane of E.coli strains expressing MPSIL0294-SBP 
produced via auto-induction in 4L SB-5052 media (see Table 2.6) and isolated using a cell 
disruptor as described in section 2.4.3. The SMALPs were purified in an identical manner to 
MPSIL0294-SBP in detergent except in a buffer composed of 50 mM Tris, 500 mM NaCl and 
10% glycerol. The particularly high concentration of NaCl was used to compensate for the 
negative charge introduced by the SMA co-polymer.  
Samples were taken throughout the SMALP purification process in order to assess the success 
of each stage. These samples were then analysed electrophoretically on a 12% SDS-PAGE gel 
followed by extensive staining in Coomassie blue (see Figure 4.4). Interestingly there appears 
to be an abundance of an unidentified protein produced with a weight of approximately 25 
kDa in the inner membranes isolated from an E.coli strain expressing MPSIL0294. This 
endogenous E.coli protein appears to be insoluble in the presence of the SMA co-polymer as it 
does not appear in the adjacent ‘supernatant’ sample but it was present when MPSIL0294-SBP 
was purified in detergent (see chapter 3).  Several proteins were subsequently eluted from the 
resin as bands appear at approximately 100, 55 and 25 and 20 kDa.  
In order to confirm the presence of MPSIL0294-SBP SMALPs the elution fractions were pooled, 
dialysed in order to remove the 250 mM imidazole in the elution buffer and concentrated prior 
to analysis via western blotting probed with an anti-polyhistidine tag antibody conjugated with 
HRP as well as a Coomassie stained 12% SDS-PAGE. The gel and western blot shown in Figure 
4.5 provide confirms the presence of MPSIL0294 in Figure 4.4. The Coomassie stained SDS-
PAGE gel resolves several bands which do not appear on the western blot of the same sample. 
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This therefore indicates a large degree of co-elution of endogenous E.coli proteins. Protein 
bands occur at approximately 100, 50, just above 25 and just below 20 kDa. The 50 kDa protein 
has a polyhistidine tag as proven by its appearance on the western blot and is therefore 
MPSIL0294. The identities of the other proteins cannot be determined definitively, but due to 
its propensity to spontaneously bind to IMAC resin it is quite likely that the 100 kDa protein 
band is AcrB. This is a common contaminant of IMAC on E.coli produced proteins due to its 
histidine rich C-terminal (Veesler, Blangy et al. 2008). There are several different endogenous 
proteins which could be the identity of the other protein bands on the gel which have been 
shown to commonly contaminant protein samples purified via IMAC with E.coli membranes, 
for example the cadmium response protein YodA (22.3 kDa) or chloramphenicol 
acetyltransferase (CAT- 25.5kDa) (Bolanos-Garcia and Davies 2006) such as . It could be argued 
that these endogenous proteins should not interfere with downstream attempts to screen 
MPSIL0294-SBP SMALPs as they have no way of binding a streptavidin coated surface and 
therefore should be washed away following immobilisation.  
 
Figure 4.4: Purification of MPSIl0294-SBP SMALPs: Samples taken throughout the solubilisation and purification 
of MPSIL0294-SBP with SMA co-polymer analysed on a 12% SDS-PAGE gel stained with Coomassie blue. ‘Total’ is 
a sample taken from the membrane after solubilisation with SMA, ‘Supernatant’ is a sample of the solubilised 
material alone, ‘Flow-Through’ is a sample of the material which passed through the column. 
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Figure 4.5: Analysis of final MPSIL0294-SMALPs samples: The elution fractions of MPSIl0294-SMALPs were 
pooled, dialysed and concentrated before analysis via Coomassie stained 12% SDS-PAGE gel and western blotting 
probed with an anti-polyhistidine tag antibody conjugated with HRP.    
4.3.2 The biotinylation of various membrane protein SMALPs  
Samples of AcrB, VcCNT and NupC SMALPs were prepared by Dr. Vincent Postis and Zhenyu 
Hao in the University of Leeds and were produced in an identical manner as described in 
section 2.4.4. In order to bind these samples to streptavidin coated plates as part of the phage 
display process each of these samples were biotinylated using EZ-Link® NHS-SS-Biotin (Thermo 
scientific) in an identical manner as described in section 2.4.6 on site in the MedImmune 
facility located in Cambridge. These samples were first subjected to extensive dialysis in order 
to exchange the buffer in which they were stored in from the 50 mM Tris, 500 mM NaCl and 
10% glycerol buffer to PBS, 500 mM NaCl and 10% glycerol. Samples were each then 
biotinylated with a 5 molar excess of biotin targeting primary amine groups such as lysine 
residues within the protein SMALPs. The samples were then analysed by SDS-PAGE stained 
with Coomassie blue and Western blotting probed with an anti-biotin antibody.     
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The gel and blot shown in Figure 4.6 indicate that the VcCNT and NupC SMALP samples (and to 
a much lesser extent both the AcrB SMALPs and detergent solubilised samples) contain various 
impurities, which might limit the specificity if hits acquired by the phage display procedure.  
As expected, after biotinylation, all target membrane proteins are detected with Western 
blotting with biotin antibodies (Figure 4.6). Especially those at approximately 30 kDa in NupC 
and VcCNT, 50 kDa in the detergent solubilised AcrB and 30 kDa in AcrB SMALPs. The samples 
were then immobilised on a streptavidin coated surface and subjected to two rounds of phage 
display.  
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Figure 4.6 Biotinylation of samples of the various members of the membrane protein panel: Samples of NupC, 
VcCNT and AcrB SMALPs along with detergent solubilised AcrB were biotinylated using a 5 molar excess of EZ-
Link® NHS-SS-Biotin (Thermo scientific) and analysed via Coomassie stained SDS-PAGE and western blotting 
probed with anti-biotin antibody conjugated with HRP.  
4.4 Quality control of alternative detergent free methods of 
protein solubilisation with MPSIL0294 via ELISA 
Samples of MPSIL0294-SBP SMALPs and nanodiscs were subjected to indirect ELISA on 
neutravidin coated plates, in the same way its detergent solubilised counterparts were (see 
section 3.6.1). This ELISA was performed in order to prove that the nanodiscs and SMALPs 
could successfully be immobilised onto a surface via the SBP tag. The resultant graph in Figure 
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4.7 shows that despite the fact that the MPSIL0294-SBP nanodiscs seem to saturate the plate, 
they produce a trace which is 3.5 times smaller than the detergent solubilised MPSIL0294-SBP 
(see Figure 3.9). Its highest data point is observed in the presence of 100 µg/mL with an A450nm 
reading of 0.414, the detergent solubilised MPSIL0294-SBP on the other hand achieved an 
A450nm trace of 1.4 at the same concentration. The SMALPs trace on the other hand (which used 
the same MPSIL0294 variant) failed to produce any signal and overlays that of the BSA 
negative control. This could either be due to the failure of the antibody in gaining access to the 
polyhistidine tag or due to the failure of the protein to bind to the plate, either of which could 
be a consequence of the substantial negative charge associated with the maleic acid moiety.  
In order to prove that the MPSIL0294-SBP SMALPs are capable of immobilisation via its SBP 
tag, they were re-bound to strep-tactin resin pre-equilibrated in SMALP buffer (50 mM Tris, 
10% glycerol and 500 mM NaCl, pH 8) in a disposable column (Thermo scientific). The bound 
protein was then eluted in the aforementioned SMALP buffer supplemented with 2.5, 5 and 10 
mM desthiobiotin followed by the same buffer supplemented with 5 and 10 mM biotin. 
Samples were taken throughout this procedure, including an aliquot of the resin itself after 
protein binding and elution (Figure 4.8). These samples were analysed by western blotting 
probed with an anti-polyhistidine tag antibody conjugated with HRP. The resultant blot shown 
in Figure 4.8 shows that while the majority of the SMALPs fail to bind to the resin and are 
therefore detected in the ‘Flow Through’; a proportion of the SMALPs were successfully eluted 
primarily by 2.5 mM desthiobiotin. Very faint bands can still be seen after treatment with 5 
mM of both desthiobiotin and biotin.  
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Figure 4.7: Quality control ELISA of detergent free MPSIL0294 samples: The absorbance data at 450 nm were 
recorded after samples of MPSIL0294-SBP SMALPs and nanodiscs were immobilised on a neutravidin coated 
surface and probed with an anti-polyhistidine tag antibody conjugated with HRP. Readings were then recorded 
after incubation with TMB followed by 0.5 M H2SO4. 
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Figure 4.8 Immobilisation of MPSIL0294-SBP SMALPs on strep-tactin resin: Samples of MPSIL0294-SBP SMALPs 
were bound to strep-tactin resin and samples were taken throughout the procedure in order to assess whether or 
not the protein could be immobilised via it C-terminal SBP tag. These samples were analysed by western blotting 
probed with an anti polyhistidine antibody conjugated with HRP.  
4.5 A Comparison of different methods of membrane protein 
solubilisation 
Two rounds of phage display were carried out on the various membrane protein samples 
comparing alternative methods of protein solubilisation.  These rounds of phage display (and 
the subsequent validation tests performed on the various selection outputs) were carried out 
in an identical manner as previously described for the comparison of membrane protein 
immobilisation strategies in chapter 3. In order to carry out the phage display, samples of AcrB 
SMALPs (which had been biotinylated as discussed earlier) and nanodiscs (the MSPs of which 
had undergone chemical biotinylation) were immobilised on streptavidin coated plates. 
MPSIL0294-SBP SMALPs and nanodiscs along with samples of chemically biotinylated NupC 
and VcCNT SMALPs were also prepared in a similar fashion; after which all were subjected to 
phage display as before with a functional library of DARPins (see section 2.8) the results of 
which are in Table 4.1 below.  
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The input titres, calculated before the second round of phage display, are well within expected 
parameters at 1012 as are the output titres at 105 and 106. The same is true for all of the 
sequence diversities except for the VcCNT SMALPs which had a diversity measure of 93%, 
thereby suggesting a large number of unique sequences in its selection output.    
Sample Format 
Input titre 
(cfu/mL) 
Output titre 
(cfu/mL) 
Diversity 
MPSIL0294-SBP 
Nanodisc 2.8 x 1012 4.3 x 105 82% 
SMALP 3.5 x 1012 3.2 x 105 66% 
AcrB 
Biotinylated 
Nanodisc 
3 x 1012 5 x 105 70% 
SMALP 1.1 x 1012 7.13 x 106 79% 
NupC SMALP 2.7x 1012 2.65 x  105 73% 
VcCNT SMALP 3.5 x 1012 9.5 x  105 93% 
 
Table 4.1: Overview of the input and output titres of the phage used in phage display against the detergent free 
protein samples: The input titre calculated before the second round of phage display and the subsequent output 
titres obtained after the second round with immobilised samples of membrane proteins in different presentation 
formats. The level of uniqueness in each selection has also been calculated after the removal of all repeating 
sequences.   
4.5.1 Removing streptavidin binding DARPins via Phage ELISAs on 
blank streptavidin plates 
In order to validate the selection outputs, an identical series of tests as those performed on 
the alternatively tagged proteins (see Chapter 3) were performed on the various nanodisc and 
SMALP samples. The first of which was the identification and removal of any DARPins capable 
of binding streptavidin directly via phage ELISA on blank streptavidin plates. The same A450nm 
threshold of 0.1 was imposed upon these ELISAs as it was with the validation tests performed 
on the previous samples and just like those ELISAs any DARPins which crossed this threshold 
were deemed to have the ability to bind streptavidin and were consequently removed from 
further characterisation.      
4.5.1.1 AcrB Biotinylated Nanodiscs and SMALPs 
Phage ELISAs on the selection output of AcrB biotinylated nanodiscs successfully identified 67 
DARPins which produced an A450nm reading above 0.1.This is the highest number of the 
streptavidin binding DARPins identified for all AcrB formats. The SMALPs identified 56 and the 
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detergent solubilised identified 55. In terms of the actual A450nm readings produce by the 
nanodisc DARPins, many are quite elevated relative to detergent solubilised MPSIL0294, with 
the highest value being 0.556 from DARPin C6. However none of them produce a signal above 
1.0 like both the detergent solubilised AcrB and the AcrB SMALPs. A few of these DARPins do 
appear to bind streptavidin with a moderately high affinity producing A450nm values of 0.441 
(DARPin F3), 0.484 (G7) and 0.394 (E9) (see Table 4.2).  
Of the 58 streptavidin binding DARPins identified by the phage ELISA on the AcrB SMALP 
selection output, four bound particularly tightly to the streptavidin. These DARPins produced 
A450nm readings at 1.596 (DARPin G7), 1.833 (D5), 1.955 (D8) and the highest at 1.966 (E2). 
Generally, many of the other streptavidin binding DARPins also produce signals higher than 
those identified by the nanodiscs. The DARPins which were identified as able to bind to 
streptavidin were not used in any further validation tests.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 130 
AcrB Biotinylated Nanodiscs 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 0.072 0.133 0.143 0.065 0.119 0.147 0.072 0.153 0.123 0.159 0.197 0.041 
B 0.068 0.06 0.109 0.085 0.175 0.113 0.079 0.13 0.226 0.129 0.199 0.078 
C 0.058 0.062 0.221 0.135 0.137 0.556 0.099 0.37 0.115 0.149 0.195 0.055 
D 0.081 0.06 0.123 0.109 0.242 0.368 0.161 0.242 0.189 0.166 0.229 0.055 
E 0.075 0.118 0.086 0.095 0.161 0.346 0.315 0.246 0.394 0.218 0.179 0.063 
F 0.067 0.08 0.441 0.121 0.121 0.148 0.367 0.198 0.34 0.245 0.166 0.045 
G 0.061 0.071 0.18 0.257 0.151 0.158 0.484 0.172 0.178 0.227 0.229 0.049 
H 0.059 0.073 0.176 0.115 0.147 0.151 0.283 0.339 0.207 0.24 0.334 0.072 
 
AcrB SMALPs 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 0.065 0.063 0.098 0.082 0.254 0.06 0.083 0.074 0.199 0.172 0.124 0.073 
B 0.068 0.332 0.184 0.062 0.236 0.225 0.076 0.21 0.344 0.216 0.33 0.042 
C 0.068 0.255 0.171 0.076 0.3 0.115 0.238 0.257 0.667 0.278 0.216 0.057 
D 0.105 0.159 0.219 0.607 1.833 0.143 0.058 1.955 0.301 0.093 0.266 0.059 
E 0.082 1.966 0.094 0.122 0.39 0.098 0.086 0.262 0.597 0.058 0.635 0.065 
F 0.139 0.061 0.206 0.214 0.088 0.147 0.067 0.196 0.685 0.106 0.333 0.061 
G 0.209 0.077 0.085 0.127 0.192 0.1 1.596 0.093 0.19 0.302 0.606 0.072 
H 0.094 0.075 0.071 0.063 0.279 0.06 0.165 0.249 0.06 0.075 0.419 0.078 
 
Table 4.2 Primary phage ELISA validation of the selection outputs selected against AcrB solubilised via detergent 
free methods: The data produced after a phage ELISA was performed on the selection outputs of both the AcrB 
nanodiscs and the AcrB SMALPs on blank streptavidin plates with no immobilised target protein. Both of these 
protein formats were immobilised via a biotin - streptavidin interaction during the initial phage display. The 
nanodiscs were constructed using an MSP which had undergone chemical biotinylation, while the SMALPs were 
chemically biotinylated prior to phage display. The ELISAs were probed with anti-M13 antibody conjugated with 
HRP and visualised by incubation with TMB prior to treatment with 0.5 M H2SO4 and the analysis of its 
absorbance at 450nm. DARPins which did not pass the 0.1 threshold are highlighted in green and were taken on 
for further validation while DARPins which showed weak streptavidin binding (0.1 – 0.49) are highlighted in 
yellow, DARPins which showed a moderate ability to bind streptavidin (0.5 – 0.99) are highlighted in orange and 
DARPins which strongly bound streptavidin (above 1.0) are marked in red.  The negative control was composed of 
wells with no phage added and are written in blue text.   
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4.5.1.2 MPSIL0294-SBP Nanodiscs and SMALPs 
The same initial validation test was carried out on the selection outputs of MPSIL0294-SBP 
nanodiscs and SMALPs. The nanodiscs highlighted 17 DARPins which passed the 0.1 A450nm 
threshold, while the SMALPs identified 11. Thereby making the detergent solubilised 
MPSIL0294-SBP the highest with 69 DARPins. Of the 17 nanodisc streptavidin binders 9 
DARPins produce a signal above 1.0, the highest of which is DARPin E2 and A6 which both 
produce a signal at 1.666. Of the remaining 8 DARPins, 2 produced signals above 0.9 namely 
DARPins F5 (0.938) and G9 (0.991).The SMALPS on the other hand isolated 2 DARPins with an 
A450nm above 1.0 out of the 11 DARPins which bound to streptavidin. These 2 DARPins 
produced signals of 1.359 (C4) and the highest of the DARPins, 1.572 (E6). The majority of the 
remaining DARPins A450nm readings are very close to the threshold (see Table 4.3) 
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MPSIL0294-SBP Nanodiscs 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 0.041 0.052 0.049 0.049 0.057 1.66 0.072 0.087 0.095 1.318 0.062 0.049 
B 0.045 0.048 0.042 1.282 0.049 0.045 1.418 1.652 0.075 0.056 0.061 0.04 
C 0.033 0.051 0.06 0.044 0.058 0.198 0.049 0.065 0.064 0.217 0.064 0.052 
D 0.047 0.047 0.05 0.094 0.055 0.075 0.055 0.101 0.075 0.212 0.057 0.133 
E 0.038 1.666 0.053 0.046 0.052 0.051 0.057 0.056 0.066 1.565 0.286 0.049 
F 0.041 0.044 0.051 0.039 0.938 0.064 0.077 0.053 0.059 0.218 0.048 0.038 
G 0.036 0.048 0.041 0.041 0.056 0.056 0.055 0.068 0.991 0.052 0.052 0.053 
H 0.048 1.329 0.059 0.047 0.047 0.047 1.226 0.049 0.046 0.049 0.046 0.04 
 
MPSIL0294-SBP SMALPs 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 0.07 0.063 0.063 0.068 0.057 0.061 0.088 0.056 0.074 0.064 0.058 0.048 
B 0.302 0.053 0.067 0.126 0.064 0.102 0.051 0.054 0.08 0.066 0.05 0.042 
C 0.064 0.067 0.071 1.359 0.077 0.057 0.053 0.067 0.07 0.061 0.055 0.051 
D 0.052 0.053 0.06 0.069 0.064 0.166 0.055 0.124 0.063 0.053 0.059 0.057 
E 0.267 0.054 0.055 0.062 0.065 1.572 0.104 0.054 0.055 0.05 0.056 0.056 
F 0.176 0.048 0.051 0.053 0.065 0.404 0.051 0.054 0.056 0.045 0.047 0.044 
G 0.046 0.051 0.054 0.052 0.062 0.057 0.052 0.059 0.057 0.056 0.064 0.047 
H 0.051 0.053 0.054 0.049 0.049 0.048 0.051 0.051 0.05 0.052 0.046 0.038 
 
Table 4.3: Primary phage ELISA validation of detergent free MPSIL0294 samples: The data from the phage ELISAs 
carried out on blank streptavidin plates using the selection output from MPSIL0294-SBP Nanodiscs and SMALPs. 
The ELISAs were probed with anti-M13 antibody conjugated to HRP; analysis of the A450nm was achieved via 
incubation with TMB followed by the addition of 0.5M H2SO4. DARPins which crossed the threshold of 0.1 were 
deemed to be binding directly to streptavidin and were therefore removed from further validation experiments. 
DARPins which bound streptavidin weakly (0.1 – 0.49) are highlighted in yellow, those which bound to 
streptavidin moderately (0.5 – 0.99) are highlighted in orange and those that bound streptavidin strongly (above 
1.0) are highlighted in red. The DARPins which did not bind to streptavidin and could therefore be subjected to 
further validation tests are highlighted in green. The negative control was composed of wells which were treated 
with phage and are highlighted in blue text.   
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4.5.1.3 NupC and VcCNT SMALPs 
The selection outputs produced as a result of phage display performed against NupC and its 
homologue VcCNT were also validated via phage ELISA on blank streptavidin plates. These 
ELISAs identified 54 and 10 DARPins with the ability to bind directly to streptavidin 
respectively. Despite this large difference in streptavidin binders between the two homologues 
none of them produced an A450nm signal above 1.0 as was the case with both MPSIL0294 and 
AcrB SMALPs. Instead the highest signal produced by these ELISAs was DARPin F1 from the 
NupC selection output and D7 from VcCNT (see Table 4.4).  
    NupC SMALPs 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 0.079 0.19 0.072 0.26 0.061 0.202 0.06 0.238 0.134 0.166 0.313 0.055 
B 0.065 0.111 0.28 0.066 0.344 0.059 0.09 0.455 0.273 0.448 0.073 0.055 
C 0.049 0.094 0.225 0.1 0.34 0.078 0.085 0.281 0.203 0.335 0.102 0.041 
D 0.113 0.133 0.104 0.128 0.354 0.053 0.104 0.257 0.468 0.434 0.487 0.053 
E 0.183 0.284 0.096 0.108 0.097 0.099 0.092 0.19 0.098 0.248 0.365 0.032 
F 0.661 0.1 0.093 0.063 0.463 0.119 0.194 0.334 0.221 0.187 0.274 0.06 
G 0.17 0.059 0.256 0.082 0.085 0.074 0.136 0.273 0.487 0.114 0.449 0.23 
H 0.083 0.081 0.065 0.089 0.438 0.061 0.054 0.087 0.119 0.09 0.574 0.046 
 
VcCNT SMALPs 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 0.063 0.068 0.056 0.249 0.055 0.054 0.296 0.056 0.177 0.058 0.058 0.051 
B 0.049 0.054 0.063 0.053 0.051 0.053 0.05 0.051 0.055 0.057 0.05 0.063 
C 0.046 0.057 0.058 0.056 0.058 0.055 0.295 0.058 0.059 0.059 0.057 0.058 
D 0.052 0.053 0.062 0.057 0.049 0.053 0.443 0.056 0.05 0.211 0.051 0.043 
E 0.046 0.078 0.057 0.053 0.056 0.137 0.285 0.052 0.055 0.053 0.054 0.077 
F 0.061 0.051 0.067 0.055 0.276 0.053 0.069 0.061 0.054 0.054 0.047 0.043 
G 0.044 0.051 0.055 0.055 0.059 0.056 0.315 0.058 0.051 0.051 0.054 0.05 
H 0.08 0.053 0.056 0.066 0.056 0.058 0.058 0.074 0.059 0.059 0.056 0.043 
 
Table 4.4 Primary Phage ELISA validation of selection outputs generated against NupC and VcCNT SMALPs: The 
data produced after phage ELISAs were performed using the selection outputs from the VcCNT and NupC SMALPs 
on blank streptavidin plates. The ELISA plates were probed with an anti-M13-HRP antibody conjugate and their 
A450nm were measured after incubation with TMB and subsequently 0.5M H2SO4 . DARPins which did not exceed 
the pre-determined A450nm threshold of 0.1 are highlighted in red and were taken on for further validation.        
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4.5.2 Refining selection outputs via Phage ELISA in the presence of 
target protein 
Once all DARPins with a capability to bind streptavidin alone were identified and removed, the 
phage ELISAs were repeated in the presence of 100 µg of immobilised target protein and the 
second A450nm threshold of 1.0 was once again used to confirm if a DARPin binds to its target. 
Due to the low expression and purification yields of MPSIL0294-SBP, further characterisation 
by phage ELISA was not feasible for this target protein and no further action was taken in this 
study with MSPIL0294-SBP      
4.5.2.1 AcrB Biotinylated Nanodiscs and SMALPs 
The AcrB nanodiscs and SMALPs were immobilised to the surface of streptavidin coated plates 
via chemical biotinylation (of the MSP in the nanodisc and of surface lysine residues 
aspecifically in the SMALP) and treated with the DARPins which did not produce a signal in the 
previous phage ELISAs. The resultant A450nm readings show that 4 of the remaining 21 DARPins 
produced a signal above the 1.0 threshold and may binding to AcrB (a success rate of 19%). 
These DARPins are D1 with a reading of 1.581, F1 at 1.921, E3 at 2.125 and H1 at 2.136 which 
is the highest reading on the plate. Other than these four DARPins no others are able to 
produce a reading above 0.15, therefore the cut off value of 1.0 is appropriate for this 
selection.  
In contrast to this, all of the 30 remaining DARPins from the selection output against AcrB 
SMALPs bind tightly to AcrB when tested in a phage ELISA. The lowest A450nm value was 
produced by DARPin D10 and had a value of 2.421 thereby suggesting that each DARPin is 
capable of saturating their individual wells. All of the DARPins which showed an ability to bind 
on this produced A450nm readings above 2.4 (see Table 4.5). 
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Table 4.5 Secondary phage ELISA validation of the selection outputs generated against the detergent free 
methods of AcrB solubilisation: The data produced after the second phage ELISAs were performed on 
streptavidin coated plates with 100 µg of immobilised AcrB SMALPs and Biotinylated nanodiscs on their surface. 
The ELISAs were probed with an anti-M13-HRP antibody conjugate and the A450nm values were recorded after 
incubation with TMB and subsequent colorimetric change by treatment with 0.5M H2SO4. DARPins which were 
removed after the previous phage ELISAs have been represented with black squares while all DARPins which 
produced a signal in the presence of target protein are highlighted in green. DARPins which did not show any 
binding activity in the presence of target protein (below 0.09) are highlighted in red and those which only showed 
a weak ability to bind to the target (0.1 – 0.49) are highlighted in yellow. The negative control consisted of wells 
which were treated with any phage and are highlighted in blue text. 
4.5.2.2 NupC and VcCNT SMALPs 
Samples of NupC and VcCNT SMALPs were treated in an identical manner as discussed above 
with 100 µg of each SMALP immobilised onto the surface of a streptavidin coated plate. The 
AcrB Biotinylated Nanodiscs 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 0.064 0.103 0.038 0.097 0.039 0.023 0.076 0.024 0.024 0.023 0.024 0.06 
B 0.085 0.137 0.044 0.117 0.043 0.025 0.098 0.024 0.024 0.024 0.024 0.056 
C 0.066 0.07 0.037 0.041 0.038 0.025 0.084 0.023 0.023 0.024 0.024 0.068 
D 1.581 0.044 0.044 0.05 0.045 0.025 0.054 0.024 0.023 0.024 0.026 0.058 
E 0.079 0.052 2.125 0.113 0.04 0.023 0.041 0.027 0.023 0.025 0.025 0.063 
F 1.921 0.121 0.044 0.048 0.041 0.025 0.053 0.029 0.024 0.024 0.029 0.06 
G 0.061 0.077 0.037 0.038 0.037 0.024 0.039 0.024 0.024 0.026 0.026 0.064 
H 2.136 0.101 0.045 0.049 0.044 0.023 0.051 0.024 0.026 0.024 0.025 0.056 
AcrB SMALPs 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 2.903 2.829 2.785 2.64 0.078 2.637 2.661 2.674 0.041 0.039 0.038 0.043 
B 2.542 0.062 0.134 2.579 0.26 0.063 2.611 0.061 0.064 0.048 0.062 0.038 
C 2.718 0.13 0.039 2.582 0.043 0.039 0.04 0.039 0.039 0.038 0.038 0.043 
D 0.075 0.073 0.07 0.065 0.063 0.064 2.486 0.061 0.063 2.421 0.838 0.053 
E 2.743 0.093 2.655 0.13 0.037 0.039 2.451 0.037 0.039 2.453 1.122 0.042 
F 0.138 2.679 0.095 0.064 0.062 0.064 2.514 0.062 0.063 0.065 0.062 0.037 
G 0.035 2.664 2.575 0.055 0.038 0.038 0.038 2.422 0.039 0.038 0.037 0.043 
H 2.767 2.76 2.642 2.674 0.249 2.562 0.125 0.106 2.521 2.649 0.811 0.037 
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phage ELISA results in Table 4.6 shows that the vast majority of both selection outputs 
produced a signal above the threshold. In the case of NupC 23 out of the 34 DARPins (67%) 
bound to NupC. The plate shows (as was the case of AcrB in Table 4.5) a very clear distinction 
between DARPins which bind the target and those that fail to do so with the exception of H1 
which produced a moderate reading. Once again however, the 1.0 A450nm threshold appears to 
be appropriate for this selection as the highest value was C1 with a value of 1.839.  
The VcCNTs phage ELISA plate shown in Table 4.6 shows that 60 out of 78 (77%) DARPins 
successfully produced a signal above 1.0 in the presence of immobilised target protein 
presented in SMALPs. The highest value was obtained from DARPin C1 with a value of 1.858. 
While the 1.0 threshold was appropriate for the selections against AcrB and NupC, it is more 
arbitrary for VcCNT as many of the DARPins produced readings above 0.9 such as H1, G2 and 
B3. In general both phage ELISAs for NupC and VcCNT have resulted in a cohort of DARPins 
which produce distinctively lower A450nm values than AcrB did when it was placed in a SMALP. 
The cause of this decrease is not clear, although, considering the large extracellular domain of 
AcrB it is possible that the DARPins had greater accessibility to more binding sites. The 
difference in A450nm values could alternatively be caused due to an increased amount of AcrB 
adsorbed onto the plate. 
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Table 4.6 Secondary phage ELISA validation of the selection outputs generated against NupC and VcCNT SMALPs: 
The absorbance readings recorded after phage ELISAs were performed on streptavidin coated plates onto which 
100 µg of NupC and VcCNT SMALPs were immobilised. The ELISAs were carried out the selection outputs of the 
aforementioned proteins and were probed with an anti-M13-HRP antibody conjugate. The initial colorimetric 
change was initiated by the incubation of the plate with TMB. The final change and absorbance measurements 
were taken after the addition of 0.5M H2SO4. Wells in which DARPins previously showed an affinity toward 
streptavidin alone in the previous phage ELISAs have been blacked out, DARPins which produce a signal higher 
the 1.0 threshold after treatment in this phage ELISA have highlighted in red.     
 
NupC SMALPs 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 1.551 0.042 1.823 0.045 1.705 0.041 1.712 0.042 0.041 0.039 0.041 0.042 
B 0.101 0.061 0.061 0.065 0.062 1.68 1.668 0.062 0.065 0.065 1.409 0.036 
C 1.839 1.738 0.039 0.038 0.041 0.045 0.051 0.039 0.045 0.038 0.038 0.043 
D 0.067 0.063 0.064 0.063 0.062 1.523 0.069 0.062 0.07 0.064 0.06 0.032 
E 0.043 0.042 0.049 0.045 1.397 0.066 1.183 0.038 1.635 0.039 0.038 0.04 
F 0.073 0.065 1.518 0.071 0.061 0.071 0.064 0.062 0.063 0.067 0.064 0.034 
G 1.578 1.617 0.039 1.688 1.631 1.603 0.039 0.038 0.04 0.04 0.041 0.039 
H 0.602 0.074 1.025 0.076 0.069 1.64 0.145 1.759 0.07 1.705 0.063 0.035 
VcCNT SMALPs 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 1.581 1.422 0.075 0.045 1.117 0.922 0.042 1.032 0.05 0.469 1.421 0.05 
B 1.523 1.346 0.949 1.36 1.594 0.394 1.349 1.482 1.359 1.623 1.558 0.04 
C 1.858 1.328 1.507 1.366 1.471 1.395 0.044 1.413 1.301 1.493 1.455 0.046 
D 1.299 0.079 1.285 1.411 0.91 1.297 0.068 1.203 1.439 0.088 1.46 0.086 
E 1.213 1.473 1.327 1.486 1.325 0.044 0.297 1.183 1.61 0.06 0.882 0.082 
F 1.58 1.393 1.635 1.448 0.068 1.39 1.488 0.559 1.509 1.514 1.388 0.056 
G 0.213 0.967 0.115 1.471 1.124 1.25 0.087 1.266 1.607 1.709 1.525 0.13 
H 0.947 0.186 0.6 0.081 1.632 1.565 0.142 1.481 1.581 1.25 1.765 0.037 
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4.5.3 An overview of phage display on different methods of membrane 
protein solubilisation 
The alternative protein solubilisation samples were subjected to two rounds of phage display 
identical to those performed in chapter 3, on membrane protein samples solubilised in DDM. 
The phage display was followed by the same series of validation tests which aimed to refine 
the various selection outputs by removing DARPins which bound streptavidin directly and then 
subsequently confirm their ability to bind to the target used in the phage display.  
Table 4.7 shows an overview of the results produced by the phage display and subsequent 
validation tests with regard to the number of DARPins that were available for each subsequent 
stage of testing.  When compared with the same overview shown in chapter 3 (see Table 3.6), 
the data in Table 4.7 shows that in the case of MPSIL0294, there is profound increase in the 
number of DARPins that did not produce a signal in the presence of streptavidin alone. AcrB on 
the other hand, shows fairly consistent numbers which may be the result of AcrB packing onto 
the surface of the plate in a consistent manner regardless of the solubilisation strategy 
employed.  
The DARPins were then removed from the second phage ELISA performed in the presence of 
immobilised target protein (stage 2). As previously mentioned the nanodisc and SMALP 
samples of MPSIL0294 could not be further validated due to restrictions in the availability of 
sample. The AcrB samples show an increase in the number of DARPins that appear to bind the 
target when detergent free methods of solubilisation are used. This is particularly true for the 
SMALPs, which also show a high number of DARPins binding to the selection outputs of NupC 
and VcCNT were tested in the same manner (see Table 4.7).      
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Target 
Method of 
Immobilisation 
Method of 
Solubilisation 
Stage 1 Stage 2 Stage 3 
 
MPSIL0294 
 
SBP/Streptavidin 
 
SMALP 88 77 N.D. 
Nanodisc 88 71 N.D. 
DDM 88 19 0 
 
VcCNT 
Lysine 
Biotinylation 
SMALP 88 78 65 
 
NupC 
Lysine 
Biotinylation 
SMALP 88 34 23 
 
 
 
AcrB 
Lysine 
Biotinylation 
SMALP 88 30 30 
MSP 
Biotinylation 
Biotinylated 
Nanodisc 
88 21 4 
Lysine 
Biotinylation 
DDM 88 33 0 
 
Table 4.7: An overview of the entire phage display and subsequent validation process carried out on the various 
membrane protein samples solubilised via detergent free methods:  The detergent free methods of membrane 
protein solubilisation: aimed to compare nanodiscs with SMA solubilisation in regard to their ability to isolate 
DARPins capable of binding the target proteins. The numbers with each cell represent the number of DARPins 
available for the subsequent stage. The entire process included: the initial two rounds of phage display (stage 1), 
followed by the first phage ELISA which identified all DARPins which bound streptavidin directly (stage 2), the 
second phage ELISA which provided initial confirmation of the DARPins ability to bind the various targets (stage 
3) and finally the DARPins selected for expression, purification and further analysis. Note: N.D. - No data. 
         
4. 6 Discussion and Conclusion   
In order to compare different methods of membrane protein presentation, different methods 
of detergent free solubilisation were compared, namely the production of SMALPs and 
nanodiscs. Initial attempts to analyse the nanodiscs by SEC were not conclusive based upon 
the data generated by SDS-PAGE and western blotting, due to the lack of corroboration 
between the two (see Figure 4.1 and 4.2). Typically, SEC is employed in the analysis of 
nanodiscs, however when an incorrect ratio of MSP: lipid: protein is used, the excess lipid 
often results in a broad elution profile in the void volume due to aggregates (Bao, Duong et al. 
2012, Pavlidou, Hanel et al. 2013). The peak shown in Figure 4.1 however, is relatively sharp 
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thus suggesting the correct formation of MPSIL0294-SBP nanodiscs. The inconclusive nature of 
the subsequent SDS-PAGE and western blot which were used to confirm the presence of 
nanodiscs are the reason that analysis via sucrose density gradient was used as an alternative. 
The resultant blot shown in Figure 4.3 was performed on a subsequent nanodisc preparation. 
The fact that the MSP protein band at 25 kDa is 1.7 brighter than the MPSIL0294 is expected 
due to the fact that a single nanodisc particle is composed of two MSP proteins encircling a 
phospholipid core. Confirmation that the MPSIL0294-SBP nanodiscs were properly formed is 
also provided by the ELISA shown in Figure 4.7 which confirms the presence of a polyhistidine 
tag in the nanodiscs, although it cannot be established whether the his-tag of MPSIL0294 or 
that of MSP is detected. Although the presence of two his-tags should lead to an increase in 
fluorescence, as such it is unclear why a drastic decrease in adsorption value is observed 
instead. Possible explanations for this however may be due to the decreased accessibility of 
the polyhistidine tag to the anti his-HRP antibody conjugate. Nanodiscs composed of MPS1D1 
and POPC which are estimated to have a diameter of 98 Å (9.8 nm) (Bayburt and Sligar 2010) 
while a full IgG antibody has a molecular weight of approximately 150 kDa. These two large 
molecules may sterically hinder one another thereby obstructing the antibody probe. 
Alternatively due to their large size, fewer nanodiscs may be able to pack onto the surface of 
the plate.     
The production of MPSIL0294-SBP SMALPs as described in section 2.4.4 produced samples 
which contain many contaminants. These protein bands which resolved on the Coomassie 
stained SDS-PAGE gel shown in Figure 4.5 most likely co-purified as a consequence of either 
endogenous positively charged E.coli proteins strongly interacting with the negatively charged 
maleic acid moiety within the SMA co-polymer and co-purifying as a result. Alternatively, these 
protein bands may co-purify as a result of the electrostatic interaction between the negatively 
charged maleic acid moiety and the positively charged polyhistidine tag resulting in a lower 
affinity between the his tag and the cobalt resin. It has been observed that the presence of the 
SMA polymer reduces the affinity of the polyhistidine tag for the resin. In order to overcome 
this, an increased concentration of NaCl is used along with an overwhelming excess of resin. 
This excess of resin when taken into account alongside the poor expression level of 
MPSIL0294-SBP may explain why many endogenous E.coli proteins have co-purified alongside 
the MSPIL0294-SBP SMALPs. Unfortunately the effect of these co-purified proteins on the 
phage display outcome is not known. This electrostatic interaction is also thought to reduce 
the accessibility of the tag, thereby offering a possible explanation for the SMALPs failure to 
produce a signal in the ELISA shown in Figure 4.7. This might suggest that that the availability 
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of epitopes for phage display is diminished in SMALPs. The blots in Figure 4.8 prove that the 
SBP tag on MPSIL0294 is accessible however and that this tag is capable of immobilising the 
protein onto a streptavidin surface despite the fact that a lot of SMALPs failed to do so.  
Due to the fact that such a direct comparison of different methods of immobilisation and 
solubilisation on the same protein has not been done before, an interesting continuation of 
this work would be to increase the scope of presentation methods beyond detergent 
solubilised, nanodisc and SMALP. This would involve including molecules such as amphipols 
which are conceptually similar to nanodiscs in so far as they require membrane proteins to be 
initially solubilised in detergent. The key difference is that amphipols are comprised of an 
amphipathic polymer backbone similar to SMALPs (Popot, Berry et al. 2003, Zoonens, Zito et 
al. 2014). Amphipols are particularly interesting because biotinylated amphipols are already 
available and have been used to entrap an E.coli outer membrane protein, subsequently 
immobilise it onto a streptavidin coated surface and probe it with a bacteriophage receptor 
binding protein (Basit, Shivaji Sharma et al. 2012). These could therefore be used as a direct 
comparison with the AcrB nanodiscs which were constructed with biotinylated MSPs.  
In this chapter AcrB was used as a model membrane protein in the comparison of alternative 
methods of detergent free membrane protein solubilisation in regard to their ability to isolate 
DARPins after two rounds of phage display. The solubilisation methods chosen were nanodiscs, 
which had been immobilised via an aspecifically biotinylated MSP, and SMALPs which had 
been immobilised by chemical biotinylation directly. SMALPs which had been constructed with 
NupC and VcCNT were also tested. The phage display and subsequent validation experiments 
show a consistent pattern in which screening with nanodiscs results in a higher proportion of 
the selection output binding directly to streptavidin when compared to SMALPs, however 
definitive conclusions cannot be made due to the fact that initial quality control experiments 
such as ELISAs on streptavidin coated plates were not carried out on these samples due to 
time constraints. Therefore confirmation of the SMALPs ability to bind to streptavidin coated 
surfaces would be the first experiment required in any continuation of this work.    
AcrB and MPSIL0294 are the only members of the target protein panel which have samples 
subjected to all methods of solubilisation under test in this study (DDM, nanodisc and SMALP). 
Therefore, they may provide insights into the relationship between solubilisation strategies 
and the likelihood of isolating DARPins which bind streptavidin directly. In total, 78% of the 
DARPins isolated against MPSIL0294-SBP solubilised in DDM showed an ability to bind 
streptavidin (see Table 3.2). When MPSIL0294 is solubilised with SMA the on the other hand, 
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12.5% of the DARPins selected against the resultant SMALPs showed this activity (see Table 
4.3). Finally when encapsulated in a nanodisc 19% of the DARPins selected against MPSIL0294 
were able to bind streptavidin. This would appear to suggest that detergent free methods of 
solubilisation are superior to solubilisation via DDM when isolating DARPins in phage display 
(either as a result of improved packing on the streptavidin coated surface or by increased 
accessibility to surface epitopes).  
The conclusion that detergent solubilisation is inferior in regard to the number of ‘streptavidin 
binders’ is also not supported by AcrB which shows a contradictory trend to MPSIL0294. In this 
instance, 59% of the DARPins selected against AcrB solubilised in DDM appeared to bind 
streptavidin (see Table 3.3), while 64% showed the same ability when selected against AcrB 
solubilised with SMA and finally 76% when selected against AcrB nanodiscs. The inclusion of 
NupC and VcCNT SMALPs also help to show that there is no clear relationship between the 
solubilisation method and the number of DARPins which bind streptavidin. As 61% and 11% of 
the DARPins selected against NupC and VcCNT respectively were streptavidin binders. The fact 
that these two proteins are homologues suggests that the solubilisation method and the 
number of streptavidin binding DARPins are independent factors. However, a prudent test to 
fully determine if a relationship exists between solubilisation method and the number of 
streptavidin binding DARPins, would be to tag AcrB with SBP and subject the subsequent 
samples of AcrB-SBP (solubilised in DDM, nanodiscs and SMALPs) to two cycles of phage 
display with the same DARPin library. A decrease in the number of ‘streptavidin binders’ 
selected against the nanodiscs and SMALPs, would confirm that detergent free methods of 
solubilisation are superior for SBP tagged proteins, in so far as reducing the number of 
streptavidin binding DARPins during a selection.  
When the number of DARPins that bind to the target protein (as determined with phage ELISA) 
are compared, SMALPs consistently show a significantly higher number of ‘hits’ than both 
nanodiscs and DDM solubilisation as can be seen in Table 3.6 and Table 4.7. While the AcrB 
nanodisc sample was only able to identify 4.5% of the total selection output as DARPin binders, 
the detergent solubilised samples failed to produce any DARPins capable of binding to the 
target, except for MPSIL0294-V532C which identified 2.3%. SMALPs on the other hand, 
identified 34% (AcrB), 26% (NupC) and 74% (VcCNT) of the total number of DARPins in their 
respective selection outputs, as ‘hits’.  This therefore suggests that in the comparison of 
different methods of solubilisation (DDM, SMALP or nanodisc), SMALPs are the best method 
for presenting proteins to a library of potential binding partners. Evidence for this conclusion 
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can be seen no matter the protein which has been encapsulated within the SMALP as both 
NupC and VcCNT follow this trend with a high number of DARPins which apparently bind to 
these targets being identified. The drastic difference in the number of DARPins identified 
between NupC and VcCNT also suggests that either VcCNT is better able to pack on the surface 
than NupC or that VcCNT has surface epitopes which are more accessible to the DARPins than 
NupC.    
The amino acid sequence of the DARPins isolated against AcrB SMALPs have been aligned with 
one another and compared to a third DARPin, B10 from the detergent solubilised AcrB plate 
which failed to bind (see Figure 4.9). A complete alignment of all of the binding DARPins from 
the AcrB nanodisc selection is presented in chapter 5. The alignments highlights several 
positions within the DARPin variable region which show a degree of preference toward certain 
amino acid residues, for example in position 57 where the majority of the DARPins have an 
asparagine residue and those that don’t have a tyrosine or histidine. The most prominent 
example of this conservation however is the 69th residue, which in the overwhelming majority 
of the DARPins aligned is an isoleucine and the majority which do not have this residue have a 
valine in its place, with the exception of A8 which has an alanine instead. Thereby suggesting 
that an aliphatic residue is essential for binding in this position, with the exception of H2, 
which has a serine residue.      
Some degree of DARPin cross-reactivity was tested as shown in chapter 5, as DARPins selected 
against NupC, VcCNT and AcrB SMALPs (as well as AcrB nanodiscs) were tested in ELISAs 
performed on these proteins detergent solubilised counterparts and still showed an ability to 
bind to the various proteins (see Chapter 5).       
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Figure 4.9: AcrB SMALP DARPin binder’s amino acid sequence alignment: The amino acid sequence alignment of 
DARPins that showed an ability to bind to AcrB SMALPs aligned against B10 which was selected against detergent 
solubilised AcrB. Only residues in the variable regions of the DARPins have been shown with the exception of 
B10. The N and C terminal caps are shown in black text of B10 while the variable region is in blue. The most 
common residues in each position across all of the DARPins are highlighted in green. In an instance in which two 
residues have the same frequency the second has been highlighted in red.  
Very recently the use of crystallisation chaperones has yielded a high profile crystal structure 
from the same protein family as MPSIL0294. The structure was of one of its prokaryotic 
homologues from Staphylococcus capitis and was determined using co-crystallisation with a 
nanobody which was isolated against it. However in order to obtain the crystals several 
residues were removed from the proteins N-terminal and the nanobodies were generated via 
the immunisation of llamas (Ehrnstorfer, Geertsma et al. 2014). The use of DARPins as 
crystallisation chaperones has some precedence and have been used in order to solve the 
structures of a wide range of proteins included some membrane embedded (Sennhauser and 
Grutter 2008).   
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In regard to solving crystal structures the work presented here has several benefits. Firstly, 
SMALPs are thought to entrap full length membrane protein within a lipid environment more 
reminiscent of its natural surroundings (Postis, Rawson et al. 2015). Secondly, the DARPins are 
easy to produce without the need of animals making it more widely accessible unlike antibody 
based binding partners such as nanobodies (Ehrnstorfer, Geertsma et al. 2014).          
Overall it tentatively appears as though SMALPs are superior to nanodiscs, however further 
validation is required to confirm this. Outside of phage display the physical characteristics of 
SMALPs (i.e. their stability and storage) make them a more attractive prospect to work with in 
the future. Experimental and observational evidence has shown that nanodiscs have a 
tendency to destabilise when stored at -80°C and when stored at 4°C for an excess of 2 weeks. 
SMALPs on the other hand have shown a high degree of stability after long term storage at -
80°C and several freeze-thaw cycles. Indeed even the procedure by which both of these 
protein formats are made show the same pattern, as SMALPs are made in an identical manner 
as detergent micelles while nanodiscs require a minimum of 1 week in order to remove 
detergent. Although a major drawback of the use of SMALPs as shown here is that when 
constructed with a protein which neither expresses nor purifies to a high yield, many 
impurities can co-purify. As such it is unclear whether or not these impurities are able to 
immobilise on the streptavidin surface particularly for samples which underwent aspecific 
biotinylation such as AcrB, VcCNT and NupC. Therefore the DARPin selection outputs from the 
SMALPs will require further validation to ensure that they only bind to the target instead of 
impurities or the SMA polymer itself. This validation should use a third phage ELISA in the 
presence of immobilised detergent solubilised protein. Although it is also possible that some 
DARPins will bind to the MSP of the nanodiscs, therefore the outputs from the nanodisc 
selections should be subjected to a third phage ELISA with immobilised ‘empty’ nanodiscs.                  
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Chapter 5 
 
A Characterisation of the DARPins 
identified after phage display  
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5.1 Introduction 
There are several examples in literature in which DARPins have been successfully selected 
against membrane proteins (Huber, Steiner et al. 2007, Steiner, Forrer et al. 2008). Many have 
been identified with a capability to bind therapeutically relevant receptors such as the 
epidermal growth factor receptor (EGFR) which is overexpressed in many cancers and plays a 
role in cell proliferation. The high affinity of DARPins lead to the creation of bispecific 
derivatives capable of reducing the receptors presence on the cancer cell surface by inhibiting 
receptor recycling. Bispecific DARPins were constructed using two DARPins which target 
different EGFR epitopes, with either a leucine zipper or a flexible linker (Boersma, Chao et al. 
2011). Similarly Eggel et al. also formed bivalent DARPins in an identical manner however in 
this instance two identical DARPins were used (Eggel, Baumann et al. 2009, Boersma, Chao et 
al. 2011). These bivalent DARPins have been shown to target multiple epitopes while retaining 
all of biophysical benefits which monovalent DARPins exhibit (Eggel, Baumann et al. 2009). For 
EGFR and IgE receptors, these DARPin derivatives have shown activities which rival (and in 
some cases surpass) therapeutic antibodies (Boersma, Chao et al. 2011) (Eggel, Baumann et al. 
2009). Although bivalent DARPins would only be therapeutically relevant when multimeric 
proteins are targeted. DARPins have also been conjugated with small molecule cytotoxins 
thereby increasing their pharmacokinetics and uptake. DARPin against Epithelial Cell Adhesion 
Molecule (EpCAM) were conjugated with mouse serum albumin to increase their half-life and 
to the antimitotic agent monomethyl auristatin F (MMAF) to achieve the targeted inhibition of 
cancer cell proliferation (Simon, Frey et al. 2013).    
Typically after a screen phage ELISAs are often used in order to confirm the ability of the 
selected DARPins to bind to the target of interest. These DARPins are selected arbitrarily after 
several rounds of display and are sequenced after this point. Purification of DARPins tends to 
utilise IMAC followed by further characterisation using techniques such as surface plasmon 
resonance (SPR), analytical HPLC or flow cytometry (Steiner, Forrer et al. 2008, Eggel, Baumann 
et al. 2009, Stefan, Martin-Killias et al. 2011). Their expression often requires subcloning into 
an expression vector either to avoid the production of phage coat proteins or to maximise the 
yield of DARPin (Steiner, Forrer et al. 2008, Boersma, Chao et al. 2011, Stefan, Martin-Killias et 
al. 2011). A minimum of three cycles are typically used in a selection screen thereby resulting 
in higher quality selection outputs (Stefan, Martin-Killias et al. 2011). Although Steiner et al. 
did report a monomeric DARPin against the constant domain of human IgG1 with a KD of 140 
nM (Steiner, Forrer et al. 2008). DARPins selected in this manner have been used in several 
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subsequent applications such as those described above and co-crystallisation trails which has 
shown to be very effective with DARPins (see chapter 1).                   
Chapter 3 and 4 described the use of two cycles of phage display with a naïve DARPin library 
against a panel of membrane proteins, as well as the subsequent validation tests performed on 
the various selection outputs. In this chapter, 21 DARPins from these validated selection 
outputs were selected and subjected to further study via expression, purification and the use 
of a DARPin binding assay. The DARPins include 2 which showed activity in the presence of 
detergent solubilised, labelled MPSIL0294-V532C, 6 isolated against AcrB (2 against the 
SMALPs and 4 against the biotinylated nanodiscs), 5 DARPins isolated against the VcCNT 
SMALPs and 8 DARPins which were able to bind to NupC SMALPs. These DARPins were 
selected based upon their A450nm readings produced after the two phage ELISAs shown in Table 
3.4, Table 4.5 and Table 4.6. While these previous assays used entire phage particles 
presenting the DARPins upon their surface, the assays described in this chapter shall use 
purified DARPin alone. These assays shall confirm the DARPins ability to bind their target and 
attempt a rough estimate at the affinity of the DARPin for their target. DARPins G6 and E6 will 
also be introduced in stopped flow experiments with MPSIL0294-V532C in order to investigate 
if they have any functional effect on the protein.        
5.2 Sub-cloning DARPins selected against a panel of membrane 
proteins 
Typically DARPins produced for phage display are expressed with an N-terminal signal 
recognition peptide, DsbA and a C-terminal amber stop codon between the DARPin gene and 
the phage coat protein (see chapter 1).  
Efforts to express DARPins in Medimmune have found that that high aeration of TG1 cells 
results in high levels of DARPin expressed and released into the growth medium. This was 
attempted initially, however the procedure failed to produce any extracellular DARPin. 
Therefore expression was subsequently attempted in BL21 gold cells instead as they are a non-
suppressor strain and therefore should only be able to produce soluble DARPin protein not 
fused to the M13 major coat protein - P3. The amber stop codon in the pC6 plasmid which 
houses the DARPin open reading frame (see section 2.5.6) is responsible for this. This concept 
was tested by focussing attempts at expression on a single arbitrarily selected (D1 selected 
against AcrB biotinylated nanodiscs) DARPin. The plasmid DNA was first isolated from the TG1 
cells (see section 2.3.8) and subsequently used to transform BL21 gold cells (see section 2.3.7). 
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Expression of the DARPin was performed via IPTG induction in 50 mL SB medium 
supplemented with 100 µg/mL carbenicillin as described in section 2.4.2. The cells were 
incubated at an elevated RPM (300 rpm) in order to once again subject the cells to the high 
aeration conditions that MedImmune have found to facilitate DARPin production. The 
transformed BL21 gold (DE3) cells were then subjected to a periplasmic extraction (see Section 
2.5.7).  
As can be seen in Figure 5.1 this expression protocol produced an immunogenic band in the 
cytoplasmic sample with a molecular mass between 15 and 25 kDa when the cells have been 
treated with IPTG. This band appears very faintly in the non-IPTG band and not at all in the 
periplasmic fractions. Although the mass of this band is within the correct range in regard to 
the predicted mass of a DARPin (16.6 kDa), its proximity to the 25 kDa marker is somewhat 
unexpected. The reason for this increase in mass is not clear, it could possibly be due to the 
presence of the DsbA signal sequence which would increase the predicted mass of the DARPin 
to 18.8 kDa. The fact that the DARPin failed to translocate to the periplasm provides some 
evidence for this. This failure to translocate also explains why the DARPin unexpectedly is only 
observed in the cytoplasm. Although the expression level is also very low and is barely 
detectable by western blot.   
  
 
A) 
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Figure 5.1: Periplasmic extraction of BL21 gold (DE3) cells expressing DARPins:  Samples taken from the different 
fractions produced after a periplasmic extraction was performed on cultures of BL21 gold were analysed via 
Coomassie stained 12% SDS-PAGE and western blotting probed with an anti-polyhistidine tag antibody 
conjugated with HRP. The Bl21 gold cells were transformed with plasmid pC6 in which DARPin D1 isolated against 
AcrB nanodiscs was encoded, samples treated with IPTG were compared with samples that were not. MPSIL0294 
was used as a positive control of the blot.   
Because attempts to express the DARPin in this way failed, it was decided to sub-clone the 
DARPin gene from pC6 in Figure 2.1 into the expression vector pET16B shown in, thus 
removing the potential problems associated with the DsbA signal sequence and amber stop 
codon. In order to achieve this, an N-terminal NdeI and a C-terminal BamHI cut site were 
inserted into the pC6 plasmid via PCR (see section 2.3.1) using the following primers: 
 Forward primer (introducing the NdeI site) pET16b_DP_Fwd: 
 5’ – CGATCATATGGATCTGGGAAAAAAACTGCTGGA – 3’ 
 Reverse primer (introducing the BamHI site) pET16b_DP_Rev: 
 5’ – ATCGGGATCCTCACTACAGTTTCTGCAGG – 3’ 
The amplified DARPin was inserted into an empty pET16B vector via double restriction digest 
with NdeI and BamHI followed by ligation (see section 2.3.3 and section 2.3.6). After 
transformation in Omnimax™2 in order to amplify and isolate the DNA, the correct 
B) 
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construction of each resultant plasmid was analysed via double restriction digest with NdeI 
and BamHI followed by electrophoretic analysis on a 1% agarose gel (see Figure 5.2).  Empty 
pET16B was used for the subcloning therefore upon restriction analysis the presence of a band 
at approximately 500 bp is indicative of the insertion of the DARPin gene. Figure 5.2 shows the 
agarose gel produced after 20 of the 21 selected DARPins were analysed in this manner. This 
500 bp gene is present in 19 of the 20 DARPins and the subcloning of DARPin C1 was not 
successful. The successful subcloning of the remaining DARPin (H10 selected against NupC 
SMALPs) was confirmed via sequencing. Attempts to express each were then performed in 
BL21 (see section 5.3).       
 
Figure 5.2: NdeI/BamHI double restriction analysis of pET16B-DARPin expression vectors: Following the 
experiments which sub-cloned all 20 DARPins into pET16B the resultant plasmids were analysed via 
electrophoretic separation on a 1% agarose gel after double restriction with NdeI and BamHI. Visualisation of the 
gels was performed in a Gbox from SynGene.   
5.3 The Expression and purification of the DARPins 
An initial expression test using the DARPin_pET16B constructs was performed in 5 mL cultures 
of BL21 cells following the same (albeit scaled down) methodology described in section 2.5.4. 
Whole cells samples of each expression were then pelleted and resuspended in 1 mL 2x PBS 
prior to further analysis. These samples were then diluted by mixing 1µL of them with 9 µL of 
2x PBS and 2.5 µL of loading buffer (see Table 2.8) before incubation at 95°C for 10 minutes. 
The samples were then analysed via 12% Coomassie stained SDS-PAGE (see Figure 5.3) run in 
1x Tris-glycine running buffer (see Table 2.9). A positive control DARPin prepared by 
MedImmune was run on the gel alongside the DARPins while uninduced BL21 cells were run as 
a negative control.  As previously mentioned the predicted mass of the DARPins is 
approximately 16.6 kDa and as the resultant gel shows each DARPin has successfully been 
expressed. The majority of the relevant bands have migrated to the bottom of the SDS-PAGE 
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gel and have resolved at different molecular weights and different expression levels to one 
another. Despite this, these bands are most likely the DARPins as they are the only band not 
present in the uninduced BL21 negative control. The DARPin C1 selected against NupC SMALPs 
did not express to a significant level and was therefore no longer studied leaving only 20 
DARPins remaining for further analysis. This was expected as the double restriction digest 
described above indicated the sub-cloning failed (see Figure 5.2). The sub-cloning and 
expression of C1 was repeated separately and results are not included here. 
 
 
Figure 5.3 Small scale expression test of 20 binding DARPins: Each DARPin was expressed in the E.coli strain BL21 
via IPTG induction therefore uninduced BL21 has been added as a negative control. A previously characterised 
DARPin was provided by MedImmune designated E3-5 and was used as a positive control     
 
A larger scale expression and purification of a single DARPin was attempted for a 500 mL BL21 
culture. The DARPin was purified via IMAC with cobalt resin as described in section 2.5.4 with 
the inclusion of an initial wash with 2x PBS supplemented with 10 mM imidazole followed by a 
wash using 20 mM imidazole. These samples were also analysed by 12% SDS-PAGE gel 
followed by staining with Coomassie blue (Figure 5.4). A single protein band resolved just 
above the 15 KDa marker corresponding to the DARPin with a predicted mass of 16.6 kDa. No 
DARPin was present in the flow through confirming all expressed DARPin bound to the cobalt 
resin. However, some DARPin is eluted in the wash samples with 10 and 20 mM imidazole. The 
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washes seem ineffective and are not required considering the purity of the eluted protein. 
However, a single superfluous protein might have co-purified, as shown by the unidentified 
protein at a Mr <15 kDa in the SDS-PAGE. This could also be a degradation product or an SDS-
PAGE artefact. 
 
Figure 5.4 Initial purification of DARPin C1 against VcCNT SMALPs: An initial attempt to purify a DARPin using C1 
selected against VcCNT SMALPs with samples taken throughout the purification analysed via 12% SDS-PAGE gel 
followed by staining with Coomassie blue. The flow through sample is a measure of the amount of protein which 
failed to bind to the resin and was taken from the solution realised once the resin was packed into a disposable 
column. All washes were performed by gravity flow and the peak elution fractions were collected and 
concentrated in a vivaspin concentrator with a 10 kDa molecular weight cut off.    
Following the success of the VcCNT SMALP DARPin C1 purification, large scale expressions 
were repeated for all 20 of the successfully expressed DARPins. The peak fractions of each 
DARPin were pooled and concentrated in a vivaspin concentrator with a 10 kDa molecular 
weight cut off. Samples of each purified DARPin was analysed via 12% SDS-PAGE followed by 
Coomassie staining in 1x MOPs running buffer as opposed to the buffer used in Figure 5.3 (see 
Table 2.10). Running SDS-PAGE in MOPS reduces the migration of the low molecular weight 
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protein, improving their separation.  Figure 5.5 shows that each DARPin is estimated to be 
more than 90% pure and suitable for further study. Some DARPins, such as A1 (against AcrB 
SMALPs), E3 (against AcrB nanodiscs), C1 (against VcCNT SMALPs) and E6 (against detergent 
solubilised MPSIL0294-V532C) amongst others produce a protein band at approximately 37 
kDa. Some of the DARPins have also produced a second band in very close proximity to the 
putative DARPin band, e.g., F1 (against AcrB nanodiscs) and H8 (against NupC SMALPs) 
although is somewhat common in DARPins with more than two internal repeats and is often 
caused by incomplete denaturation by SDS (Steiner, Forrer et al. 2008). There is also evidence 
of co-elution with some contaminants, for instance for A5 (against NupC 5) and G10 (VcCNT 
SMALPS).  
 
Figure 5.5: Purification of 20 DARPins from the pET16B expression vector: Each DARPin was purified via IMAC on 
cobalt resin, the peak fractions were then concentrated with a vivaspin concentrator with a 10 kDa molecular 
weight cut off and analysed on a 12% SDS-PAGE gel followed by extensive Coomassie staining. DARPin E3-5 was 
previously characterised by MedImmune and was used as a positive control for the DARPins  
5.4 An Alignment of the protein binding DARPins Sequences  
The sequences for the 20 DARPins selected for further study have been aligned and analysed in 
order to highlight any commonality between the sequences. In the sections below the 
alignment will be discussed separately for the different targets. Analysis was done in an 
identical manner as for DARPins E6 and G6 (selected against detergent solubilised MPSIL0294-
V532C) in chapter 3 (see Figure 3.12). Once again residues in the variable regions are colour 
coded, while conserved residues such as the aspartic acid residue in position 32 and the 
glycine in position 35 have been left colourless (see Figure 5.6).  
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Generally, between the sequences of each DARPin there is slight variation observed at the end 
of ‘GHLEIVEVLLK’ repeats. The next residue is always one of three residues: a tyrosine, a 
histidine or an asparagine with tyrosine being the most common. The reason for this diversity 
is not immediately clear.       
5.4.1 DARPins selected against AcrB Nanodisc 
Four DARPins selected against AcrB nanodiscs were taken for further study, DARPins D1, F1, 
H1 and E3. These DARPins do not show a great degree of sequence commonality between 
them (see Figure 5.6). This is especially apparent between positions 97 and 100 in which there 
is a large cluster of alternative residues between the different sequences. In one case, even a 
non-variable aspartic acid residue at position 98 is mutated to a histidine in DARPin H1. Indeed 
the only similarity in this region exists at position 99 between D1 which has an aspartic acid 
residue and E3 which has a glutamic acid residue. There are however individual positions 
which show commonality either in the majority of the DARPins or in all four, for example the 
first variable region of all four DARPins begins with an arginine residue at position 31, similarly 
at position 66 in which three of the DARPins have a threonine residue. Despite this, it is quite 
clear that DARPins D1 and F1 are the most similar to one another out of all the possible 
DARPin combinations with a total of 9 variable residues which are either identical, have 
sidechains with the same R group or have similar physical characteristics.  
 
  
Figure 5.6 Amino acid sequence alignment of the DARPins generated against AcrB nanodiscs which were selected 
for further study: The sequences of the four DARPins selected against AcrB nanodiscs constructed with a 
biotinylated membrane scaffold protein have been aligned in order to highlight any common themes between 
the sequences. Amino acid residues in variable regions of the DARPins have been colour coded in regard to their 
similarity to the residues in the corresponding positions in the other DARPins while conserved residues have been 
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removed. Amino acids highlighted in red show no similarity with any of the other corresponding residues, those 
in bright green are identical, yellow have either the same R group or similar physical characteristics, similarly 
those in dark green share these characteristics as those in green. Residues in grey are identical to one another but 
different from those in green in at the same position and finally those in pink are similar to one another but not 
those in yellow in the same position.     
5.4.2 DARPins selected against AcrB SMALPs 
Two DARPins which were identified as AcrB SMALP binders were chosen for further study and 
were aligned in an identical manner as above. These two DARPins showed a very low amount 
of similarity between one another with 14 out of the 18 variable amino acid residue positions 
occupied with residues with no link to one another (see Figure 5.7). As only two sequences are 
aligned, no further meaningful comparison is possible. These two DARPins are not indicative of 
the entire output which showed an ability to bind to this target which were aligned in chapter 
4 (see Figure 4.9). Indeed, the majority of the variable residues in A1 are typical of the AcrB 
SMALP DARPin output.  
  
Figure 5.7: Amino acid alignment of the DARPins generated against AcrB SMALPs selected for further study: 
DARPins A1 and A2 selected against AcrB SMALPs were chosen for further study therefore their sequences were 
aligned so that any similarity between the DARPins could be highlighted. As before, residues in the variable 
regions were colour coded in regard to their similarity to one another with red being used to classify residues 
which show no similarity, bright green denoting identical residues and yellow denoting similar residues.  
5.4.3 DARPins selected against NupC SMALPs 
Due to the relatively high number of DARPins that were aligned, it is possible to make a more 
conclusive analysis of the DARPins in the variable regions in order to determine amino acid 
preference (Figure 5.8). One the most conserved positions in the DARPin is position 36 in 
which 5 of the 8 DARPins have an alanine residue, C1 has a leucine residue (an aliphatic 
residue like alanine) and A7 and H10 both have serine residues. A second position with this 
extremely high level of sequence similarity is at position 76 at which 5 of the DARPins have a 
methionine residue while G2 and H8 both have aliphatic residues in isoleucine and alanine 
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respectively. Finally A5 has a phenylalanine in this position which, while being an aromatic 
amino acid is a derivative of alanine. 
 
 
 
Figure 5.8: Amino acid sequence alignment of the DARPins generated against NupC SMALPs selected for further 
study: The sequences of the 8 DARPins selected against NupC SMALPs were aligned so that the level of similarity 
between them could be investigated. Residues in the variable regions of the DARPins have been colour coded in 
relation to their similarity to one another at particular positions within the sequence. Residues highlighted in red 
are not related to any of the corresponding amino acids in that position, residues in yellow share the same amino 
acid characterisation with one another, similarly residues in pink are also from the same characteristic amino acid 
group separate from those in yellow. Residues in bright green are identical to one another and those in dark 
green are related to them. Residues in grey are also identical to one another but are not related to those in 
green, only residues highlighted in black are related to these. Finally residues in blue are identical to one another 
but are unrelated to those in green and grey instead only residues in violet are related to them.     
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5.4.4 DARPins selected against VcCNT SMALPs  
Within the five DARPins selected against the VcCNT SMALPs, the sequence of C10 was 
unfortunately not available and therefore could not be aligned with the other VcCNT SMALP 
DARPins. The other four DARPins were successfully aligned, the results of which can be seen in 
Figure 5.9. The four DARPins show several positions which have a high degree of sequence 
similarity between one another. For example with the exception of G10, the 69th residue in the 
DARPins is an isoleucine and both of these residues are aliphatic amino acids. Similarly in 
position 67 all the DARPins except H11 have an asparagine residue or position 111 in which all 
of the DARPins with the exception of G10 (which has a histidine) have a valine residue.  
 
Figure 5.9: Amino acid sequence alignment of the DARPins generated against VcCNT SMALPs selected for further 
study: The sequences of the DARPins selected against VcCNT SMALPs and chosen for further study were aligned. 
DARPins C10 which was also further characterised did not have an available sequence and so was not included in 
this particular alignment. The residues in the variable positions were colour coded in relation to their similarity to 
one another. Residues in red were not related to the other amino acids in the same position, residues in yellow 
were from the same amino acid group. Residues in bright green are identical to one another and those in dark 
green are from the same amino acid group as these residues.      
5.5 Confirming the DARPins ability to bind via ELISA 
To test whether the various DARPins are able to bind to their respective targets, three ELISAs 
were performed in which the DARPins were tested in duplicate with a serial dilution ranging 
from 10 µM to 1 pM. In each case 10 µg of target membrane protein was adsorbed onto a 
solid surface. Adsorption was used due to the fact that a polyhistidine tag is present on all of 
the target membrane proteins as well as the DARPins, therefore his-tag antibodies could not 
be used to detect the DARPin binding and an alternative method was required. To this end, 
DARPins were biotinylated with NHS-biotin (Thermo Scientific) and probed with streptavidin-
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HRP (see section 2.10) and A450nm readings were recorded after treatment with TMB and 0.5 M 
H2SO4 the absorbance reading at 450 nm was plotted for each DARPin concentration. Due to 
the aspecific nature of the biotinylation it is not known what affect it will have upon DARPin 
binding. It could be that biotinylation of the DARPin reduces its affinity for its target. It is 
thought however, that biotinylation leaves enough of the DARPin unaffected that it should 
retain its stability and its ability to bind target epitopes. During the ELISA procedure both the 
initial protein adsorption and treatment of the immobilised target with DARPin was carried out 
in the presence of DDM in an attempt to retain the targets native confirmation. Although the 
possibility of denaturation upon adsorption on the maxisorb plate cannot be excluded, the fact 
that these ELISAs were performed on detergent solubilised protein does help to occlude the 
possibility of false positives in the selection output, in a similar manner as the use of Tween-20 
in a typical ELISA. 
The majority of the 20 DARPins that were tested in this manner showed a significant difference 
when in the presence of their immobilised targets as determined with a T-test against the 
negative control (negative controls consisted of the DARPin under test without any membrane 
protein target present). Even at the highest concentration tested (10 µM), DARPin binding 
failed to saturate and no ‘plateau’ was observed (as one expects on an IC50 graph). Unspecific 
‘background’ was also monitored by performing the ELISA without DARPins. The background 
absorbance readings were subtracted from those of the DARPins and negative controls.  
5.5.1 DARPins selected against detergent solubilised MPSIL0294-
V532C 
 Two DARPins were selected against chemically biotinylated MPSIL0294-V532C after two 
rounds of phage display. They were subsequently analysed via ELISA, the resultant data of 
which is shown in Figure 5.10. 
The ELISAs show that both DARPins are able to bind to MPSIL0294-V532C, where E6 gives 
higher absorbance values (note different axis in Figure 5.12). The data produced by G6 exhibits 
larger standard deviations than E6, which mean that less of the data points are significantly 
different from the negative control. Nonetheless, a very similar trend are found for E6 and G6. 
As previously mentioned the data fails to plateau which therefore makes it not possible to 
determine the IC50 for either E6 or G6. Instead a lower limit for the IC50 can be estimated which 
is 100 nM.  
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Figure 5.10: DARPin binding ELISA performed against DARPins selected against DDM solubilised MPSIL0294-
V532C: Purified samples of DARPins E6 and G6 were subjected to aspecific biotinylation with NHS-biotin prior to 
their use against 10 µg samples of detergent solubilised unlabelled MPSIL0294-V532C, adsorbed onto the surface 
of Nunc Maxisorp® plates. Samples were probed with 10 µM to 1 pM DARPin prior to analysis with Streptavidin-
HRP. Absorbance readings at 450 nm were recorded after the plates incubated in TMB solution for 2 mins 
followed by treatment with 0.5 M H2SO4. Each data point on the graph represents the average of six tests 
subtracted from a background reading which was measured using 10 µg BSA in the presence of no DARPin. The 
negative control was DARPin tested in blank wells with no target protein. The standard deviation of each data 
point was also calculated and the statistical significance was determined by a one tailed T-test. Each significantly 
different data point has been highlighted with a green asterisk.      
 
5.5.2 DARPins selected against AcrB SMALPs and Nanodiscs 
As for NupC-V532C, samples of detergent solubilised AcrB were aspecifically adsorbed onto 
the surface of a Nunc Maxisorp® plate and probed with DARPins. Two of these DARPins (A1 
and A2) were selected against AcrB SMALPs and the ELISAs (see Figure 5.11) show that despite 
the lack of commonality in the sequences of these two DARPins (see Figure 5.7) both produced 
similar binding curves. However neither DARPin saturated binding at 10 µM but both have 
similar adsorption values at this concentration. As for MPSIL0294-V532C, negative controls 
were measured without target protein and the data sets were analysed for a significant 
difference using a two tailed T-test. Despite the similarities between the two traces. In the A2 
trace the data points might start to level off typical of an IC50 plot. However, the low 
absorbance values and standard deviations in the data points, makes an unambiguous 
assessment impossible and for both DARPins only a lower limit can be determined for the IC50 
of 100 nM. 
 
N = 3 
 161 
 
Figure 5.11 DARPin binding ELISA performed against DARPins selected against AcrB SMALPs: 10 µg of detergent 
solubilised AcrB was aspecifically adsorbed onto the surface of Nunc Maxisorp® plates and treated with a serial 
dilution of DARPin A1 and A2 from 10 µM – 1 pM. The DARPins showed an ability to bind AcrB SMALPs 
particularly tightly after two rounds of phage display and two rounds of subsequent validation. The plates were 
probed with streptavidin-HRP and the absorbance at 450 nm was analysed after incubation with TMB and 
subsequent exposure to 0.5 M H2SO4.The negative control for both ELISAs was the DARPin without the target 
protein present and all of the readings have been adjusted for background signals by subtracting the absorbance 
reading produced by BSA alone. Each ELISA was also repeated three times with duplicates of each concentration, 
error was calculated by the standard deviation of all six of these data points and the significance between the 
test data and negative control was calculated by a 2 tailed t-test. Data points which are significantly different 
from the negative have been highlighted with a green asterisk.         
 
The traces produced by ELISAs performed on the DARPins selected against AcrB nanodiscs (see 
Figure 5.12) show that all of the DARPins are able to bind to detergent solubilised AcrB to 
some extent, however, the best binder when both statistical significance and A450nm readings 
are taken into account is E3. When compared in terms of significance, D1 is the best as it is 
significantly different from the negative control at every concentration other than 100 nM, F1 
is only significantly different from the negative control down to a concentration of 100 nM, 
H1s significance ceases after 1 µM, and finally E3 is significantly different from its negative 
control down to 10 nM. The highest absorbance reading however, shows that E3 performs the 
best out of the DARPins. When 10 µM of DARPins is used on the ELISA the reading produced by 
E3 is substantially higher (approximately twice as large) than D1, F1 and H1. Like all of the 
other ELISAs performed in this Chapter, negative controls were performed without membrane 
protein present. The negative controls of H1 and F1, however, suffers from a higher than usual 
degree of fluctuations. This effect is aggravated in the graph due to the small values of the 
absorbance readings in these results. 
N = 3 
 162 
 
Figure 5.12: DARPin binding ELISA performed against DARPins selected against AcrB nanodiscs:  This ELISA was 
carried out on 10 µg of immobilised AcrB solubilised with DDM using a serial dilution of DARPin from 10 µM to 1 
pM. Each ELISA was repeated three times and each concentration was tested in duplicate, the negative control 
was the DARPin tested in the absence of AcrB and background noise was corrected for by subtracting all of 
absorbance readings from those produced by BSA alone. Statistical significance was determined by two tailed t-
test, all data points which are significantly different from their corresponding negative control are highlighted 
with a green asterisk.     
5.5.3 DARPins selected against NupC SMALPs 
The traces produced by the DARPins selected against NupC SMALPs show that 5 of the 6 
DARPins successfully bind to the target. DARPin A3 fails to follow the expected data trend but 
remains significantly different from the negative control throughout the serial dilution, 
suggesting a concentration independent binding although considering the A450nm readings it is 
likely that this arbitrary binding is quite poor. All of the DARPins show a significant increase 
over the various negative controls at most concentrations, more so than the other DARPins 
which have been tested in this manner. The exception being H10, the negative control of 
which comes into closer proximity with the test data than any of the other NupC DARPins, thus 
suggesting that the DARPin does not bind to NupC particularly well. As with the other ELISAs, 
the data fails to plateau and therefore an affinity for the DARPins cannot be determined. 
Instead a lower estimate of 100 nM for DARPins C2, G2, H8 and H10 can be given. The traces 
produced by DARPins A3 and A5 however do not have allow a clear estimate to be given. 
N = 3 
 163 
When the data trends along with the absorbance readings are considered, C2 and G2 appear 
to be the most promising DARPins and could be used in co-crystallisation trails (see Figure 
5.13). 
 
 
Figure 5.13: DARPin binding ELISA performed against DARPins selected against NupC SMALPs:  This ELISA was 
carried out on 10 µg of immobilised NupC solubilised with DDM using a serial dilution of DARPin from 10 µM to 1 
pM. Each ELISA was repeated three times and each concentration was tested in duplicate. The data has been 
compared with a negative control which consisted of the DARPin tested in the absence of NupC and background 
noise was corrected for by subtracting all of the absorbance readings from those produced by BSA alone. 
Statistical significance was determined by two tailed t-test, all data points which are significantly different from 
their corresponding negative control are highlighted with a green asterisk. 
N = 3 
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5.5.4 DARPins selected against VcCNT SMALPs 
Samples of detergent solubilised VcCNT were produced via the protocol described in section 
2.5.3, as shown in Figure 5.14 samples taken throughout the purification procedure were 
analysed via SDS-PAGE and western blotting. As was the case with previously described 
purifications, the samples taken throughout the procedure give an insight into the state of the 
protein. From Figure 5.14 it is evident that VcCNT expresses well (see intense band in the 
‘Total’ sample of the Coomassie stained gel and its counterpart on the western blot). The vast 
majority of this protein is successfully solubilised and only a minimal amount of VcCNT did not 
successfully bind to the resin. The final yield of VcCNT was determined to be 4.35 mg from 
100mg of membrane produced in a 30 L fermentation after extensive dialysis and 
concentration in a viva spin concentrator with a 60 kDa molecular weight cut off.       
Like the other ELISAs, the absorbance readings produced at 450 nm have been plotted and 
compared with a negative control consisting of the DARPin analysed in the absence of 
immobilised target protein (Figure 5.15). All five DARPins produce statistically significant data 
above 100 nM except for C1 which is only significantly different from its negative control at 10 
µM. When the error of H11 is considered it appears to be the most consistent DARPin out of 
those chosen for further study (along with E3, C2 and G2 in Figure 5.12 and Figure 5.13 
respectively), as the level of error is minimal across the entire data set. H11 also produces the 
highest absorbance reading with 10 µM of DARPin out of all 20 DARPins studied, with a value 
of 0.345. Unfortunately like the previously discussed ELISAs, the range of concentrations used 
in Figure 5.15 is not wide enough to produce a plateau in the trace therefore an affinity cannot 
be determined this way and for all five DARPins only a lower value of 1 M can be given.  
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Figure 5.14: IMAC Purification of detergent solubilised VcCNT: Samples taken throughout the purification of 
VcCNT were analysed via 12% SDS-PAGE stained with Coomassie blue and western blotting probed with an anti-
polyhistidine tag antibody conjugated with HRP. Each sample was normalised to a volume of 10 µL, therefore the 
‘Total’ ‘Supernatant’ and ‘Flow Through’ represents 0.02% of the original sample. The ‘Pellet’ represents 0.1% 
and the two washes represent 0.05%. The eluted protein was subjected to extensive dialysis and concentration in 
a viva spin concentrator with a 60 kDa molecular weight cut off, it represents 0.33% of the original sample. 
 
A) B) 
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Figure 5.15: DARPin binding ELISA performed against DARPins selected against VcCNT SMALPs:  The ELISAs were 
performed in the presence of 10 µg of detergent solubilised VcCNT which was aspecifically adsorbed onto the 
surface of a Nunc Maxisorp® plate and probed with a serial dilution of each DARPin ranging from 10 µM to 1 pM. 
The negative control consisted of each DARPin analysed in the absence of target protein and all data points were 
subtracted from the background noise, determined by the analysis of BSA in the absence of DARPin. Each ELISA 
was repeated three times and each concentration was tested in duplicate in order to calculate the error by 
standard deviation. Statistical significance was determined by a two- tailed T-test and all data which is 
statistically significant from its negative control counterpart is highlighted with a green asterisk.    
 
 
N = 3 
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5.7 Discussion and Conclusions  
While it was not possible to determine the specific affinity of the DARPins for the various 
target proteins, the ELISAs confirm that the DARPin are able to bind as they produce 
significantly higher levels of absorbance at 450 nm in the presence of adsorbed target protein. 
They do not however confirm that the DARPins are specific for their targets. In order to 
confirm the specificity of the DARPins, future ELISAs will need to be performed on plates with 
other membrane proteins adsorbed on their surface. The assays shown in Figure 5.11, Figure 
5.13 and Figure 5.15 were performed using DARPins which were selected against SMALPs, the 
ELISAs however were performed on detergent solubilised protein. The results therefore prove 
that the DARPins are not binding directly to the SMA polymer. This is also true of the assay in 
Figure 5.12 which was performed on DARPins selected against AcrB nanodiscs, the fact that 
significant data was produced in the presence of detergent solubilised AcrB proves that the 
DARPins are not binding to MSP directly (which is a risk when nanodiscs are used in selection 
experiments). Unfortunately, the DARPin assay which was carried out on the two DARPins 
selected against detergent solubilised MPSIL0294-V532C (chemically labelled via biotin 
maleimide) does not exclude the possibility that the DARPins may bind to the SBP or avitag. 
The fact that they were performed on unlabelled MPSIL0294-V532C in DDM micelles however 
does exclude binding to PEG linker.  
The seemingly poor affinity of the DARPins isolated in this study are in stark contrast with 
previous studies which have isolated DARPins in a similar manner as detailed here and have 
resulted in DARPins with sub-nanomolar affinities (Zahnd, Wyler et al. 2007, Steiner, Forrer et 
al. 2008). However many of these studies used a mixture of solid and solution based selections 
and a higher number of phage display cycles thereby reducing the number of background 
binders.  
The poor affinity of the DARPins may also be a result of certain limitations with the assay, for 
instance, every membrane protein under test had a polyhistidine tag, thereby making it 
difficult to distinguish if the DARPins are binding directly to the tag or the protein, although 
this is unlikely as the large surface area of a DARPin most likely would not bind a linear epitope 
such as a polyhistidine tag. Similarly, the aspecific nature of the DARPin biotinylation 
procedure may have untold consequences on the affinity of the DARPin to the target. In the 
case of the DARPins selected against SMALPs and nanodiscs, the low affinity may also be a 
consequence of the DDM which was present throughout all of the ELISAs. This DDM was added 
in an attempt to retain the target proteins native confirmation after adsorption, the presence 
of micelles however may occlude the surface epitopes which the selected DARPins target, 
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thereby interfering with DARPin binding (see Chapter 1). Ideally this assay should be replaced 
with an alternative which probes the protein in their native membrane environments.  In 
future selection projects this assay works as a first step in the confirmation of the DARPins 
ability to bind a His-tagged target protein however It would need to be followed by a repeat of 
the assay with adsorbed protein lacking a polyhistidine tag so that the N-terminal His tag on 
the DARPins could be detected via an anti-polyhistidine antibody conjugated with HRP, 
thereby excluding direct binding of the His-tag. It would also be beneficial if this assay was 
followed up with an assay which does not require the DARPin to be biotinylated such as size 
exclusion chromatography (SEC), flow cytometry or SEC-MALLs. In either the case biophysical 
techniques such as surface plasmon resonance (SPR) would be the subsequent validation test 
in order to elucidate the DARPins affinities.  
Despite the limitations of the assay, several DARPins have been identified which show promise 
in their ability to bind to their targets. These DARPins are prime targets for crystallisation 
chaperones in order to elucidate the structure of VcCNT (DARPin H11), NupC (G2 and C2) and 
MPSIL0294 (E6). Although it must be considered that while biotinylation of the DARPin was 
confirmed, the extent of biotinylation was not, the extent of biotinylation could affect the 
DARPins affinity and performance in the ELISAs. Despite this, G2, C2 and H11 (from Figure 5.13 
and Figure 5.15 respectively) are considered to be best DARPin binders based upon the 
consistency that the results displayed in the DARPin binding ELISAs. E6 is also considered one 
of the most promising DARPins based upon the number of data points which show a significant 
increase in absorbance compared to its negative control, while retaining the expected 
absorbance trend (see Figure 5.10). In follow up studies the extent of biotinylation should be 
measured using the HABA method (see section 2.4.4).  
With the data from the DARPin ELISAs the sequences of the most promising DARPins were 
aligned with one another (see Figure 5.16A). Firstly the sequences of DARPins G2 and C2, 
selected against NupC SMALPs, show very little similarity overall other than a small cluster of 
residues at positions 34, 36 and 44 which have an asparagine, an alanine and a histidine 
residue. Despite the fact that out of the DARPins selected against NupC, only G2 and C2 have 
all three of these residues in these positions, the importance of them is not clear. The residues 
do not share any physical characteristics (only two of the residues are hydrophilic, polar and 
neutral) and despite their presence the DARPin assays in Figure 5.13 show that G2 produced 
absorbance readings almost twice as high as C2. Other than this, the only other position with 
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some similarity between the two is the 69th residue (a valine in G2 and an isoleucine in C2) 
both of which are aliphatic residues.  
DARPins A1 and E3 selected against AcrB SMALPs and nanodiscs, respectively, can also be 
considered some of the best DARPins which have been identified based upon their consistent 
absorbance readings. However these DARPins will not be used in co-crystallisation trails as the 
crystal structure of AcrB has already been elucidated (Murakami, Nakashima et al. 2002), as 
well as insights into the nature of AcrB in association with DARPins, which showed that the 
DARPins bound to the periplasmic domain of AcrB (Brandstatter, Sokolova et al. 2011). It was 
also observed that several the stoichiometry of the DARPin with AcrB was dependent upon the 
multimeric variant of AcrB that they tested with, although it was shown that the DARPin was 
able to bind to AcrB in a stronger manner than the interactions between AcrB monomers 
(Brandstatter, Sokolova et al. 2011). AcrB was chosen to be a as a model target protein to 
compare SMALP technology, nanodiscs and detergent micelles as a method to present the 
target during phage display screening. As discussed previously, DDM micelles of AcrB failed to 
select any DARPins which passed our selection criteria, while it was possible to select four 
DARPins against nanodiscs AcrB and thirty DARPins again SMALPs AcrB. This suggests that the 
SMALPs are a better format for isolating potential binding partners. However, the first round 
validation tests of DARPins selected against SMALP AcrB was performed by binding assays of 
full phage to SMALP AcrB, and false positives could have been selected, e.g. DARPins binding 
to the SMA polymer. Thus, I performed the ELISA assay discussed in this chapter, and this 
confirmed the binding of DARPins A1 and E3 to detergent-solubilised AcrB (Figure 5.11 and 
5.12, respectively). An alignment of both of their sequences (see Figure 5.16B) shows that the 
tyrosine at position 90 is the only place in which both DARPins have the same residue. 
However it has already been shown that in this position a tyrosine is one of the preferred 
residues in all DARPins, therefore there is most likely not any real significance in this. Other 
than this, the two DARPins have similar residues in three other positions; the isoleucine and 
leucine in position 33, the valine and isoleucine in position 102 and the arginine and lysine at 
position 110.  
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Figure 5.16: Amino acid sequence alignment of the most promising DARPins: The sequences of the most 
promising DARPins selected against the same target have been aligned in order to highlight any sequence 
similarity between them. The DARPins aligned are; A) G2 and C2 selected against NupC SMALPs and, B) DARPins 
A1 and E3 selected against AcrB SMALPs and nanodiscs respectively. Residues highlighted in red are not related 
to one another, those in yellow share some physical characteristics and those in green are identical.     
Thus, it is evident that both nanodiscs and SMALPs AcrB are suitable formats to present a 
target protein in a phage display screening. However because only one unique DARPin 
successfully bound AcrB SMALPs and nanodiscs it is not possible to draw meaningful 
conclusions regarding which format is better.   
SMALPs are better in regard to their production however, which is less time intensive than 
nanodiscs. Also SMA solubilised membrane proteins can generally be stored longer than 
nanodiscs. Observational evidence has shown that nanodiscs only remain stable for a 
maximum of 2 weeks when stored at 4°C. It has also been observed in this project that 
nanodisc construction requires up to two weeks in order to remove all traces of detergent and 
are unable to withstand storage at -80°C. Considering the vast amount of time required in their 
construction and the complications in their storage, the fact that the DARPins which are 
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isolated are of a similar quality as those selected against SMALPs provides a strong argument 
to suggest that SMALP are a preferable presentation platform for membrane proteins.  
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Chapter 6 
 
Discussion and future directions 
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Selecting DARPins against immobilised membrane proteins is a well-established concept 
(Boersma, Chao et al. 2011, Stefan, Martin-Killias et al. 2011, Mittal, Bohm et al. 2012). 
Screening experiments often lead to the generation of high affinity binders some of which are 
capable of effecting protein function and thus show promise as potential drug candidates 
(Eggel, Baumann et al. 2009, Stefan, Martin-Killias et al. 2011). The screens however, often use 
detergent solubilised membrane protein which has been immobilised via aspecific adsorption 
or biotinylation. Depending upon the detergent selected, some potential surface epitopes may 
be engulfed within the micelle, thereby rendering them inaccessible to any potential binding 
partner (see chapter 1). Therefore, the primary aim of this thesis was to compare alternative 
methods of membrane protein immobilisation and presentation with regard to their ability to 
select DARPins capable of binding a panel of model membrane proteins after two rounds of 
phage display.  
To compare alternative methods of protein immobilisation, alternative protein tags were 
cloned onto the C-terminal of a model membrane protein. The initial model protein was a 
divalent metal ion transporter from Enterococcus faecalis designated MPSIL0294. Three 
different C-terminal tags were inserted downstream from a polyhistidine tag: a streptavidin 
binding peptide (SBP), an avitag which had undergone in vivo biotinylation and the chemical 
biotinylation of a C-terminal cysteine residue substituted for the valine residue at position 532 
via site directed mutagenesis (see chapter 3). A second model membrane protein, AcrB – a 
component of a multi drug efflux pump from E.coli, was chemically biotinylated with NHS-
biotin also.  
Comparative ELISAs showed that the three MPSIL0294 variants differed in their ability to 
immobilise on neutravidin coated plates, when probed with an anti polyhistidine antibody 
conjugated with HRP (see Figure 3.13). Out of the three variants, MPSIL0294-V532C showed 
the highest reading on the plates. Therefore, for the following reasons I hypothesis this higher 
reading is due to a lower surface coverage, which lead to an increase in the accessibility of the 
C-terminal polyhistidine tag. Firstly, the MPSIL0294 variants were also tested with FACs 
analysis after immobilisation on streptavidin coated magnetic beads (see Figure 3.14). In 
contrast to the multiwell plates, the FACs showed that MPSIL0294-V532C was unable to 
immobilise to the same extent as the other two variants, possibly due to its lower labelling 
efficiency. I therefore hypothesize that less packing of an immobilised membrane protein on a 
solid surface may lead to the increased accessibility of epitopes to an antibody.  
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Each of the MPSIL0294-variants were subjected to two rounds of phage display followed by 
validation of the resultant selection outputs via phage ELISA (see Section 3.7). Out of the three 
MPSIL0294 variants and detergent solubilised AcrB, MPSIL0294-V532C produced the highest 
number of ‘false-positive’ DARPins that bound strongly streptavidin (see Table 3.6). This may 
be due to MPSIL0294-V532Cs lower coverage on the pates leading to an increased exposure of 
streptavidin to the DARPin library. 
Thus I propose that a decrease in surface packing may lead to the increased generation of 
DARPins which bind streptavidin. Interestingly, MPSIL0294-V532C was also the only variant 
capable of selecting DARPins that bound the target, supporting the hypothesis that saturation 
of the surface may be a hindrance in the pursuit of binding partners during a selection, 
although more data is required to confirm this. Another comparative phage display which 
compared different levels of surface coverage would address this issue. This could either be 
achieved in an identical manner as described above, or by immobilising lower concentrations 
of protein onto the surface prior to a selection. This is especially interesting due to the fact 
that such a comparison in phage display has not been attempted before and the importance of 
factors such as coverage of a surface by a target is often overlooked in the literature.  
All of the MPSIL0294 variants were solubilised in DDM; a twelve carbon maltoside which 
produces large micelles. If the size of large micelles reduce the accessibility of surface epitopes 
to the DARPins (see Chapter 1), this will not be detected in this study. Therefore a comparative 
phage display using protein solubilised in different detergents would determine if the size of 
the detergent micelle is a factor in the number of binding partners successfully identified. It is 
expected that, as the carbon chain of the detergent decreases, more of the target protein will 
become accessible and therefore produce more binding DARPins. 
As stated, this study also aimed to compare alternative methods of membrane protein 
presentation in regard to their ability to isolate DARPins after phage display. Therefore, a panel 
of membrane proteins were solubilised in SMALPs and nanodiscs and in a comparative study. 
The panel of proteins included MPSIL0294-SBP SMALPs and nanodiscs, AcrB SMALPs and 
nanodiscs, the E.coli concentrative nucleoside transporter NupC in SMALPs and NupCs 
homologue from Vibrio cholera VcCNT in SMALPs (see Chapter 4). All members of this panel 
were subjected to chemical biotinylation with NHS-biotin, with the exception of the 
MPSIL0294-SBP and AcrB nanodisc samples; as the former is able to bind streptavidin directly, 
while the latter were constructed with a biotinylated MSP. Once again comparative ELISAs 
were performed on samples of MPSIL0294-SBP nanodiscs and SMALPs to test their ability to 
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immobilise on neutravidin coated plates. The nanodisc samples followed the trend established 
by its detergent solubilised counterparts although with a substantially lower magnitude, while 
the SMALPs failed to produce a significant signal (see Figure 4.7). This may theoretically be due 
to a decrease in the accessibility of the tag to the polyhistidine antibody due to the large size 
of nanodiscs (9.8 nm) (Bayburt and Sligar 2010) and SMALPS (9-12 nm) and the large molecular 
weight of the antibody-HRP conjugate.  
It might be that a lower coverage or loading, leads to decreased levels of steric hindrance 
between the individual MPSIL0294 proteins. This hypothesis could be tested via an ELISA that 
compares increasing surface coverages of MPSIL0294-V532C. This coverage could be 
monitored using quartz crystal microbalance with dissipation monitoring (QCM-D) with a 
streptavidin coated QCM chip. ELISAs would then be subsequently performed on the chips 
themselves, the result of which should display an inverse correlation with the surface coverage 
if the conclusion is correct. As stated above, the DDM micelle, nanodiscs and SAMLPS are all 
large constructs. Therefore, the effect sample size has on the success of the ELISA could be 
tested through use of a smaller probe. For instance, if the samples were immobilised via their 
His-tags on Ni-NTA covered plates they could be subsequently probed streptavidin-HRP and 
detected with TMB. Despite the fact that the streptavidin HRP is approximately 100 kDa it is 
smaller than a full length IgG antibody (150 kDa). This probe is still rather large however; 
therefore samples of MPSIL0294-avitag or MPSIL0294-V532C nanodiscs could be probed with 
biotin-HRP which is substantially smaller. Although ELISAs which employed biotin-HRP would 
need to be performed on blank maxisorp plates in order to ensure the biotin-HRP does not 
bind directly to the neutravidin. Although a direct comparison between the two experiments 
would not be accurate as the different probes would have different sensitivities. An alternative 
follow up to this work would be a comparative ELISA with a smaller target protein. The 
predicted mass of MPSIL0294 is approximately 60 kDa which is larger than the mass of 
streptavidin itself. It therefore seems likely that when the protein saturates the streptavidin 
coated surface it would sterically hinder a large antibody probe from gaining access to its 
epitope. The ELISA data presented in this study is unable to determine whether the readings 
are due to the polyhistidine tag on the MPSIL0294-SBP or the his tag of the MSP, therefore 
repeating this ELISA on empty nanodiscs will show if the MSP polyhistidine tag is accessible. 
Alternatively, if biotin-HRP is employed as stated earlier, it could also distinguish between the 
two. 
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The SMALPs failed to produce a signal using an ELISA with anti-his-HRP, which might be due to 
the electrostatic interaction between the strong negative charge of the maleic acid moiety and 
the positive charge of the polyhistidine tag (see Figure 4.7). This electrostatic interaction has 
also been shown to reduce the affinity of the tag to the cobalt resin. The reduced affinity was 
evident from the elution of SMALPs at low imidazole concentrations which, in compound with 
the poor expression level of MPSIL0294 and the excess of resin used in its purification, is the 
most likely reason for its lower purities compared to the detergent-solubilised proteins. The 
accessibility of the SBP tag on MPSIL0294 was therefore confirmed by binding the protein to 
streptactin, which proved to be successful, although only a limited fraction of the protein was 
shown to bind. The protein which failed to bind to the streptactin resin may be due to 
shielding of the SBP tag by the SMA polymer. It would therefore be an interesting follow up to 
repeat this streptactin binding assay with a large linker between the C-terminal of the protein 
and the tag. Distancing both the polyhistidine tag as well as the SBP tag may also alleviate the 
issues observed during the purification MPSIL0294 SMALPs.       
The two rounds of phage display were performed on the panel of membrane proteins followed 
by two phage ELISA validation tests, the first of which highlighted the number of DARPins 
capable of binding streptavidin (see Section 4.4). The result of this validation test showed that 
AcrB nanodiscs produced the highest number of streptavidin binders (76% of the selection 
output) followed by the AcrB SMALPs (64%). The prevalence of streptavidin binders to 
somewhat unexpected considering the fact that the phage library was initially deselected 
against blank streptavidin coated surfaces. Nevertheless, for AcrB, the detergent solubilised 
sample (59%) gave the best results in this respect, with the least numbers of selected DARPins 
binding to streptavidin. This trend is not seen in samples of MPSIL0294-SBP as the proportion 
of the selection outputs isolated against DDM solubilised protein which bound streptavidin 
was 78%, compared with 19% of the nanodiscs and 12.5% of the SMALPs.  
Compared to published instances of selection with DARPins, four rounds of selection in 
ribosome display was deemed sufficient to produce a library of DARPin inhibitors which bound 
specifically to DDM solubilised AcrB which had been biotinylated. Prior to the selection against 
the AcrB, the DARPins were subjected to two deselection procedures against neutravidin, BSA 
and biotinylated maltose binding protein (Sennhauser, Amstutz, Briand, Storchenegger, & 
Grütter, 2006). Similarly a study performed three rounds of phage display against the Fc 
domain of human IgG1 and reportedly began to isolate high quality binders after the second 
round with very little aspecific binding to a streptavidin or neutravidin. In this study a mixture 
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of solid selection (in which target proteins are immobilised on a solid surface such as a plate) 
and solution selection (in which target proteins are immobilised onto the surface of beads 
capable of staying in solution such as streptavidin coated magnetic Dynabeads®) (Steiner, 
Forrer, & Plückthun, 2008).  
Thus when the number of streptavidin or aspecific binders that were isolated in this study is 
considered, it appears clear that the deselection procedure employed was insufficient. Also 
considering the low affinity of the binders isolated it appears clear that a phage display 
protocol that combined solid and solution selections, as well as increasing the number of 
panning rounds, may have improved the selection outputs. Follow up studies must use a more 
extensive deselection process, possibly introducing multiple rounds of deselection, with both 
streptavidin and neutravidin. If subsequent selection aim to generate particularly strong 
binders then a competitive selection strategy could be employed. In competitive selections, a 
known associate of the immobilised target protein can be added to a later panning round. In 
theory the strongest binders will be retained and bind to the target, while weaker binders are 
outcompeted by the associate. This protocol has been demonstrated to vastly increase the 
affinity of scFVs against HM-1 killer toxin (HM-1)-neutralizing monoclonal antibodies (nmAb-
KT) by adding the toxin HM-1 after four rounds of phage display (Kabir, Krishnaswamy, 
Miyamoto, Furuichi, & Komiyama, 2009).                
The reason for this difference is not clear, therefore repeating the two rounds of phage display 
with AcrB tagged with SBP would be an essential experiment to perform in order to determine 
the relationship between solubilisation method and the selection of streptavidin binders. 
These experiments should also be seen in relation to the coverage or ‘loading’ efficiency of the 
target, as discussed above. This relationship would be further clarified if follow up studies 
increased the number of formats under test to include biotinylated amphipols. In order to 
increase the applicability of this work it would also be beneficial to include different antibody 
mimetics such as scFVs, nanobodies and adhirrons (see section 1.4) in order to see if 
solubilisation method has a similar effect on their selection.       
The second of the validation tests selected the DARPins that were capable of binding the 
target and showed that 34% of the selection output against AcrB SMALPs was capable of 
binding the protein. The relatively high number of binding DARPins was also shown in samples 
of NupC SMALPs (26%) and particularly VcCNT (74%) (see Table 4.13). The study shows that 
the proportion of DARPin binders selected against SMALPs is substantially higher than both 
nanodiscs and detergent solubilisation, as only 4.5% of the AcrB nanodisc selection output 
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bound to the target while no DARPins bound to DDM solubilised AcrB. Of all the DDM 
solubilised protein tested, the only selection output to produce positive DARPins was that of 
MPSIL0294-V532C (2.3%). This provides a clear suggestion that detergent free methods of 
solubilisation are superior and that nanodiscs are inferior to SMALPs. Unfortunately due to the 
low yield of MPSIL0294-SBP SMALPS and nanodiscs, they could not be included in the second 
validation test and it was thus not possible to distinguish between genuine DARPin binders and 
false positives. However, the SMALPs success provides further credence to the notion that I 
proposed earlier, that a decrease in surface coverage may lead to an increase accessibility to 
potential epitopes on the surface of a plate. When taken in conjunction with my second 
hypothesis, that the MPSIL0294-SBP SMALPS may struggle to saturate a streptavidin covered 
surface due to shielding of the SBP tag by the SMA polymer. A limitation of this hypothesis is 
the fact that the SMALPs discussed above were immobilised via chemical biotinylation not SBP, 
therefore, phage display performed on SMALPs constructed with the samples of AcrB tagged 
with SBP suggested earlier would better test this hypothesis.  
The most natural progression from this thesis is a comparative study with a wider range of 
membrane proteins particularly GPCRs, which have successfully been solubilised in SMALPs 
and are the leading target of novel pharmaceutical agents (Salon, Lodowski et al. 2011, 
Jamshad, Charlton et al. 2015). Of particular importance is the inclusion of eukaryotic proteins 
such as human NRAMP.  
20 DARPins were selected for further characterisation and confirmation of their ability to bind 
to their targets. While the aim of this study was not to produce high affinity DARPins and due 
to the low number of cycles (two) in the phage display, it is not unexpected that all the 
DARPins have micro-molar affinity (see Section 5.5). In order to isolate confirmation specific 
DARPins, DDM was present throughout the ELISAs. It is possible that the apparent affinities in 
the ELISA studies are influenced by biotinylation of the DARPins, which may have reduced their 
affinity. The number of cycles in future selections will need to increase if high affinity DARPins 
are required. The ELISAs help to exclude DARPin binding to the MSP of nanodiscs and the SMA 
copolymer. However, they do not exclude binding to the polyhistidine tag, therefore the next 
step in this study would be to perform biophysical analysis of these DARPins through SEC and 
SPR.  
The most promising DARPins isolated in this study are H11 selected against VcCNT SMALPs, G2 
and C2 (NupC SMALPs), E6 (MPSIL0294-V532C). The use of these DARPins as crystallisation 
chaperones would also be a good follow up study to this thesis. It may also be beneficial to 
 179 
perform mutagenic analysis in order to determine their essential residues and subsequently 
attempt to improve their affinities. As well as including DARPin E6 in the MPSIL0294 Zn uptake 
assay, to investigate if it’s binding has functional consequences on MPSIL0294.  
Of particular interest are DARPins E3, selected against AcrB nanodiscs, and A1, selected against 
AcrB SMALPS (see Section 5.5.2). Both of these DARPins produced absorbance traces which 
are almost identical to one another with a very similar maximum absorbance reading at 10 µM 
of DARPin. These two DARPins do not share a high level of sequence similarity in their variable 
regions. This suggests that DARPins of a similar quality can be selected to both nanodisc and 
SMALP targets. However, nanodiscs take lot longer to produce and lack stability. As SMALP 
targets resulted in a higher number of ‘positive’ DARPins, I conclude that SMALPs are the best 
presentation method for the selection of DARPins tested in this thesis.             
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Appendix 1 
General lab chemicals were procured from the following suppliers:  
All lipids were bought from Avanti Polar Lipids Inc. http://www.avantilipids.com/    
BDH Laboratory Supplies Merck Ltd, http://www.bdhme.com/product-lab.htm 
PageRular™ plus pre-stained ladder, precision plus protein™ standards were purchased on Bio-
Rad Microscience Ltd., http://www.bio-rad.com/ 
Disposable PD-10 desalting columns and the superdex 200 10/300 GL columns were purchased 
from GE Healthcare UK, http://www.gelifesciences.com/ 
Carbenicillin, Isopropyl β-D-1-thiogalactopyranoside (IPTG), Dithiothreitol (DTT was purchased 
from Melford Laboratories Ltd., http://www.melford.co.uk/ 
The anti polyhistidine antibody/ HRP conjugate was purchased from R&D systems 
All other chemicals were purchased from Sigma-Aldrich Chemical Company, 
http://www.sigmaaldrich.com/ 
Supersignal® west pico chemiluminescence substrate, EZ-Link® Maleimide-PEG11-Biotin, 
Hispur™ cobalt resin were purchased from Thermo Fisher Scientific, 
http://www.piercenet.com/ 
Reagents for molecular biology, protein purification were obtained from the following 
manufacturers: 
BDH Laboratory Supplies Merck Ltd, http://www.bdhme.com/product-lab.htm 
Bio-Rad Microscience Ltd., http://www.bio-rad.com/ 
Fisher Scientific UK Ltd, http://www.fisher.co.uk/ 
DDM was purchased from Glycon Biochemicals, http://www.glycon.de/  
http://www.merckmillipore.co.uk/chemicals 
Fluozin-1 was purchased from Invitrogen Life Technologies, 
http://www.invitrogen.com/site/us/en/home.html 
Melford Laboratories Ltd., http://www.melford.co.uk/ 
Merck Millipore (also for Calbiochem®, Novabiochem® and Novagen®), 
Restriction endonucleases, buffers and enzymes New England Biolabs, 
http://www.neb.com/nebecomm/default.asp 
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Wizard® SV gel and PCR clean up system kit, Wizard® Plus SV miniprep kit were purchased 
from Promega, http://www.promega.com/ 
Qiagen, http://www.qiagen.com/default.aspx 
EDTA free protease inhibitor cocktail was purchased from Roche Diagnostics, 
http://www.roche.co.uk/portal/uk/diagnostics 
Severn Biotech, Ltd, http://www.severnbiotech.com/  
Sigma-Aldrich Chemical Company, http://www.sigmaaldrich.com/ 
Thermo Fisher Scientific, http://www.piercenet.com/ 
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Appendix 2 
The DNA sequence of the gene encoding His6-tagged MPSIL0294, aligned with the 
corresponding amino acid sequence: 
 
ATGCCTAGGAAAAATTCAGAAGAACATGAACCAAAGCAAAGACATCATTTGATTGAATAT 
 M  P  R  K  N  S  E  E  H  E  P  K  Q  R  H  H  L  I  E  Y  
GCAAATGGTCCTTCGCTTGAAGAAATTAATGGCACCATCGACGTGCCTAAAAATATGAGT 
 A  N  G  P  S  L  E  E  I  N  G  T  I  D  V  P  K  N  M  S  
TTTTGGAAAACGTTATTTGCTTACTCAGGTCCAGGAGCATTGGTAGCAGTGGGGTATATG 
 F  W  K  T  L  F  A  Y  S  G  P  G  A  L  V  A  V  G  Y  M  
GATCCAGGAAACTGGTCTACTTCAATTACTGGGGGACAAAATTTTCAATATTTATTGATG 
 D  P  G  N  W  S  T  S  I  T  G  G  Q  N  F  Q  Y  L  L  M  
TCGATTATTTTAATTTCCAGTTTGATTGCAATGTTGCTCCAATATATGGCTGCTAAATTA 
 S  I  I  L  I  S  S  L  I  A  M  L  L  Q  Y  M  A  A  K  L  
GGCATTGTTTCACAGATGGATTTAGCACAAGCGATTCGTGCTAGAACTAGTAAGACGTTA 
 G  I  V  S  Q  M  D  L  A  Q  A  I  R  A  R  T  S  K  T  L  
GGTATTGTATTATGGATTTTAACAGAGTTAGCAATTATGGCTACAGATATCGCTGAAGTT 
 G  I  V  L  W  I  L  T  E  L  A  I  M  A  T  D  I  A  E  V  
ATCGGGGGCGCAATTGCCTTATATTTATTATTTCATATTCCTTTAGGTCTGGCTGTCTTC 
 I  G  G  A  I  A  L  Y  L  L  F  H  I  P  L  G  L  A  V  F  
ATTACGGTATTTGATGTTTTACTTTTGTTGTTATTGACAAAAATTGGTTTTAGAAAAATT 
 I  T  V  F  D  V  L  L  L  L  L  L  T  K  I  G  F  R  K  I  
GAAGCTATTGTTGTTGCTTTAATTGTTGTTATTTTTGTGATTTTTGCTTATCAAGTGGCA 
 E  A  I  V  V  A  L  I  V  V  I  F  V  I  F  A  Y  Q  V  A  
TTGTCAAATCCAGTATGGGGAGATGTAATTAAAGGGCTGGTTCCTAGCGCAGAAGCTTTT 
 L  S  N  P  V  W  G  D  V  I  K  G  L  V  P  S  A  E  A  F  
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TCTACATCACATGCGGTGAATGGGCAAACGCCACTGACAGGTGCATTGGGGATTATTGGT 
 S  T  S  H  A  V  N  G  Q  T  P  L  T  G  A  L  G  I  I  G  
GCAACAGTGATGCCTCATAATTTGTATTTACATTCTTCTGTTGTGCAAAGTCGTAAAATT 
 A  T  V  M  P  H  N  L  Y  L  H  S  S  V  V  Q  S  R  K  I  
GATCGTAAAGATAAAACCGATATTCAACGCGCTTTACGCTTTTCAACTTGGGATTCTAAT 
 D  R  K  D  K  T  D  I  Q  R  A  L  R  F  S  T  W  D  S  N  
ATTCAATTAACGATGGCATTTTTTGTTAACTCTTTATTATTGATTATGGGTGTGGCCGTT 
 I  Q  L  T  M  A  F  F  V  N  S  L  L  L  I  M  G  V  A  V  
TTTAAATCCGGCAGTGTCAAAGATCCTTCATTCTTTGGTTTGTTTGATGCTTTATCAAAT 
 F  K  S  G  S  V  K  D  P  S  F  F  G  L  F  D  A  L  S  N  
CCAGCGGTTATGAGTAATTCTATTTTAGCGCATATTGCAGGTTCTGGAATTTTATCAATT 
 P  A  V  M  S  N  S  I  L  A  H  I  A  G  S  G  I  L  S  I  
TTATTTGCGGTAGCCTTATTGGCATCAGGACAAAATTCAACAATTACAGGAACGTTAACT 
 L  F  A  V  A  L  L  A  S  G  Q  N  S  T  I  T  G  T  L  T  
GGTCAAATCATTATGGAAGGGTTTATTCATATGCGCGTACCAATTTGGTTACGTCGGATG 
 G  Q  I  I  M  E  G  F  I  H  M  R  V  P  I  W  L  R  R  M  
GTCACACGTTTGTTATCTGTTATTCCTGTCTTAATCTGTGTTTTAATGACCAGCGGAAAA 
 V  T  R  L  L  S  V  I  P  V  L  I  C  V  L  M  T  S  G  K  
AGTACAGTGGAGGAGCATATTGCGATTAATAATTTAATGAACAATTCACAAGTTTTTCTA 
 S  T  V  E  E  H  I  A  I  N  N  L  M  N  N  S  Q  V  F  L  
GCATTTGCTTTGCCATTTTCGATGTTGCCTTTACTGATGTTTACAGATAGCCGTGTTGAA 
 A  F  A  L  P  F  S  M  L  P  L  L  M  F  T  D  S  R  V  E  
ATGGGTGAACATTTTAAAAACTCGTGGTTAATTAAATTGTTAGGCTGGGTTTCTGTCATT 
 M  G  E  H  F  K  N  S  W  L  I  K  L  L  G  W  V  S  V  I  
GGCTTAATTTACCTCAATATGAAAGGTTTACCTGATCAAATTGAAGGATTCTTCGGTGAT 
 G  L  I  Y  L  N  M  K  G  L  P  D  Q  I  E  G  F  F  G  D  
AATCCGACAGCGAGTCAAATTACGTTAGCCGATAATATTGCCTATGTCATCATAGCACTC 
 N  P  T  A  S  Q  I  T  L  A  D  N  I  A  Y  V  I  I  A  L  
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GTCATCCTCTTGTTAGTTTGGACGGTTGTGGAATTATATAAAGGCGATAAACGATATGCA 
 V  I  L  L  L  V  W  T  V  V  E  L  Y  K  G  D  K  R  Y  A  
CAGCAGCTTGCAGCTATGGAGCAACAAGTAGAGGAGGTTAAACCTGCAGGACTGGAAGTA 
 Q  Q  L  A  A  M  E  Q  Q  V  E  E  V  K  P  A  G  L  E  V  
CTATTTCAAGGACCACATATGCGTGGCAGCCACCATCACCATCACCATCACCAT 
 L  F  Q  G  P  H  M  R  G  S  H  H  H  H  H  H  H  H  
Note: Highlighted in blue is the codon which was altered by site-directed mutagenesis in order 
to construct pVA3. Highlighted in yellow is the sequence of the Arg-Gly-Ser-His6-tag. 
The DNA sequence of the Avitag-encoding region present in plasmid pVA1, aligned 
with the corresponding amino acid sequence: 
 
CTGGAAGTTCTGTTCCAGGGTCCGCATATGGGCAGCGGTCTGAACGACATCTTCGAAGCTCAGAAAATCGAATGGCACGAA  
L  E  V  L  F  Q  G  P  H  M  G  S  G  L  N  D  I  F  E  A  Q  K  I  E  W  H  E   
GGCAGCCGTGGCAGCCACCATCACCATCACCATCACCAT 
 G  S  R  G  S  H  H  H  H  H  H  H  H 
Note: Highlighted in grey is an HRV cleavage site. In red is the sequence of the avitag with the 
lysine to which biotin becomes attached highlighted in blue. The Arg-Gly-Ser-His6-tag is 
highlighted in yellow. 
 
The DNA sequence of the SBP tag-encoding region present in plasmid pVA2, aligned 
with the corresponding amino acid sequence: 
 
CTGGAAGTTCTGTTCCAGGGTCCGCATATGGGCAGCATGGACGAAAAAACCACCGGTTGGCGTGGTGGTCACGTTGTTGAA 
 L  E  V  L  F  Q  G  P  H  M  G  S  M  D  E  K  T  T  G  W  R  G  G  H  V  V  E  
GGTCTGGCTGGTGAACTGGAACAGCTGCGTGCTCGTCTGGAACACCACCCGCAGGGTCAGCGTGAACCGGGCAGCCGTGGC 
 G  L  A  G  E  L  E  Q  L  R  A  R  L  E  H  H  P  Q  G  Q  R  E  P  G  S  R  G  
AGCCACCATCACCATCACCATCACCAT 
 S  H  H  H  H  H  H  H  H 
Note: Grey highlighting indicates the position of an HRV cleavage site. The SBP tag responsible 
for binding streptavidin is highlighted in green. The Arg-Gly-Ser-His6-tag is highlighted in 
yellow. 
 
